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The article presented in chapter 2 of this thesis is used with permission from the 
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Durocher, Dr. Jason Carter. All data collection was conducted in the laboratory of Dr. 
Carter at Michigan Technological University. My personal contribution to the article 
included recruitment, orientation, conduction, data analysis and statistical analysis of the 
study. I had a significant role in the authorship of the Introduction, Methods, and Results 
sections, with a smaller but significant contribution to the Discussion section.  
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Abstract 
Hypertension is the most prevalent form of cardiovascular disease (CVD) in the 
world, and is known to increase the risk for developing other diseases. Recently, the 
American Heart Association introduced a new classification of blood pressure, 
prehypertension (PHT). The criteria for PHT include a systolic of 120-139 mmHg and/or 
a diastolic blood pressure of 80-89 mmHg. It has been observed that individuals with 
PHT have a higher risk of developing hypertension later in life. Therefore, it is important 
to understand the mechanisms contributing to PHT in order to possibly prevent 
hypertension. Omega-3 fatty acids found in fish oils have been suggested as a means of 
lowering blood pressure. However, little is known on the effects of fish oil in PHT 
humans. Therefore we conducted two studies. In Study 1 we investigated PHT and 
normotensive (NT) individuals during a mental stress task. Mental stress is known to 
contribute to the development of hypertension. In Study 2 PHT and NT subjects were 
placed in an eight week double-blind placebo controlled study in which subjects 
consumed 9g/day of either fish oil or placebo (olive oil) in addition to their regular diets. 
Subjects were tested during a resting baseline (seated and supine), 5 minutes of a 
mental stress task, and 5 minutes of recovery both pre and post supplementation. We 
measured arterial pressure (AP), heart rate (HR), muscle sympathetic nerve activity 
(MSNA), and forearm and calf vascular responses. In Study 1 PHT demonstrated 
augmented AP and blunted vasodilation during mental stress, but MSNA did not change. 
In Study 2, fish oil did not directly influence blood pressure, MSNA or vascular 
responses to mental stress. However, it became clear that fish oil had an effect on some 
but not all subjects (both PHT and NT). Specifically, subjects who experienced a 
reduced blood pressure response to fish oil also demonstrated a decrease in MSNA and 
HR during mental stress. Collectively, the investigations in this dissertation had several 
novel findings. First, PHT individuals demonstrate an augmented pressor and blunted 
vascular response to mental stress, a response that may be contributing to the 
development of hypertension. Second, fish oil does not consistently lower resting blood 
pressure, but the interindividual responses may be related to MSNA.  Third, fish oil 
attenuated the heart rate and MSNA responses and to mental stress in both PHT and 
NT. In conclusion, we found that there are both similarities and differences in the way 
PHT and NT individuals respond to mental stress and fish oil. 
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Chapter 1 
 
Literature Review 
 
1.1  Hypertension 
Over 80 million Americans are diagnosed with at least one form of cardiovascular 
disease (CVD). The most prevalent form of CVD is hypertension, affecting 76.4 million 
Americans and as many as 1 billion people worldwide (Chobanian et al., 2003). 
Cardiovascular related mortality, such as ischemic heart disease and stroke, increase 
dramatically when a comorbidity of high blood pressure is present. Additionally, 7.1 
million people die from hypertension related causes annually (Brundtland, 2002; 
Chobanian et al., 2003).  
The concept that the blood circulates in the body was first suggested in the early 
1600s by William Harvey (Harvey, 1628). At the time this was a giant step forward in the 
understanding of the human body and how it functions. Nearly 100 years later the first 
measurements of blood pressure were taken by Stephen Hales (Booth, 1977), who 
measured blood pressure from an artery of a horse using a nine-foot glass tube. The 
technique of analyzing blood pressure was later refined and modified by Jean Poiseuille 
(1828) and Carl Ludwig (1847) to essentially the method we use today (Norris, 1917). 
However, even before measurements of arterial pressure were conducted there seemed 
to be an understanding of a type of “hard pulse disease,” which we now know as 
hypertension (Esunge, 1991). 
The classification of hypertension is considered to be a systolic arterial blood 
pressure ≥140 mmHg and/or a diastolic arterial blood pressure ≥90 mmHg (Chobanian 
et al., 2003). Keith et al. (1974) found that there was a direct relationship with increased 
blood pressure and incidence of cardiovascular disease. Furthermore, risk of developing 
cardiovascular disease increases 2-fold when systolic arterial blood pressure is 130-139 
mmHg and/or diastolic arterial blood pressure is 85-89 mmHg (Vasan et al., 2001). 
These findings initiated the introduction of a new classification known as 
prehypertension. Having a systolic blood pressure of 120-139 mmHg and/or diastolic 
blood pressure of 80-89 mmHg is now classified as “prehypertensive.” Prehypertension 
is associated with an increased risk of developing hypertension later on in life (Vasan et 
al., 2001; Moreira et al., 2008). The reasons for this increased risk remain unclear. 
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Arterial pressure is closely regulated by the nervous system. Control of whole body 
arterial blood pressure is done through a negative feedback mechanism known as the 
arterial baroreflex. Modified stretch receptors located in the aortic arch, carotid sinuses 
and the cardiopulmonary blood vessels detect elastic changes in the arterial wall. Once 
a stretch is detected the baroreceptors send afferent nerve signals back to the area of 
the brain known as the medulla, more specifically the nucleus tractus solitarus. A reflex 
mechanism is then triggered sending efferent sympathetic and parasympathetic nerve 
signals down to the cardiovascular system to either increase or decrease blood 
pressure, respectively.  
It has been recognized that arterial baroreceptors reset during hypertension. This effect 
is seen in studies comparing arterial blood pressure oscillations in normotensive and 
hypertensive subjects. Both groups responded similarly to vasoactive drugs, with the 
hypertensive group operating at a higher blood pressure compared to normotensive 
controls (Wallin et al., 1973). Mechanisms behind the resetting of the baroreflex remain 
in question, but overactive sympathetic nerve activity remains a primary suspect.  
With the introduction of new techniques to test sympathetic nerve activity (i.e. 
microneurography and norepinephrine (NE) spillover) studies of borderline and mild 
hypertensive individuals suggest that augmented sympathetic nerve activity contributed 
to hypertension (FitzGerald et al., 1981; Anderson et al., 1989). Urine and plasma NE 
have also been shown to be elevated in established hypertension (Esler & Nestel, 1973; 
Goldstein, 1983). Collectively, these findings provided important insight into the 
differences between hypertension and normal healthy humans. Similar discrepancies 
began to appear between these populations during physiological and psychological 
stimuli.   
Sympathetic nerve activity increases during a mental challenge in most individuals 
(Anderson et al., 1987; Tidgren & Hjemdahl, 1989; Wallin et al., 1992; Carter et al., 
2005; Carter & Ray, 2009), and the concurrent increase in blood pressure and nerve 
activity does not follow the classic inverse relationship between sympathetic 
vasoconstrictor activity and arterial pressure seen at rest (Wallin et al., 1973; Durocher 
et al., 2011). This altered neurovascular responses to stress has been suggested as a 
possible mechanism contributing to the development of hypertension (Esler et al., 2008). 
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Therefore, understanding how to assess autonomic nerve activity, and how neural and 
cardiovascular respond to mental stress is clinically relevant. 
 
1.2  Measuring  Autonomic Nerve Activity 
1.2.1  Hemodynamic Measurements 
Perhaps the oldest and most commonly used assessment of sympathetic and 
parasympathetic activity is done by examining changes in hemodynamic measurements 
(i.e. arterial pressure and heart rate). The autonomic nervous system innervates the 
heart and the blood vessels affecting both heart rate and blood pressure. During 
physiological and psychological stress, sympathetic nerves increase heart rate and 
blood pressure (Barcroft, 1946). For example, during exercise sympathetic nerve 
activation causes heart rate to increase and blood vessels in non-active areas (i.e., gut, 
kidneys, etc.) to constrict resulting in an increase in blood pressure (Rushmer et al., 
1959). Sympathetic nerves innervate the heart causing an increase in heart rate 
(measured in beats per minute), stroke volume (i.e. the amount of blood per minute), 
and cardiac output (i.e. the amount of blood that exits the heart per minute). Constriction 
of the vascular wall increases total peripheral resistance which increases blood pressure  
(Shepherd, 1987). Arterial pressure is a measure of the relationship between cardiac 
output and total peripheral resistance, the equation of which is shown below (Heymans, 
1958): 
 
Mean Arterial Pressure = Cardiac Output x Total Peripheral Resistance 
 
This direct relationship allows for analysis of changes in pressure as direct 
changes in the cardiovascular system, which in turn infers changes in autonomic control. 
In such a way, an increase in heart rate and blood pressure is an indication of 
sympathetic nerve stimulation and parasympathetic withdrawal, and likewise a decrease 
represents parasympathetic activation and sympathetic withdrawal. Therefore, 
monitoring changes in hemodynamic measurements gives us an indirect, but 
informative, method of analyzing autonomic function.  
There are several positive aspects of hemodynamic assessment of autonomic 
nerve activity. These measurements are non-invasive and easy to conduct. Heart rate is 
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easily measured using electrocardiography, and requires relatively inexpensive 
equipment to acquire and analyze. Similarly, blood pressure can be measured using a 
simple, inexpensive sphygmomanometer. Modern methods for recording these variables 
can now be done virtually anywhere, including remotely so subjects do not have to be 
confined to a laboratory setting, and are free to move about while their hemodynamics 
are being monitored continuously. However, there are limitations to these 
measurements. One limitation is that there is a high amount of variability between 
subjects. Hemodynamics are influenced by many factors (i.e. activity, time of day, 
anxiety, etc.), and reproducibility is not always accurate because of these conditions 
(Parati et al., 1988). Another limitation is that hemodynamic are indirect measurements 
of autonomic acitivity, and subject to the methods used to stimulate them. These 
limitations make it difficult to support hemodynamic measurements as a sole measure of 
autonomic activity. However, taken in combination with other measurements, 
hemodynamics can provide an important picture of whole body peripheral nerve 
function. 
 
1.2.2  Heart Rate Variability – Spectral Analysis  
Heart rate, as stated above, is an important hemodynamic measurement that 
indirectly depicts autonomic nerve function. The sympathetic and parasympathetic 
branches of the peripheral nervous system innervate the heart, thus affecting the 
increase and decrease of heart rate, respectively. This reciprocal relationship between 
sympathetic and parasympathetic branches is known as sympathovagal balance 
(Malliani et al., 1991). Early analysis of heart rate variability looked primarily at the 
individual variability between resting heart rate measurements (Malmo & Shagass, 
1949). However, more recent analyses of the neural control of heart rate has been made 
possible with more advanced computer and mathematic capabilities using a method 
known as power spectral analysis of heart rate variability.  
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Figure 1.1.  A representation of two cardiac cycles as seen in a typical electrocardiogram 
recording. The P-wave represents atrial depolarization, the QRS complex represents ventricular 
depolarization, and the T-wave represents ventricular repolarization. The time-distance, in 
milliseconds, between consecutive R-waves is known as the R-R Interval (RRI). 
 
This technique utilizes mathematical equations to analyze changes in the R-R 
intervals (RRI) of each cardiac cycle. A representative model of two cardiac cycles is 
depicted in figure 1.1.Analysis of oscillations in RRIs throughout the time series can be 
reported as frequency and amplitude, and are compared to determine strength of 
autonomic activity (Pagani et al., 1986; Malliani et al., 1991). For example, an increase 
in the RRI would suggest influence from the vagus (parasympathetic) nerve, and a 
decrease in RRI would signify sympathetic control over heart rate. High frequency (HF) 
oscillations (~0.25 Hz) are representative of primarily parasympathetic nerve activity 
from the vagus nerve. Low frequency (LF) oscillations (~0.1 Hz) demonstrate both 
sympathetic and parasympathetic activity (Pomeranz et al., 1985; Pagani et al., 1986). 
The relationship between both peripheral nervous system branches on heart rate control 
is further represented by the ratio between the two frequencies, known as the LF/HF 
ratio (Pagani et al., 1986). Power spectral analysis can serve as an important tool in 
interpreting autonomic control of cardiovascular function. 
There are several limitation associated with heart rate variability. Similar to 
standard hemodynamics, power spectral analysis is bound to multiple external factors 
affecting heart rate and blood pressure. Additionally, there is speculation as to the 
accuracy of the use of computational analysis as a means of measuring autonomic 
P-wave T-wave
Q 
R 
S 
R 
R-R Interval
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activity instead of direct recordings (Eckberg, 1997). Nevertheless, power spectral 
analysis of heart rate variability has given us valuable insight into the neural 
mechanisms contributing to cardiovascular function, and when used in conjunction with 
other techniques can provide a more complete measure of neural-cardiovascular 
interactions. 
 
1.2.3  Norepinephrine – Urine and Plasma 
Measurements of catecholamine levels in blood (i.e. plasma NE and epinephrine) 
and urine are commonly used to assess sympathetic activity. Early research in cats 
demonstrated a correlation with sympathetic nerve firing and NE release into the blood 
(Brown & Gillespie, 1957). Engelman et al. (1970) performed an enzymatic assay to 
analyze catecholamines in human plasma and urine, and were able to isolate circulating 
norepinephrine. The technique provided a more specific method of assessing 
sympathetic activity. Sympathetic nerves primarily excrete NE as their neurotransmitter. 
Molecules exit the pre-synaptic neuron and enter the synaptic space where NE can 
either bind to the post-synaptic neuron, be metabolized by catechol-O-
methyltransferase, be absorbed into the circulation, or be taken back into the pre-
synaptic neuron (Hertting, 1964). Any amount of NE not used or recycled is dissipated 
and taken up into the blood stream, and further filtered by the kidneys into the urine. It is 
in these two areas (plasma and urine) that NE can provide a measure of whole body 
sympathetic activity (Hjemdahl, 1984). However, the use of plasma or blood samples 
only provides a small, singular measurement of overall activity. Additionally, a high level 
of plasma NE does not always indicate a high level of nerve activity (Goldstein 2003). 
Acute sympathetic measurements are not measurable with this method, and the amount 
of NE absorbed into the blood is a small fraction (5-10%) of total neurotransmitter 
excreted at the nerve synapses (Grassi & Esler, 1999). Though plasma and urine NE 
measurements give us an idea of whole body sympathetic activation, the picture is not 
complete, and does not provide a means of continual measurement of neural activity. 
 
1.2.4  Norepinephrine – Regional Spillover 
The limitations that plasma and urine NE measurements pose brought about the 
introduction and implementation of a technique for measuring plasma NE kinetics, also 
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known as NE spillover rate (Esler et al., 1989). This process uses the infusion of 
radioactive-labeled NE to measure the appearance rate of NE in the plasma. The 
spillover is acquired by measuring the relationship between the radio-labeled NE 
infusion rate and the appearance of radioactive NE in the plasma (Esler et al., 1979; 
Esler et al., 1989). The benefit of NE spillover compared to a simple plasma sampling is 
that through use of arterial or venous catheter, plasma uptake of NE can be measured in 
real-time at specific regions not otherwise accessible (i.e. cardiac and renal regions) 
(Esler et al., 1984a). The measurement of NE kinetics is currently the only technique 
used in humans that can measure activity in deep, region specific tissue beds. However, 
NE spillover has its drawbacks. Spillover measures overall sympathetic outflow via NE 
measurements, but the exact source of the NE is unknown. Sympathetic nerves release 
the neurotransmitter NE, but this same molecule is released by the adrenal gland as 
well, and the spillover technique is not able to determine the source of NE (Esler et al., 
1984a). Furthermore, this technique is not a direct measurement of sympathetic nerve 
activity. Although there are drawbacks and it is only used in a few laboratories 
throughout the world, NE spillover is recognized as a robust and superior method of 
measuring sympathetic tone.  
 
 1.2.5  Microneurography 
A major advancement in our ability to measure sympathetic nerve activity 
occurred in the late 1960s. Direct peripheral muscle nerves were successfully recorded 
in humans by using a tungsten needle with a microelectrode at the tip, and inserted into 
a nerve fascicle to obtain multi-unit discharge of activity (Hagbarth & Vallbo, 1967; 
Vallbo & Hagbarth, 1967; Hagbarth & Vallbo, 1969). This technique, termed 
microneurography, was refined and found to be a very useful tool in measuring 
sympathetic nerve activity (Figure 1.2) (Delius et al., 1973). Moreover, microneurography 
is currently the only direct method of measuring sympathetic nerve activity in humans 
(Grassi & Esler, 1999). The microneurographic technique measures post-ganglionic 
multi-fiber efferent sympathetic nerve activity to skeletal muscle beds, referred to as 
muscle sympathetic nerve activity (MSNA) (Vallbo et al., 2004). MSNA is typically 
measured as integrated bursts of activity per minute. MSNA bursts are coupled to the 
cardiac cycle, and if a burst of activity is going to occur, it will do so in one cardiac cycle 
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(Delius et al., 1972). Therefore, reporting MSNA as bursts per 100 heartbeats is also an 
accepted quantification. Total MSNA activity is another measurement commonly 
reported. Total MSNA takes into account not only the burst activity per minute but also 
the amplitude and area underneath each integrated burst (Sundlof & Wallin, 1978). 
Because MSNA is most commonly measured as multifiber nerve recordings, multiple 
integrated sympathetic firings demonstrate varying amplitudes of firing strength. To 
account for this, analysis of total activity is employed using a baseline normalization 
procedure. 
Microneurography has several strong attributes. First, it is currently the only 
direct method of assessing sympathetic neural activity in humans. Second it correlates 
strongly with other measures of autonomic activity such as the NE spillover technique 
(Wallin et al., 1981). Another advantage is that it allows for continuous measurement of 
 
 
 
 
Figure 1.2.  A representative neurogram and the corresponding blood pressure for one minute of 
baseline. Notice the relatively close relationship between oscillations in blood pressure and nerve 
activity. MSNA, muscle sympathetic nerve activity; a.u., arbitrary units 
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activity during different interventions. Techniques such as plasma/urine NE 
measurements only take isolated samples, thus providing a non-continuous 
measurement of sympathetic activity. However, there are disadvantages associated with 
microneurography. The technique is mildly invasive and can only be done by trained 
individuals. It is highly variable between individuals, though it remains highly 
reproducible when tested over a period of time, even up to years later (Sundlof & Wallin, 
1977). Another disadvantage is that the technique is sensitive to movement, and the 
electrode can become dislodged easily. Therefore, it is only possible to use 
microneurography in a laboratory setting, with subjects typically in the supine or seated 
positions. Despite these limitations, microneurography, along with norepinephrine 
spillover, remains the “gold-standard” for assessing sympathetic nerve activity. 
 
1.3  Neural Responses to Mental Stress 
The advancement in our ability to measure autonomic nerve activity has allowed 
us to further investigate the effect of psychological stress in humans. Mental stress 
consistently increases heart rate, blood pressure and forearm blood flow, which are 
closely linked with the sympathetic and parasympathetic nervous systems (Blair et al., 
1959; Barcroft et al., 1960). Simultaneous neuroendocrine responses can also be 
observed during this cardiovascular response to mental stress (Hjemdahl et al., 1984). 
Ultimately, markers for established psychological distress were identified as an increase 
in heart rate and force contraction, skeletal muscle vasodilation, and increased 
circulating catecholamines (Herd, 1991).  
Epinephrine is strongly linked to the mental stress response. When compared to 
non-psychological stimuli, such as the cold pressor test, mental stress causes a greater 
increase in heart rate, skeletal muscle vasodilation and increased circulating 
epinephrine. This is compared to no increase in epinephrine during a physical stressor 
like the cold pressor test (LeBlanc et al., 1979). Notably, norepinephrine levels were 
greater during cold pressor test compared to mental stress. Because norepinephrine is 
closely linked with the sympathetic nervous system, these findings provided early 
evidence that a combination of circulating catecholamine and sympathetic nerve 
responses were causing the physiological changes during mental stress. 
 10
Circulating plasma norepinephrine has been closely linked with sympathetic 
nerve activity (Wallin, 1984). Today, the most common means of measuring sympathetic 
nerve activity include plasma or urine norepinephrine sampling, radioactive labeled 
norepinephrine spillover from cardiac and renal sympathetic beds, and 
microneurographic measurements of MSNA from the peroneal nerve. Plasma 
norepinephrine measurements have been shown to increase during mental stress 
(Dimsdale & Moss, 1980; Jones et al., 1996). However, in one study mental stress 
increased plasma norepinephrine in older, but not young, subjects (Ng et al., 1994). 
Norepinephrine spillover has also been shown to increase during a mental challenge 
(Goldstein et al., 1987; Lindqvist et al., 1993; Wilkinson et al., 1998). MSNA recordings 
during mental stress typically demonstrate increases in sympathetic nerve activity 
(Anderson et al., 1987; Hjemdahl et al., 1989; Wallin et al., 1992; Carter et al., 2005; 
Carter & Ray, 2009), but recent work highlights substantial variability regarding the 
MSNA reponses to mental stress (Carter & Ray, 2009). 
 
1.4  Cardiovascular Responses to Mental Stress 
The reaction of the body to stress is a compensatory mechanism. The human 
body is placed under stress constantly throughout any given day. Psychological and 
emotional stressors, in particular, are known to place a great amount of strain on both 
mental and physiological parameters in the human body. In “The Expression of the 
Emotions in Man and Animals” Charles Darwin describes a general state of expression 
(Darwin, 1886). The common response in animals is an activated nervous system, 
muscle trembles, a combination of emotions such as rage, joy and terror. Further 
observation of fear and astonishment resulted in multiple changes to a biological system, 
including increases in heart rate, pale skin, muscle trembles, widely open eyes and 
mouth (Darwin, 1886). Years later, Walter Cannon would describe these same 
responses as an “emotional experience” (Cannon, 1914). Additionally, Cannon and 
others discovered specific physiological changes that occur during emotional stimuli, 
most notably the release of adrenaline (i.e. epinephrine) from the adrenal glands 
(Newton, 1930).  He also noted a specific interaction with the physiological system and 
“sympathin” (Cannon, 1933). We now refer to sympathin as noradrenaline (i.e. 
norepinephrine), the main neurotransmitter released from sympathetic neurons. This 
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hormone response causes a response similar to that directed by nervous system, which 
includes pupil dilation, blood vessel constriction and rapid heart rate (Cannon, 1914).  
Cannon introduced the term “fight or flight” to describe the sympathetic nervous 
system’s reaction to stressors (Cannon, 1927). These findings introduced an important 
idea to our current views of multiple physiological systems’ responses to emotional 
stress. The autonomic nervous system is comprised of the parasympathetic and 
sympathetic nervous systems, and is a primary controller of the cardiovascular system. 
However, as Cannon and others discovered, there is an interaction in adrenergic activity 
from the nervous and endocrine systems (Cannon, 1933). More specifically, the 
autonomic nervous system and adrenal (medulla and cortex) responses work in parallel. 
However, Hans Selye is widely credited with highlighting a clinical reason for studying 
neuroendocrine responses to psychological stress.  
The “General Adaptation Syndrome” was first proposed by Hans Selye (Selye, 
1936). Selye discovered, by accident, that psychological stress to rats resulted in 
specific physiological responses, specifically an enlargement of the adrenal glands and 
increased ulcers. This sparked a whole new line of “stress” research. Investigations into 
the general response to different stressors such as cold, injury, exercise, drugs and 
others were conducted producing what Selye termed the general adaptation syndrome. 
Responses to many different types of stress results in “systemic damage”, and originate 
in the hypothalamus which can influence processes throughout the body including the 
adrenal glands, heart, and vascular system (Selye & Fortier, 1950). 
In years to follow, Brod et al. (1959) reported that a mental stress task such as 
mental arithmetic caused similar physiological response as emotional stress or fear. 
Notably heart rate and blood pressure increased, and interestingly blood flow increased 
to peripheral muscles and decreased in the renal vascular bed. Forearm vasodilation 
during mental stress has been observed repeatedly in multiple studies (Barcroft & 
Edholm, 1945; Blair et al., 1959; Rusch et al., 1981; Dietz et al., 1994; Carter et al., 
2005) and has led to the description of a classic “defense reaction” (Herd, 1991).  
Peripheral blood flow in forearm and calf muscular beds are common 
measurements during a mental challenge. When blood flow to the peripheral muscles 
was studied during post-hemorrhagic fainting, there was a marked vasodilation at which 
the point when faint occurred (Barcroft & Edholm, 1945). Interestingly, it has been 
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observed that fainting also occurs during emotional distress, and studies began to 
incorporate mental and emotional stress as a means of analyzing cardiovascular 
responses during faint (Roddie, 1977). 
Forearm vasodilation consistently increases during mental and emotional stress 
(Blair et al., 1959; Barcroft et al., 1960; Rusch et al., 1981; Dietz et al., 1994; Kuipers et 
al., 2008). Calf blood flow has been found to increase in some studies (Blair et al., 1959; 
Kuipers et al., 2008), but not all (Rusch et al., 1981). The proposed mechanisms 
contributing to vasodilation in the limbs include sympathetic mediated adrenergic 
responses, nitric oxide (NO) release from the endothelium, and circulating 
catecholamines. 
The response to mental and emotional stress observed in these investigations 
fits with Cannon’s “fight or flight” description. However, it has become clear that mental 
stress reactivity is more complicated than simply preparing the body for fight or flight. 
Observing and analyzing this stress response has become crucial to our understanding 
of how mental and emotional stress contributes to the risk of cardiovascular disease. 
With the improvements in technology it has become easier to measure changes in heart 
rate, blood flow, and autonomic nerve activity. This has been crucial in our 
understanding of the how neurological and humoral responses to stress influence health 
in humans. 
 
1.5 Mental Stress and Cardiovascular Disease 
It has been noted that an acute mental stress can adversely affect cardiovascular 
health. One example of this is seen in the increased number of cardiac related deaths 
following a traumatic event such as a major earthquake (Leor et al., 1996). Additionally, 
electrocardiogram recordings during an earthquake event have shown that heart rate 
significantly increased in patients. Spectral analysis of this response suggested an 
increased sympathetic nerve response and reduced parasympathetic tone (Huang et al., 
2001). Furthermore, mental and emotional stress are closely linked with cardiovascular 
diseases such as myocardial ischemia (Deanfield et al., 1984), endothelial dysfunction 
(Spieker et al., 2002), atherosclerosis (Lynch et al., 1997) and hypertension (Esler et al., 
2003). Perhaps the most well known study to linking stress and risk for cardiovascular 
disease was performed by Timio et al. (1988). They found that cloistered nuns, secluded 
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from society and living a very controlled and non-stressful lifestyle, did not experience 
the typical rise in blood pressure often seen with increasing age (Timio et al., 1988). 
Further, it has been suggested that chronic mental stress leads to a rise in blood 
pressure over time (Esler et al., 2008). The mechanisms by which mental stress affects 
cardiovascular disease are not fully understood, but a clear link exists, particularly in 
hypertension. 
 
1.6 Treatment of Hypertension 
Hypertension has been linked to a number of cardiovascular-related deaths. 
Therefore, early treatment and/or prevention of high blood pressure has become a 
primary focus in clinical care. Treating hypertension through pharmacological or non-
pharmacological methods can reduce the risk of stroke, myocardial infarction, and heart 
failure (Neal et al., 2000). Current treatment of hypertension is primarily focused on 
pharmacological intervention. Common types of anti-hypertensive medications include 
diuretics, ACE inhibitors, α and β-blockers and calcium channel blockers (Epstein, 
2010).  Most patients require at least two medications to lower their blood pressure 
(Cushman et al., 2002; Epstein, 2010). It is evident that cost of treatment for 
hypertension can escalate quickly. The American Heart Association recently projected 
that the cost of hypertension treatment will increase from $130.4 billion in 2008 to $200.3 
billion in 2030 (Heidenreich et al., 2011). Therefore, it is prudent to investigate alternate 
methods of treatment and prevention of high blood pressure. 
The most recent joint report on hypertension currently lists lifestyle modifications 
as the only non-pharmacological treatment plan (Chobanian et al., 2003).  Lifestyle 
modifications include weight loss, diet and exercise. The effects of omega-3 fatty acids, 
found in fatty fish or extracted from certain plants, have intrigued many patients and 
clinicians as a potential non-pharmacological approach to blood pressure control.  
Supplementation with omega-3 fatty acids has been shown to reduce blood 
pressure in hypertensive but not normotensive individuals (Appel et al., 1993; Morris et 
al., 1993). There is also some debate as to the dosage needed to observe a blood 
pressure lowering effect. Studies have found that doses are only effective in very high 
amounts, such as 15 g/day (Knapp & FitzGerald, 1989). Other studies suggest that 
moderate amounts are capable of lowering blood pressure in those with mild-
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hypertension (Appel et al., 1993; Morris et al., 1993). Additionally, Howe et al. (1991) 
found that fish oil was most beneficial in lowering blood pressure when combined with a 
low sodium diet in spontaneously hypertensive rats. It is suggested that when combined 
with other non-pharmaceutical methods, such as lifestyle and dietary modifications, 
omega-3 fatty acid supplementation may be beneficial in lowering blood pressure, 
particularly in mildly hypertensive individuals (Howe, 1995). Prevention of hypertension 
through omega-3 fatty acid supplementation, particularly in prehypertensive individuals 
who are at higher risk for development of hypertension, seems possible. 
 
1.7  Polyunsaturated Fatty Acids  
Throughout history there have been home remedies that claim to be cure-all 
drugs. These non-pharmaceutical and “natural” medicines have always been popular 
among individuals and main-stream media. Some of these medicinal tools have proven 
useless and sometimes dangerous, yet others have been effective. In particular, dietary 
modifications have been viewed as an obvious measure in disease prevention. Certain 
populations throughout the world have strikingly lower rates of cardiovascular disease 
(CVD) than in the United States or Western Europe, and diet is believed to contribute 
heavily to these differences. One such group that has shown remarkably low incidence 
of CVD is the Inuit Culture in Alaska and Greenland (Bang et al., 1971). Analysis of the 
Inuit diet revealed a much higher consumption of polyunsaturated fatty acids (PUFAs), 
specifically from marine oils, when compared to their Danish counterparts (Bang et al., 
1980). These findings led to both interest and research on fish oil, and its effect on 
health and cardiovascular risk. 
Recently, public awareness of PUFA health benefits has dramatically increased. 
Since the studies conducted by Bang and colleagues (1971 & 1980), the idea that fish oil 
could influence CVD has grown considerably. However, the mechanisms by which these 
“healthy” fats influence human physiology remain unclear. There are many suggested 
benefits of increasing PUFA consumption into the American diet, but one benefit, 
lowering blood pressure, seems to be at the forefront of public opinion.  
It is well-documented that unsaturated fats have more health benefits when 
compared to saturated fatty acids. The difference between PUFA’s and saturated fatty 
acids is found in their molecular structure. Saturated fatty acids contain single bonds 
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between carbon molecules. Unsaturated fats are organic molecules containing one or 
more double bond in the general fatty acid structure; therefore, PUFAs are unsaturated 
fats with two or more double bonds. Table 1.1 shows a list of common saturated and 
unsaturated fats.  
The most common PUFAs in a typical diet are omega-3 and omega-6 fatty acids. 
Omega-3 fatty acids include α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). Omega-6 fatty acids include arachidonic acid and linoleic 
acid. The differences between these two types of PUFAs are determined by the location 
of the first double bond in their chemical structures. Omega-3 fatty acids are named as 
such because the sight of the first double bond in the fatty acid chain occurs at the 3rd 
carbon. Comparatively, omega-6 fatty acids first double bond is found at the 6th carbon. 
This seemingly small difference in structure appears to have dramatic implications on 
metabolism and integration in the body.  
It has been suggested that the risk of developing cardiovascular disease 
decreases as the ratio of omega-6 to omega-3 fatty acids decreases, with the ideal ratio 
being 1:1. Currently, the typical American diet consumes a 15:1 omega-6/omega-3 ratio 
(Simopoulos, 2008). It has been hypothesized that a lack of omega-3 fatty acids in the 
diet may be contributing to the high incidence of cardiovascular disease found in the 
United States. This has led to a strong push for the general population to incorporate 
more foods containing omega-3 fatty acids in them, such as fish, flax seed, certain nuts 
and vegetable oils (Kris-Etherton et al., 2003). The omega-3 fatty acids EPA and DHA 
are commonly found in marine animals. These are essential fatty acids, meaning they 
cannot be synthesized by the human body. The beneficial effects marine oils in reducing 
cardiovascular disease are believed to be through improved lipoprotein composition, 
endothelial and smooth muscle function, atherosclerotic plaque build-up, inflammatory 
mediators and peripheral nervous system function. Three of these, anti-inflammatory 
response, endothelial proliferation and the peripheral nervous system, are believed to be 
the primary contributors to lowering arterial blood pressure (Das, 2000; Abeywardena & 
Head, 2001). 
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Table 1.1. Examples of saturated and unsaturated fatty acids.  
 
 
 
EPA and DHA are “less” inflammatory, more so than anti-inflammatory. The 
structures of omega-3 fatty acids, and products from their breakdown and integration 
into biological cells are the first processes that lead to their influence on the inflammation 
process. The source of PUFA’s health benefits lies in the multiple double bonds in the 
chemical structures. A greater number of double bonds lead to an increased fluidity in 
the cell membranes (De Caterina et al., 1998; Hashimoto et al., 1999). This altered 
membrane structure triggers the formation of specific types of cytokines and 
inflammatory mediators such as prostaglandins, tumor necrosis factor and interleukins 
(Endres et al., 1989; De Caterina et al., 2000). These molecules are inflammatory 
triggering products, but the properties of the structures of the mediators derived from 
EPA have anti-inflammatory properties compared to arachidonic acid. For example, 
arachidonic acid, an omega-6 fatty acid, is the precursor to active inflammation 
mediators prostaglandin PG2 and thromboxane TXB2. The omega-3 fatty acid EPA is the 
precursor to PG3 and TXB3 which are less active inflammatory agents (Terano et al., 
1986). In this way, omega-3 fatty acids are less-inflammatory when compared to their 
Name Formula* Structure 
Saturated  
Palmitic Acid 16:0 
 
   
Unsaturated  
Arachidonic Acid 20:4 (n-6) 
Eicosapentaenoic Acid (EPA) 20:5 (n-3) 
Docosahexaenoic Acid (DHA) 22:6 (n-3) 
Formulas presented as number of carbons in the chain:number of double bonds (carbon 
at which the first double bond occurs); n-3, omega-3 fatty acid; n-6, omega-6 fatty acid 
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omega-6 counterparts. Additionally, changes in the inflammatory response may have an 
effect on localized endothelial function. 
Peripheral vasculature is highly influenced by endothelial function. Fish oils are 
suggested to improve endothelial function. Endothelial tissue can contribute to local 
vasodilation as well as constriction. For example, angiotensin II is a known 
vasoconstrictor while nitric oxide is a vasodilator. It is believed that an imbalance in 
these vasoactive actions is one of the causes of endothelial dysfunction and 
hypertension. Vasoactive agents such as angiotensin II, nitric oxide, endothelial derived 
hyperpolarizing factor, eicosanoids and endotholin are believed to be influenced by EPA 
and DHA (Gibbons, 1997; Harris et al., 1997; Noll et al., 1997).  
Another potential mechanism, and the primary focus of this thesis, is that fish oil 
decreases blood pressure through the parasympathetic and sympathetic nervous 
systems. Although the exact mechanisms for these affects are unclear, it has been 
suggested that omega-3 fatty acids have a direct influence on peripheral nervous system 
function. 
 
1.8  Summary and Hypotheses 
The purpose of this dissertation is two-fold.  First, we aim to compare the 
neurovascular responses to mental stress in prehypertensive and normotensive 
humans. Second, the effects of omega-3 fatty acid supplementation will be used to 
determine if there is a possible health benefit to fish oil supplementation in regards to 
blood pressure regulation and prevention of cardiovascular disease, specifically 
hypertension. The link between mental stress and possible mechanisms in the 
development of hypertension has led us to propose the following hypotheses. 
Hypothesis 1:  Previously, it has been shown that young borderline hypertensive 
subjects demonstrated an augmented pressor response during mental stress compared 
to normotensives (Santangelo et al., 1989; Matsukawa et al., 1991; Jern et al., 1995). 
Mechanisms suggested to contribute to the augmented pressor response in borderline 
hypertensives include a blunted forearm vasodilation response (Santangelo et al., 1989) 
and augmented MSNA responses to mental stress when compared to normotensives 
(Matsukawa et al., 1991). The neural and vascular responses to mental stress have not 
been examined collectively in these populations. Additionally, based on recent evidence 
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regarding MSNA responses to mental stress (Carter & Ray, 2009), the results reported 
by (Matsukawa et al., 1991) may not be representative of the majority of the population. 
Therefore, in Study 1 we aimed to comprehensively investigate blood pressure, heart 
rate, MSNA and vascular responses to mental stress. We hypothesized that young 
prehypertensive males would elicit an augmented blood pressure and MSNA 
response, but a blunted vasodilation response to mental stress compared to 
normotensives.  
 
Hypothesis 2: Psychological stress is a known contributor to the development of 
hypertension (Esler et al., 2008). Though the mechanisms underlying the development 
of this cardiovascular disease are not fully understood, it has been suggested that 
omega-3 fatty acid supplementation via fish oil may contribute to the prevention and 
treatment of hypertension (Appel et al., 1993; Morris et al., 1993; Mori, 2006). Studies 
investigating omega-3 fatty acids and mental stress have suggested blunted sympathetic 
activity (i.e., epinephrine) as a mechanism by which blood pressure may be lowered 
(Delarue et al., 2003). However, direct measurements of sympathetic neural activity 
have not been investigated during mental stress, and no studies have examined 
prehypertensive responses to mental stress following omega-3 supplementation. In 
Study 2 we hypothesized that supplementation with omega-3 fatty acids, 
specifically fish oil, would lower resting blood pressure in prehypertensive 
subjects compared to normotensive. Furthermore, we hypothesized that fish oil 
would blunt the blood pressure and MSNA, and augment the vascular responses 
to mental stress in these same prehypertensive individuals compared to 
normotensives.    
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Chapter 2 
 
Neurovascular Responses to Mental Stress in Prehypertensive Humans 
 
The material contained in this chapter was previously published in the Journal of Applied 
Physiology  
 
Schwartz, CE, Durocher, JJ, Carter, JR. (2011). Neurovascular responses to mental 
stress in prehypertensive humans. Journal of Applied Physiology 10, 76-82. Doi: 
10.1152/japplphysiol.00912.2010 
 
2.1  Introduction 
Mental stress has been linked to several cardiovascular diseases, including 
hypertension (Esler et al., 2003; Esler et al., 2008). Hypertensive and prehypertensive 
individuals, as well as normotensives with a family history of hypertension, have all 
demonstrated an augmented pressor response to mental stress (Falkner et al., 1979; 
Santangelo et al., 1989; Matsukawa et al., 1991; Widgren et al., 1992; Jern et al., 1995). 
Although this hypertensive response is well documented, few studies have examined the 
mechanisms underlying this response.  
Mental stress consistently induces forearm vasodilation (Blair et al., 1959; 
Barcroft et al., 1960; Roddie, 1977; Carter et al., 2005), and evidence suggests that 
prehypertension blunts this response (Santangelo et al., 1989). The mechanism(s) 
responsible for this attenuated response remain unresolved, but an augmented 
sympathetic neural response has been suggested. Specifically, Matsukawa et al. 
(Matsukawa et al., 1991) reported that MSNA responses to mental stress were 
augmented in borderline hypertensives when compared to normotensives. 
Unfortunately, concurrent vascular responses were not assessed (Matsukawa et al., 
1991) and MSNA responses to mental stress are highly variable (Carter & Ray, 2009). 
Therefore, the present study aims to determine both forearm vascular and MSNA 
responses to mental stress in prehypertensive and normotensive adults. We hypothesize 
that prehypertension will blunt forearm vasodilation and augment MSNA responses to 
mental stress. Understanding the mechanisms responsible for the augmented pressor 
response to mental stress is clinically relevant, and may lead to better intervention 
strategies to help prevent, or at least delay, the development of prehypertension and/or 
hypertension. 
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2.2  Methods 
2.2.1  Subjects 
35 healthy men (18 normotensive, age 23 ± 2 yrs; 17 prehypertensive, age 22 ± 
1 yrs) participated in the study. Normotensive subjects were defined as having a resting 
systolic pressure less than 120 mmHg and diastolic pressure less than 80 mmHg. 
Prehypertensive subjects were defined as having a resting systolic pressure of 120-139 
mmHg and/or a diastolic pressure of 80-89 mmHg. This is consistent with current blood 
pressure classifications (Chobanian et al., 2003). Subject exclusion criteria included 
smoking, diabetes, use of blood pressure medication, and autonomic dysfunction. 
Normotensive (24 ± 1 kg/m2) and prehypertensive (26 ± 1 kg/m2) subjects had similar 
body mass indices (P=0.13). Subjects were asked to refrain from exercise, caffeine and 
alcohol for 12 hours prior to being tested. This experimental protocol was approved by 
the Michigan Technological University Institutional Review Board (Approval Protocol No. 
M0172), and all participants signed an informed consent form. 
 
2.2.2  Experimental Design 
Subjects reported to the laboratory on the three consecutive days. Testing 
occurred at the same time of day to avoid diurnal fluctuations in autonomic 
measurements. Resting blood pressures were measured in the seated position three 
times after 5 minutes of rest on each of the three consecutive days, and reported as the 
mean. Height and weight were recorded following the resting blood pressure readings on 
the third day. After resting measurements were taken on day three, subjects were 
instrumented for the mental stress autonomic function test, which included 5 minutes of 
supine rest (baseline), 5 minutes of mental stress (mental arithmetic), and 5 minutes of 
supine rest (recovery). Mental arithmetic consisted of subtracting the number 6 or 7 from 
a 2-3 digit number continuously as investigators encouraged the subject to respond 
quickly. The 2-3 digit number was changed every 5-10 seconds. MSNA, heart rate (HR), 
beat-to-beat blood pressure, forearm and calf blood flow were recorded throughout the 
protocol. 
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2.2.3  Measurements 
Arterial blood pressure was measured using two techniques. Resting arterial 
blood pressure was measured three times (separated by approximately one minute 
intervals) over three consecutive days using an automated sphygmomanometer and 
reported as a mean value (i.e., 9 readings over 3 days). Beat-to-beat arterial blood 
pressure was recorded continuously via Finometer (Finapres Medical Systems, 
Amsterdam, The Netherlands) during the mental stress protocol (i.e., baseline, mental 
stress, and recovery). The Finometer accurately determines relative changes in arterial 
blood pressure, but should not be used to determine absolute values. Therefore, the 
Finometer was used to determine precise changes in arterial blood pressure that 
occurred during mental stress, while the sphygmomanometer allowed us to compare 
baseline arterial blood pressures (Table 1). Arterial blood pressures are expressed as 
systolic (SAP), diastolic (DAP), and mean (MAP) arterial pressures. Three day average 
MAP is calculated using the classic formula MAP = DAP + 0.333 (SAP – DAP). Supine 
baseline measurements of MAP are generated by each cardiac cycle waveform 
produced by the Finometer. HR was recorded with the automated sphygmomanometer 
during the 3 consecutive days of blood pressure monitoring, and with a three-lead 
electrocardiogram during the mental stress protocol.   
Forearm and calf blood flow were measured using venous occlusion 
plethysmography. Changes in forearm and calf blood flow were measured via mercury-
in-silastic strain gauges placed around the subject’s forearm and calf at the point of 
greatest circumference. Cuffs were placed around the subjects left wrist, upper arm, 
thigh and ankle. The wrist and ankle cuffs were inflated to 220 mmHg to occlude blood 
flow to the hand and foot, while the upper arm and thigh cuffs were inflated to 60 mmHg 
for 8 seconds and deflated for 7 seconds (i.e. 15 second blood flow intervals).  
Multifiber recordings of MSNA were made by inserting a tungsten microelectrode 
into the peroneal nerve of a resting leg. A reference electrode was inserted 
subcutaneously 2-3 cm from the recording electrode. Both electrodes were connected to 
a differential preamplifier, and then to an amplifier (total gain of 80,000) where the nerve 
signal was band-pass filtered (700-2000 Hz), and integrated (time constant, 0.1) to 
obtain a mean voltage display of nerve activity. Satisfactory recordings of MSNA were 
defined by spontaneous, pulse synchronous bursts that increased during end-expiratory 
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apnea, and did not change during auditory stimulation. A loss or shift of the neurogram 
during mental stress prevented analysis of MSNA data in 14 subjects; thus we report 
MSNA burst frequency responses to mental stress in a total of 21 subjects (10 
normotensive, 11 prehypertensive). Total MSNA responses to mental stress are 
presented for 19 subjects (9 normotensive, 10 prehypertensive).   
 
2.2.4  Data Analysis 
Data were imported and analyzed in the WinCPRS software program (Absolute 
Aliens, Turku, Finland).  R-waves were detected and marked in the time series. Bursts of 
MSNA were automatically detected on the basis of amplitude using a signal-to-noise 
ratio of 3:1, within a 0.5 s search window centered on a 1.3 s expected burst peak 
latency from the previous R-wave. Potential bursts were displayed and edited by one 
investigator. The average burst area occurring during baseline was normalized to a 
mean value of 100. MSNA was expressed as bursts per minute, bursts per 100 heart 
beats, and total MSNA (i.e., the sum of the normalized burst areas per minute).  
Forearm and calf blood flows were analyzed as percent change, and used to calculate 
vascular resistance and vascular conductance. Vascular resistance was calculated as 
MAP divided by limb blood flow, while vascular conductance was calculated as the 
reciprocal (i.e., limb blood flow divided by MAP). 
 
2.2.5  Statistical Analysis 
All data were analyzed statistically using commercial software (SPSS 15.0, 
SPSS Inc., Chicago, Illinois, USA). A two-way repeated measures ANOVA was utilized 
to determine if changes in MSNA, SAP, DAP, MAP, HR, forearm and calf vascular 
resistance and conductance occurred during baseline and mental stress, and across trial 
groups (normotensive and prehypertensive). Post-hoc analyses were performed using 
least significant difference pairwise comparisons. Resting variables were compared 
using independent t-tests. Means were considered significantly different when P < 0.05.  
All results are expressed as mean ± SE. Hemodynamic variables are presented 
as 5 min averages in results text and 1 min averages in figures to provide more detail on 
differences between groups. Although there were group differences in forearm vascular 
responses, data are only presented as 5 min averages as this was more conducive to 
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the sampling technique (venous occlusion plethysmography). Finally, MSNA and calf 
vascular responses were not different between groups regardless of analysis (i.e., 
minute by minute vs. 5 min averages), so data are presented as 5 min averages. 
 
2.3  Results 
Table 2.1 reports seated resting blood pressure and heart rate values taken over 
three consecutive days. Resting SAP, DAP, and MAP were greater in prehypertensive 
than normotensive subjects, while resting HR was not different across groups. Table 2.2 
reports supine baseline MSNA, along with limb blood flow, vascular resistance, and 
vascular conductance to the forearm and calf. Forearm blood flow was significantly 
greater in prehypertensive compared to normotensive subjects, while all other baseline 
variables were not different between groups (Table 2.2).  
Figure 2.1 demonstrates that increases in SAP (Δ9 ± 2 mmHg vs. Δ14 ± 2 
mmHg; P<0.05), DAP (Δ8 ± 1 mmHg vs. Δ11 ± 1 mmHg; P<0.05) and MAP (Δ10 ± 1 
mmHg vs. Δ14 ± 1 mmHg; P<0.05) during mental stress were significantly greater in 
prehypertensive compared to normotensive subjects (condition x group interaction for 
∆SAP and ∆MAP were significant at P<.05, condition x group interaction for ∆DAP was 
considered significant at P=.065). 
 
 
 
 
Table 2.1. Resting hemodynamics for normotensive and prehypertensive subjects.   
 
 Normotensive Prehypertensive 
Variable Day 1 Day 2 Day 3 Mean Day 1 Day 2 Day 3 Mean 
SAP (mmHg)   113 ± 2 112 ± 1 111 ± 1   112 ± 1   127 ± 2*   126 ± 2*  127 ± 2*  127 ± 2*
DAP (mmHg)     65 ± 2   64 ± 2   64 ± 2     64 ± 1   71 ± 2*   71 ± 2*   70 ± 2*    71 ± 2*
MAP (mmHg)     81 ± 1   80 ± 1   80 ± 1     80 ± 1   90 ± 2*   89 ± 2*   89 ± 2*    89 ± 2*
HR (beats/min)     69 ± 3   68 ± 2   68 ± 2     68 ± 2   75 ± 3   74 ± 3   76 ± 3    75 ± 3 
Values are mean ± SE (n = 18 for normotensive, and n = 17 for prehypertensive). SAP, 
systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial blood pressure; 
HR, heart rate; *Significantly different (P<0.05) from corresponding normotensive value. 
Measurements were recorded after 5 minutes of seated rest at the same time of day over 
three consecutive days with an automated sphygmomanometer. 
 
 
 24
Table 2.2. Baseline values for normotensive and prehypertensive subjects.   
Variable Normotensive Prehypertensive P value 
MSNA (bursts/min)      10 ± 2         11 ± 2      P=0.78 
MSNA (bursts/100 hb)      17 ± 3         16 ± 3      P=0.88 
FBF (mL/100mL/min)     2.5 ± 0.3        3.4 ± 0.3*      P=0.03 
FVR (mmHg/mL/100mL/min)      35 ± 2         30 ± 4      P=0.28 
FVC (mL/100mL/min/mmHg)   0.03 ± 0.003      0.04 ±  0.004      P=0.13 
CBF (mL/100mL/min)     2.1 ± 0.2        2.4 ± 0.2      P=0.25 
CVR (mmHg/mL/100mL/min)      42 ± 3         42 ± 4      P=0.99 
CVC (mL/100mL/min/mmHg)   0.03 ± 0.002      0.03 ± 0.002      P=0.80 
Values are mean ± SE. MSNA, muscle sympathetic nerve activity (n = 15 for 
normotensive and n = 16 for prehypertensive); FBF, forearm blood flow (n = 17 for 
normotensive and n = 16 for prehypertensive); FVR, forearm vascular resistance; 
FVC, forearm vascular conductance; CBF, calf blood flow (n = 17 for normotensive 
and n = 15 for prehypertensive); CVR, calf vascular resistance; CVC, calf vascular 
conductance;  *Significantly different between groups. 
 
 
Figure 2 demonstrates that mental stress significantly increased MSNA from 
baseline when expressed as bursts per minute (normotensive: 11 ± 2 to 18 ± 3 
bursts/min, P<0.05; prehypertensive: 11 ± 3 to 18 ± 3 bursts/min, P<0.05) or total MSNA 
(normotensive: 3918 ± 718 to 10064 ± 1295 a.u., P<0.05; prehypertensive: 5591 ± 1360 
to 13417 ± 2684 a.u., P<0.05). In contrast to blood pressure, MSNA responses to mental 
stress were not different between groups (Figure 2.2).   
Figure 2.3 represents the forearm blood flow responses during mental stress in 
normotensive and prehypertensive subjects. Although mental stress increased forearm 
blood flow in both groups, increases were significantly blunted in prehypertensive 
subjects (Δ116 ± 16% vs. Δ62 ± 11%; P<0.01). Likewise, decreases in forearm vascular 
resistance (Δ-41 ± 4% vs. Δ-18 ± 5%; P<0.01) and increases in conductance (Δ95 ± 
14% vs. Δ37 ± 8%; P<0.001) during mental stress were blunted in prehypertensive 
subjects. In contrast, calf blood flow (Δ43 ± 11% vs. Δ36 ± 6%), resistance (Δ-12 ± 5% 
vs. Δ-8 ± 4%) and conductance (Δ29 ± 10% vs. Δ19 ± 5%) responses during mental 
stress were similar between groups (Figure 2.4).  
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Figure 2.1. Changes in SAP, DAP, MAP and HR during 5 minutes of mental stress in 
normotensive, NT (n=18) and prehypertensive, PHT (n=16) subjects. Mental stress elicited a 
significant pressor response in both groups, and this response was augmented in PHT subjects. 
Mental stress increased HR in both NT and PHT subjects, and there was no significant difference 
between groups.  *P<0.05 from corresponding NT value. 
 
 
 
Figure 2.2. Changes in MSNA bursts per minute and total MSNA during 5 minutes of mental 
stress in normotensive (NT) and prehypertensive (PHT) subjects. Mental stress increased MSNA 
burst frequency and total MSNA in both groups. These responses were not significantly different 
between groups (burst frequency: time × group, P=0.43; total MSNA: time × group, P=0.29). 
*P<0.05 from baseline; N.S., no significance; a.u., arbitrary units per minute. 
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Figure 2.3. Changes in forearm blood flow (FBF), vascular resistance (FVR) and vascular 
conductance (FVC) during 5 minutes of mental stress. Mental stress elicited forearm vasodilation 
in both groups, but these responses were blunted in prehypertensive, PHT (n=15) compared to 
normotensive, NT (n=17) subjects (time × group = P<0.01, all). *P<0.05 from baseline. 
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Figure 2.4. Changes in calf blood flow (CBF), vascular resistance (CVR) and vascular 
conductance (CVC) during 5 minutes of mental stress. Mental stress elicited calf vasodilation in 
normotensive, NT (n=17) and prehypertensive, PHT (n=14) groups, and these responses were 
not different between groups (time × group, P>0.20, all). *P<0.05 from baseline, N.S., no 
significance. 
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2.4  Discussion 
 The present study compared neurovascular responses to mental stress in 
prehypertensive and normotensive subjects, and our data reveal three major findings. 
First, mental stress elicited an augmented pressor response in prehypertensive subjects. 
Second, this augmented pressor response was associated with an attenuated forearm 
vasodilation. These findings are consistent with previous work (Santangelo et al., 1989; 
Matsukawa et al., 1991; Jern et al., 1995). Third, prehypertension did not alter MSNA 
responses to mental stress. This finding is novel and provides new mechanistic insight 
into the well documented, yet poorly understood, link between mental stress and 
hypertension. Collectively, our data indicate that blunted forearm vasodilation, not 
augmented MSNA, contributes to a more dramatic increase of arterial blood pressure 
during mental stress in prehypertensive subjects.  
Several studies have shown augmented blood pressure responses to mental 
stress in prehypertensive compared to normotensive subjects (Santangelo et al., 1989; 
Matsukawa et al., 1991; Jern et al., 1995). Similar results have also been seen in 
subjects with a family history of hypertension (Widgren et al., 1992; Noll et al., 1996). 
Furthermore, an augmented pressor response to stress in normotensives may even help 
predict the development of hypertension (Matthews et al., 2004; Esler et al., 2008). In 
the present study, we report an augmented pressor response to mental stress in 
prehypertensive subjects. Thus, our findings are consistent with previous studies and 
strengthen the rationale to determine potential mechanisms that may be responsible for 
this augmented response.  
Matsukawa et al. (Matsukawa et al., 1991) reported an elevated blood pressure 
response to mental stress in borderline hypertensives, and suggested that the difference 
was likely due to a decrease in MSNA in normotensives and no change in the borderline 
hypertensives. However, recent evidence (Carter & Ray, 2009) suggests that the 
findings of Matsukawa et al. (Matsukawa et al., 1991) may not represent typical MSNA 
responses to mental stress. Specifically, a recent retrospective analysis of 82 
neurograms from normotensive subjects indicated that nearly 90% of subjects 
demonstrated an increase or no change in MSNA, while ~10% were classified as 
“negative” MSNA responders (≤∆-3 bursts/min) (Carter & Ray, 2009). Therefore, the 
findings of Matsukawa et al. (Matsukawa et al., 1991), which reported a significant 
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sympathoinhibition of MSNA during mental stress in normotensive subjects, may not 
represent a normal distribution with regards to typical MSNA responses to mental stress. 
The present study demonstrates similar increases of MSNA during mental stress in 
normotensive and prehypertensive patients. We attribute differences between our data 
and the findings of Matsukawa et al. (Matsukawa et al., 1991) to the inherent variability 
of MSNA responses to mental stress in humans (Carter & Ray, 2009). However, it is 
important to note that in the present study, 10 of 10 normotensive subjects and 10 of 11 
prehypertensive subjects demonstrated an increase or no change in MSNA during 
mental stress. These ratios are consistent with a recent large-scale study that reported 
MSNA either increases or does not change during mental stress in approximately 90% 
of adults (Carter & Ray, 2009). Therefore, we are confident in our data and conclude that 
MSNA responses to mental stress are similar in normotensive and prehypertensive 
populations.   
Whereas prehypertension did not alter MSNA responses to mental stress, it did 
alter forearm vascular responses. Specifically, prehypertension blunted the classic 
forearm vasodilatory response associated with mental stress. Blunted forearm vascular 
responses to physiological stressors are associated with increased incidence or risk of 
hypertension (Takeshita et al., 1982; Santangelo et al., 1989; Boutcher et al., 2009). For 
example, young normotensive individuals with a family history of hypertension display a 
reduction in peak forearm blood flow (Boutcher et al., 2009) and an increased forearm 
vascular resistance during (Takeshita et al., 1982) and after (Boutcher et al., 2009) 
reactive hyperemia. Moreover, borderline hypertensives demonstrate increased forearm 
vascular resistance and MAP during mental stress (Santangelo et al., 1989). Thus the 
present study, which demonstrates blunted forearm vascular responses to mental stress 
in prehypertensive subjects, is consistent with previous work (Santangelo et al., 1989) 
and offers new insights by demonstrating that the blunted forearm vascular response to 
mental stress is not accompanied by altered MSNA.   
A recent study reports similar MSNA responses to mental stress in the arm and 
leg (Carter et al., 2005), making it reasonable to assume that other mechanisms beyond 
MSNA may be responsible for the blunted forearm vasodilation to mental stress in our 
prehypertensive subjects. However, it should be noted that other studies have reported a 
divergence in arm and leg MSNA (Anderson et al., 1987) and decreases of arm MSNA 
 30
(Halliwill et al., 1997) during mental stress. We recognize the absence of arm MSNA 
data as a limitation to the present study, but do not believe this lessens the impact of the 
data. Our primary focus remains on mechanisms responsible for the augmented pressor 
response to mental stress in prehypertensive subjects, not the mechanisms underlying 
forearm vasodilation. Both leg MSNA and forearm vascular conductance have been 
independently proposed as potential mechanisms contributing to the augmented pressor 
response, and the present study advanced our knowledge by demonstrating that blunted 
forearm vasodilation, not augmented MSNA, is a primary contributor. This is important 
as it had previously been assumed that augmented MSNA was a likely contributor 
(Matsukawa et al., 1991). However, we recognize that other potential mechanisms might 
include vasoconstriction to non-muscular beds, including renal, splanchnic and skin 
(Brod, 1963; Wallin et al., 1973; Tidgren & Hjemdahl, 1989; Kuipers et al., 2008); future 
work will have to address these vascular beds. 
As previously noted, passive MSNA withdrawal has been suggested as a 
potential mechanism for the forearm vasodilation associated with mental stress (Halliwill 
et al., 1997), but this remains debatable (Carter et al., 2005) and other mechanisms 
have been proposed (Dietz et al., 1994; Lindqvist et al., 1996; Cardillo et al., 1997). 
Specifically, both nitric oxide (Dietz et al., 1994; Cardillo et al., 1997; Cardillo et al., 
1998) and circulating epinephrine (Lindqvist et al., 1996) have been shown to contribute 
to forearm vasodilation during mental stress. Of interest to the present study, Cardillo et 
al. (Cardillo et al., 1998) reported that nitric oxide mediated vasodilation during mental 
stress was attenuated in hypertensives, and this could be due to possible endothelial 
dysfunction. We did not assess nitric oxide levels in the current study, but it seems 
reasonable to speculate that the blunted forearm vasodilation during mental stress in 
prehypertensive subjects may be related to altered nitric oxide responses.  
 Although mental stress does not typically modulate calf vasculature (Rusch et al., 
1981; Carter et al., 2005), calf vasodilation has been observed during mental stress 
(Kuipers et al., 2008). Therefore, the modest, yet significant, calf vasodilation reported in 
the present study is reasonable and consistent with prior work. Importantly, calf 
vasodilatory responses to mental stress were similar in normotensive and 
prehypertensive subjects. Thus, prehypertension appears to elicit divergent limb 
vascular responses to mental stress. The clinical consequence of this divergent vascular 
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response remains unclear, but it is consistent with other studies reporting divergent limb 
vascular responses during physiological stessors in both animals (Wilson et al., 2006) 
and humans (Monahan & Ray, 2002; Lawrence et al., 2010).    
In conclusion, the present study demonstrates that prehypertension elicits a more 
dramatic pressor response to mental stress when compared to normotensive subjects. 
This augmented pressor response appears to be related to blunted forearm vasodilation, 
but not augmented MSNA. These findings provide new insight into the complex 
relationship between mental stress and hypertension. 
 
2.5  Perspectives 
Despite attempts to recruit young, prehypertensive women, we were only successful in 
the recruitment of 17 prehypertensive men. Accordingly, we caution the extrapolation of 
the present data to women. A growing body of evidence suggests that the relations 
between MSNA and arterial blood pressure regulation differ in men and women (Joyner 
et al., 2010), and we cannot speculate how these differences might translate to the 
present findings. Although young, otherwise healthy women have a lower incidence of 
prehypertension than their young, male counterparts (Izzo, 2007), they have a much 
higher incidence of anxiety and panic disorder (Westenberg & Liebowitz, 2004). The 
long term impact of these more ‘chronic’ stressors on arterial blood pressure remains 
unclear, but evidence suggests that such chronic stressors are linked to essential 
hypertension via autonomic mechanisms (Esler et al., 2008). Whereas the present study 
focused on neurovascular responses to acute mental stress in prehypertensive men, 
future investigations might focus on not only prehypertensive women, but also chronic 
stress. 
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Chapter 3 
 
Omega-3 Fatty Acids and the Neurovascular Responses to Mental Stress in 
Humans 
 
3.1 Introduction 
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) found in fish oil, have been suggested as a possible non-
pharmaceutical treatment of cardiovascular disease (CVD), including hypertension (Burr, 
1989; Morris et al., 1993; Marchioli et al., 2002; Thies et al., 2003; Yamagishi et al., 
2008). Currently, over 76 million people suffer from high blood pressure (Roger et al., 
2011). Hypertension has been shown to increase the risk of stroke, ischemic heart 
disease and cardiac related mortality (Kannel, 1975; MacMahon et al., 1990; van den 
Hoogen et al., 2000). A small reduction in blood pressure may have clinical significance 
on the impact on cardiovascular health (Collins et al., 1990).  
Fish oil has been reported to lower blood pressure in hypertensive individuals 
(Appel et al., 1993; Morris et al., 1993; Geleijnse et al., 2002). However, omega-3 fatty 
acids demonstrate mixed effects in mild hypertension (Levinson et al., 1990; Singer, 
1990; Morris et al., 1993), and do not appear to have a hypotensive influence on 
individuals with normal blood pressures (Appel et al., 1993; Morris et al., 1993). 
Collectively, it appears that fish oil may have an increasingly preventative effect as 
resting blood pressure increases.  
Chronic mental stress is a known contributor to hypertension (Esler et al., 2008), 
and typically elicits augmented neural and cardiovascular responses (Cannon, 1927; 
Blair et al., 1959; Barcroft et al., 1960; Carter & Ray, 2009). Augmented sympathetic 
nerve activity (Esler et al., 1986; Egan et al., 1987; Anderson et al., 1989) and altered 
peripheral vascular function are two proposed mechanisms contributing to the 
development of hypertension. Animal studies demonstrate reduced blood pressure, 
cardiac sympathetic activity and sympathoadrenal responses, as well as improved 
vascular compliance, following omega-3 supplementation (Bayorh et al., 1989; Chin-
Dusting et al., 1998; Nishimura et al., 2000; Rousseau-Ralliard et al., 2009). However, 
investigations in humans are less clear. Fish oil has demonstrated both decreases and 
no change in resting blood pressure (Appel et al., 1993; Morris et al., 1993) and 
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sympathetic nerve activity (Delarue et al., 2003; Monahan et al., 2004). Additionally, 
vascular responses in humans following omega-3 supplementation appear to be 
improved (Kenny et al., 1992; Mori et al., 2000; Khan et al., 2003). However, few studies 
have investigated the effect of fish oil in humans during a psychological challenge.  
Delarue et al. (2003) reported that circulating catecholamines, an indirect 
measure of sympathetic neural activity, were reduced during mental stress after fish oil 
supplementation. More recently, Monahan et al. (2004) measured muscle sympathetic 
nerve activity (MSNA) responses following omega-3 supplementation and demonstrated 
augmented responses to physiological stressors, although mental stress was not 
investigated. Borderline hypertensive subjects have demonstrated augmented MSNA as 
well as augmented norepinephrine responses to mental stress (Eliasson, 1985; 
Anderson et al., 1989; Matsukawa et al., 1991). Therefore, investigating the effects of 
fish oil on MSNA during mental stress may provide information as to the beneficial 
effects of omega-3 fatty acids on the development of hypertension. 
Recently, the National Heart, Lung and Blood Institute and the American Heart 
Association introduced prehypertension as a new category of blood pressure 
classification. These individuals demonstrate a resting blood pressure in between normal 
and high categories, and represent a population at higher risk of developing 
hypertension (Vasan et al., 2001; Moreira et al., 2008). Early intervention, such as fish 
oil supplementation, may play an important role in preventing the onset of hypertension 
(Fuchs, 2010). However, the mechanisms by which fish oils act in reducing blood 
pressure in prehypertensive subjects remain unclear.  
Therefore, the aim of this study was to investigate MSNA and vascular 
responses to mental stress before and after omega-3 supplementation in 
prehypertensive and normotensive individuals. We hypothesized that fish oil would 1) 
lower resting blood pressure and MSNA in prehypertensive individuals, 2) blunt the 
blood pressure and MSNA responses to mental stress in the prehypertensive group, and 
3) augment vasodilatory responses to mental stress in prehypertensive individuals 
compared to normotensive. Identifying the mechanism(s) by which omega-3 fatty acids 
lower blood pressure may help us further understand the development of hypertension, 
and provide a possible preventative and/or therapeutic measure against the onset of 
cardiovascular disease. 
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3.2 Methods 
3.2.1 Subjects 
Thirty-eight normotensive subjects (18 men, 20 women) age 24 ± 1 yrs and 29 
prehypertensive subjects (28 men, 1 woman) age 24 ± 1 yrs participated in this study. 
Normotension was classified as a resting systolic blood pressure less than 120 mmHg 
and a resting diastolic blood pressure of 80 mmHg. Prehypertension was classified as a 
resting systolic blood pressure of 120-139 mmHg and/or a diastolic blood pressure of 
80-89 mmHg (Chobanian et al., 2003). All subjects signed an informed consent and 
refrained from caffeine, alcohol and exercise for at least 12 hours before testing. 
Exclusion criteria for participants included smoking, diabetes, autonomic dysfunction, 
and use of blood pressure medication. This study was approved by the Michigan 
Technological University Institutional Review Board (Approval Protocol No. M0172). 
 
3.2.2 Experimental Protocol 
All subjects were randomly assigned into this double-blind, placebo controlled 
investigation, and were tested before (pre) and after (post) 8 weeks of fish oil or placebo 
(olive oil) supplementation. Subjects reported to the Integrative Physiology Laboratory at 
Michigan Technological University at the same time of day for three consecutive days 
during the pre- and post-treatment sessions. The protocol for both pre- and post-
treatments are outlined in Figure 3.1.  
Upon completion of the pre-treatment testing, subjects were randomly assigned 
into the fish oil or placebo (olive oil) group. Participants ingested 9 grams/day of fish oil 
pills (1.6g EPA, 1.1g DHA) or 9 grams/day of placebo pills for 8 weeks. A pill diary and 
regular email and phone reminders were issued to the subjects to track compliance 
according to the study terms. Subjects were asked to maintain current diet and exercise 
habits during the 8 week supplementation period. After 8 weeks of treatment, subjects 
returned to the laboratory for post-treatment testing, and completed the same protocol 
outlined above (Fig.3.1). Two subjects in the prehypertensive group were unable to 
complete the post autonomic testing procedure, but did complete the seated resting 
blood pressure measurements. Therefore, autonomic testing during mental stress is 
reported for 27 prehypertensive subjects. 
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Figure 3.1. The experimental protocol for pre and post testing for subjects. Testing protocols 
were identical pre and post fish oil or placebo supplementation and were separated by 8 weeks. 
 
 
3.2.3 Measurements 
Heart rate was measured using a 3-lead electrocardiogram. Arterial blood 
pressure was measured utilizing two different methods. Seated resting blood pressures 
were obtained using the IntelliSense® automated sphygmomanometer (Model HEM-
907XL, Omron Healthcare, Inc., Bannockburn, IL). A cuff was placed around the upper 
arm in line with the brachial artery and inflated to approximately 200mmHg to occlude 
blood flow to the arm. Pressure was then slowly released allowing for systolic and 
diastolic arterial pressures to be recorded by the automated sphygmomanometer. 
Seated resting recordings were taken 3 times each day, separated by 1 minute between 
readings and following 5 minutes of seated rest. Importantly, all pre- and post-treatment 
blood pressure measurements were recorded at the same time of day to limit diurnal 
blood pressure variations as a potential confounder (Richards et al., 1986). Beat to beat 
arterial pressure was recorded using the Finometer (Finapres Medical Systems, 
Amsterdam, The Netherlands) on the middle finger throughout autonomic testing. The 
Finometer is an ideal technique for measuring beat-to-beat changes in arterial pressure, 
but is not accurate and reproducible in measuring absolute values. Therefore, we used 
the seated resting brachial arterial pressure as absolute resting values and the 
Finometer for recording relative changes during mental stress and recovery.  
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Multifiber recordings of MSNA were recorded using the microneurography 
technique. Briefly, a tungsten microelectrode was inserted into the common peroneal 
nerve located in the popliteal region of the knee or at the base of the fibular head of the 
lower leg. A reference electrode was inserted subcutaneously 2-3 centimeters away 
from the recording electrode. Both electrodes were connected to a preamplifier and 
amplifier. The signal was amplified 80,000 times, band-pass filtered (700-2000 Hz) and 
integrated (time constant, 0.1s) to obtain a mean voltage display of nerve activity. MSNA 
was determined by observing spontaneous multifiber bursts of activity, and confirmed by 
having the subject perform end-expiratory apnea with a resultant increase in MSNA. The 
signal was distinguished from skin sympathetic nerve activity by performing auditory 
stimulation with no subsequent neural reaction. A shift in the neurogram during mental 
stress prevented recordings in 18 normotensive (11 fish oil, 7 placebo) and 17 
prehypertensive (9 fish oil, 8 placebo) individuals. Therefore, nerve recordings are 
reported in only 30 (20 normotensive, 10 prehypertensive) subjects for the mental stress 
portion of the study. 
Arm and leg blood flow were measured using venous occlusion plethysmography 
(D.E. Hokanson, Inc., Bellevue, WA). Occlusion cuffs were placed around the left upper 
arm, wrist, thigh, and ankle. The wrist and ankle cuffs were inflated to 220mmHg in order 
to temporarily prevent circulation to the hand and foot. The arm and thigh cuffs were 
then inflated to 60mmHg for 7 seconds and deflated for 8 seconds (i.e. 4 readings per 
minute). Inflation of the collecting cuffs allows arterial blood flow into the forearm and 
calf, but prevents venous flow return. Strain gauges were placed around the greatest 
circumference of the forearm and calf allowing for direct measurements of changes in 
arm and leg circumference. Technical issues and artifact during mental stress prevented 
the analysis of forearm and calf blood flow in several subjects. We were able to record 
forearm measurements in 29 fish oil subjects and 26 placebo subjects, while in the calf 
we recorded measurements in 28 fish oil and 25 placebo subjects. 
 
3.2.4 Data Analysis  
Data were recorded using WinDaq/Pro data acquisition software (DATAQ 
Instruments Inc., Akron, Ohio), and imported into WinCPRS (Absolute Aliens, Turku, 
Finland) software package for analysis. R-waves from the electrocardiogram were 
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detected and marked in the time series. Integrated bursts of MSNA were detected as a 
3:1 burst-noise ratio within a search window of 0.5 seconds based on an average 
expected burst peak latency of 1.3 seconds following the previous R-wave. Spontaneous 
bursts of MSNA were normalized to the average burst size during baseline, and 
designated a value of 100 arbitrary units. Sympathetic bursts of activity were expressed 
as burst frequency (bursts/minute), burst incidence (bursts/100 heartbeats) and total 
activity (arbitrary units). Total MSNA was determined as the burst activity multiplied by 
the average normalized area under the burst. This analysis accounts for the change in 
the size of the burst per minute. Blood flow data were analyzed using the NIVP3 
software (D.E. Hokanson, Inc., Bellevue, WA). Percent changes in flow per time were 
analyzed in both the forearm and calf. Absolute limb blood flow, as well as limb vascular 
resistance and conductance were reported. Vascular resistance was calculated as the 
mean arterial pressure divided by the absolute blood flow measurement, whereas 
vascular conductance was calculated as the reciprocal of resistance (i.e. blood flow 
divided by mean arterial pressure). 
 
3.2.5 Statistical Analysis 
Data are presented as mean ± SE and analyzed using commercial software 
SPSS 18.0 (SPSS Chicago, IL). Effects of fish oil and placebo at rest and mental stress 
were analyzed in the normotensive and prehypertensive groups, respectively.  Resting 
values were compared using a 1-between (fish oil vs. placebo) by 1-within (pre vs. post) 
repeated measures ANOVA. Statistically significant differences were analyzed post-hoc 
using paired t-tests. Significance was determined as P < 0.05. 
The mental stress condition was analyzed using a 1-between (fish oil vs. 
placebo) by 2-within (pre vs. post; baseline vs. mental stress) repeated measures 
ANOVA. Those analyses that showed a significant (P < 0.05) interaction were further 
analyzed post-hoc using a paired t-test when comparing pre vs. post within groups as 
well as independent t-tests when analyzing between groups. Prehypertensive and 
normotensive groups were analyzed separately in order to better compare individual 
group responses to fish oil or placebo supplementation. These groups were further 
combined into one group, and analyzed using a 1-between (fish oil vs. placebo) by 2-
within (pre vs. post; baseline vs. mental stress) repeated measures ANOVA. Any 
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interactions that were significantly different were further analyzed post-hoc using a 
paired t-test. 
Mauchly’s test of sphericity was performed for all ANOVA analyses in order to 
test for differences between variances. A significant (P < 0.05) result led to the use the 
Huynh-Feldt (sphericity values greater than 0.75) or Greenhouse-Geisser (sphericity 
values less than 0.75) correction factors. 
 
3.3 Results 
3.3.1 Resting Baseline Measurements for Prehypertensive and Normotensive Subjects 
Resting blood pressure and heart rate values for normotensive and 
prehypertensive groups are reported in Tables 3.1 and 3.2 respectively. There were no 
differences in SAP, DAP, MAP or HR following fish oil or placebo supplementation. 
Resting forearm and calf vascular measurements are presented in Tables 3.3 and 3.4 
for normotensive and prehypertensive groups, respectively. FBF, FVR, FVC, CVR and 
CVC all showed a significant time effect (pre vs. post) in the normotensive group, but 
these responses were not different between fish oil and placebo groups. All limb blood 
flow measurements in the prehypertensive group were not statistically altered by either 
fish oil or placebo.  
Resting MSNA measurements are represented in Fig. 3.2. In the normotensive 
group, MSNA burst frequencies were not significantly different following either fish oil or 
placebo supplementation (fish oil, 11 ± 2 to 10 ± 1 bursts/min; placebo, 10 ± 2 to 13 ± 2 
bursts/min; time, P=.73; time x drug interaction, P=0.16). Similarly, MSNA incidences  
were not different following either fish oil or placebo supplementation (fish oil, 18 ± 3 to 
16 ± 2 bursts/100 heart beats; placebo, 17 ± 2 to 19 ± 3 bursts/100 heart beats; time, 
P=0.86; time x drug interaction, P=0.34).  Similar findings were observed in the 
prehypertensive individuals (Fig. 3.2). 
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Table 3.1. Resting hemodynamics before and after 8 weeks of fish oil supplementation or 
placebo in normotensive adults. 
 Pre-Treatment Post -Treatment 
Variable Day 1 Day 2 Day 3 Ave Day 1 Day 2 Day 3 Ave 
Normotensive, Fish Oil Group (n=19):      
SAP (mmHg)   110 ± 2 109 ± 2 110 ± 2   110 ± 1   109 ± 1   107 ± 2   106 ± 3   107 ± 2 
DAP (mmHg)     65 ± 1   67 ± 1   66 ± 1     66 ± 1   67 ± 1     67 ± 1     66 ± 1     66 ± 1 
MAP (mmHg)     80 ± 1   81 ± 1    80 ± 1     80 ± 1   81 ± 1     80 ± 1     75 ± 4     80 ± 1 
HR (beats/min)     71 ± 2   70 ± 2   72 ± 3     71 ± 2   69 ± 3     69 ± 3     75 ± 3     71 ± 2 
Normotensive, Placebo Group (n=19):      
SAP (mmHg)   108 ± 2 107 ± 2 105 ± 2   107 ± 2   107 ± 2   106 ± 2   108 ± 2   107 ± 2 
DAP (mmHg)     66 ± 2   65 ± 2   65 ± 1     65 ± 1   68 ± 1     64 ± 1     67 ± 1     66 ± 1 
MAP (mmHg)     80 ± 1   79 ± 1    78 ± 1     79 ± 1   81 ± 1     78 ± 1     80 ± 2     80 ± 1 
HR (beats/min)     74 ± 3   73 ± 2   75 ± 2     74 ± 2   76 ± 3     73 ± 3     78 ± 2     76 ± 2 
Values are mean ± SE. SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, 
mean arterial blood pressure; HR, heart rate. All time and time × drug interactions were P>0.05. 
 
 
Table 3.2. Resting hemodynamics before and after 8 weeks of fish oil supplementation or 
placebo in prehypertensive adults. 
 Pre-Treatment Post -Treatment 
Variable Day 1 Day 2 Day 3 Ave Day 1 Day 2 Day 3 Ave 
Prehypertensive, Fish Oil Group (n=15):      
SAP (mmHg)   127 ± 2 126 ± 2 126 ± 1   127 ± 1   126 ± 2   124 ± 1   126 ± 2   125 ± 2
DAP (mmHg)     68 ± 3   69 ± 3   67 ± 3     68 ± 2   70 ± 2     68 ± 2     65 ± 2     68 ± 2
MAP (mmHg)     88 ± 2   88 ± 2    87 ± 2     88 ± 2   88 ± 2     87 ± 1     85 ± 1     87 ± 1
HR (beats/min)     77 ± 4   73 ± 3   76 ± 4     73 ± 2   71 ± 3     74 ± 3     72 ± 2     73 ± 2
Prehypertensive, Placebo Group (n=14):      
SAP (mmHg)   128 ± 3 126 ± 2 127 ± 2   126 ± 2   123 ± 2   122 ± 2   125 ± 2   123 ± 2
DAP (mmHg)     73 ± 2   74 ± 2   74 ± 2     74 ± 2   73 ± 2     73 ± 2     74 ± 2     74 ± 2
MAP (mmHg)     91 ± 2   91 ± 2    92 ± 2     92 ± 1   90 ± 2     89 ± 2     91 ± 2     90 ± 2
HR (beats/min)     74 ± 3   71 ± 3   73 ± 3     76 ± 3   72 ± 4     74 ± 3     76 ± 4     74 ± 3
Values are mean ± SE. SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, 
mean arterial blood pressure; HR, heart rate. All time and time × drug interactions were 
P>0.05. 
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Table 3.3. Baseline values for normotensive subjects pre and post fish oil or placebo 
supplementation. 
Variable 
Fish Oil Placebo Time 
Interaction 
Time x 
Drug 
Interaction PRE POST PRE POST 
FBF (units)  2.5 ± 0  2.8 ± 0  2.2 ± 1  2.5 ± 1 0.05 0.81 
FVR (mmHg/units)   45 ± 5   40 ± 5   49 ± 5   41 ± 5* 0.02 0.68 
FVC 
(100*units/mmHg)  2.7 ± 0  3.2 ± 0*  2.4 ± 0  2.9 ± 0* 0.01 0.95 
CBF (units)  2.0 ± 0  2.2 ± 0  2.2 ± 0  2.3 ± 0 0.14 0.70 
CVR (mmHg/units)   54 ± 4   45 ± 4*   46 ± 5   40 ± 3* 0.01 0.56 
CVC 
(100*units/mmHg)  2.1 ± 0  2.4 ± 0*  2.5 ± 0  2.8 ± 0* 0.01 0.93 
Values are mean ± SE. MSNA, muscle sympathetic nerve activity (n = 16 for fish oil and n = 17 
for placebo); FBF, forearm blood flow (n = 18 for fish oil and n = 18 for placebo); FVR, forearm 
vascular resistance (n = 18 for fish oil and n = 18 for placebo); FVC, forearm vascular 
conductance (n = 18 for fish oil and n = 18 for placebo); CBF, calf blood flow (n = 16 for fish oil 
and n = 16 for placebo); CVR, calf vascular resistance (n = 16 for fish oil and n = 16 for 
placebo); CVC, calf vascular conductance (n = 16 for fish oil and n = 16 for placebo) 
*Significantly different from pre value for fish oil or placebo, respectively. 
 
 
 
Table 3.4. Baseline values for prehypertensive subjects pre and post fish oil or placebo 
supplementation. 
Variable 
  
Fish Oil Placebo Time 
Interaction 
Time x 
Drug 
InteractionPRE POST PRE POST 
FBF (units)  3.9 ± 0  3.5 ± 0  3.2 ± 0  3.4 ± 1 0.80 0.37 
FVR (mmHg/units)   27 ± 3   30 ± 3   33 ± 3   37 ± 6 0.21 0.75 
FVC 
(100*units/mmHg)  4.1 ± 0  3.9 ± 0  3.4 ± 0  3.7 ± 1 0.96 0.55 
CBF (units)  2.8 ± 0  3.0 ± 0  2.4 ± 0  2.5 ± 0 0.48 0.82 
CVR 
(100*mmHg/units)   36 ± 3   35 ± 4   42 ± 2   44 ± 5 0.92 0.57 
CVC (units/mmHg)  3.0 ± 0  3.4 ± 0  2.5 ± 0  2.7 ± 0 0.16 0.67 
Values are mean ± SE. MSNA, muscle sympathetic nerve activity (n = 11 for fish oil and n = 10 
for placebo); FBF, forearm blood flow (n = 14 for fish oil and n = 13 for placebo); FVR, forearm 
vascular resistance (n = 14 for fish oil and n = 13 for placebo); FVC, forearm vascular 
conductance (n = 14 for fish oil and n = 13 for placebo); CBF, calf blood flow (n = 14 for fish oil 
and n = 11 for placebo); CVR, calf vascular resistance (n = 14 for fish oil and n = 11 for 
placebo); CVC, calf vascular conductance (n = 14 for fish oil and n = 11 for placebo).  
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3.3.2 Resting Measurements for Combined Non-Hypertensive Subjects 
We combined normotensive and prehypertensive groups into one non-
hypertensive group in order to increase statistical power of our analyses. Combining the 
normotensive and prehypertensive groups yielded no differences in blood pressure or 
muscle sympathetic nerve activity responses after fish oil or placebo. Resting values for 
the combined groups are represented in Table 3.5. There were no significant 
interactions between fish oil and placebo supplementation groups at rest. 
 
 
 
 
Table 3.5. Baseline values for combined non-hypertensive subjects pre and post fish oil or 
placebo supplementation. 
  
  
Fish Oil Placebo Interaction 
P-Value PRE POST PRE POST 
SAP (mmHg) 117 ± 2 115 ± 2 115 ± 2 114 ± 2 0.53 
DAP (mmHg)   67 ± 1   67 ± 1   69 ± 1   69 ± 1 0.79 
MAP (mmHg)   84 ± 1   83 ± 1   84 ± 1   84 ± 2 0.67 
HR (beats/min)   72 ± 2   72 ± 2   75 ± 2   75 ± 2 0.82 
MSNA (bursts/min)   11 ± 1   10 ± 1   12 ± 1   12 ± 2 0.72 
MSNA (bursts/100hb)   17 ± 2   16 ± 2   18 ± 2   18 ± 2 0.98 
FBF (units)  3.1 ± 0.2  3.1 ± 0.2  2.6 ± 0.2  2.8 ± 0.3 0.51 
FVR (mmHg/units)   37 ± 3   35 ± 3   42 ± 3   40 ± 3 0.86 
FVC (100*units/mmHg)  3.3 ± 0.3  3.5 ± 0.3  2.7 ± 0.2  2.4 ± 0.3 0.60 
CBF (units)  2.4 ± 0.2  2.6 ± 0.2  2.3 ± 0.1  2.4 ± 0.2 0.67 
CVR (100*mmHg/units)   46 ± 3   40 ± 3   45 ± 3   42 ± 3 0.50 
CVC (units/mmHg)  2.5 ± 0.2  2.9 ± 0.2  2.4 ± 0.1  2.8 ± 0.2* 0.73 
Values are mean ± SE (n = 34 for fish oil, and n = 33 for placebo unless noted). SAP, systolic 
arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial blood pressure; HR, 
heart rate; MSNA, muscle sympathetic nerve activity (n = 27 for fish oil and n = 27 for placebo); 
FBF, forearm blood flow (n = 32 for fish oil and n = 31 for placebo); FVR, forearm vascular 
resistance (n = 32 for fish oil and n = 31 for placebo); FVC, forearm vascular conductance (n = 
32 for fish oil and n = 31 for placebo); CBF, calf blood flow (n = 30 for fish oil and n = 27 for 
placebo); CVR, calf vascular resistance (n = 30 for fish oil and n = 27 for placebo); CVC, calf 
vascular conductance (n = 30 for fish oil and n = 27 for placebo). 
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We further investigated the relationships between blood pressure changes and 
MSNA changes during rest, and these are presented as figure 3.3 and 3.4. A significant 
correlation was found between the changes in MAP and MSNA burst frequency following 
fish oil supplementation (R=0.354, P=0.03) compared to placebo (R= -0.036, P=0.86). 
Likewise, a correlation was observed when comparing changes in MAP and MSNA burst 
incidence following fish oil (R=0.325, P=0.05) and placebo (R=-0.062, P=0.758) 
supplementation. Similarly, a significant change was seen in the change in MSNA bursts 
per minute (R=-.466, P=.007), and MSNA bursts per 100 heart beats (R=-.429, P=.013) 
when compared to the resting HR before supplementation. 
 
 
 
 
 
Figure 3.2. Resting MSNA pre and post fish oil and placebo supplementation in normotensive 
and prehypertensive groups. There was no significance between pre and post treatments. 
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Figure 3.3. Linear regressions of combined non-hypertensive subjects following fish oil or 
placebo supplementation. Significance was considered as P<0.05 
 
 
3.3.3 Hemodynamic Responses to Mental Stress in Prehypertensive and Normotensive 
Subjects 
Blood pressure responses to mental stress in normotensive and prehypertensive 
subjects are represented in figure 3.4. In normotensives, mental stress significantly 
increased SAP (fish oil, ∆12 ± 2 to ∆13 ± 2 mmHg; placebo, ∆9 ± 1 to ∆8 ± 2 mmHg; 
P<.001), DAP (fish oil, ∆10 ± 1 to ∆11 ± 1 mmHg; placebo, ∆8 ± 1 to ∆8 ± 1 mmHg; 
P<.001), MAP (fish oil, ∆12 ± 1 to ∆13 ± 1 mmHg; placebo, ∆10 ± 1 to ∆9 ± 1 mmHg; 
P<.001), but these responses were similar across supplementation groups (time x 
condition x drug interactions , P>.202).  
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Figure 3.4. Linear regressions between change in MSNA and resting HR following omega-3 
supplementation in combined non-hypertensive subjects following fish oil or placebo 
supplementation. Significance was considered as P<0.05 
 
 
 
Similarly in prehypertensives, mental stress significantly increased SAP (fish oil, 
∆15 ± 3 to ∆14 ± 3 mmHg; placebo, ∆14 ± 3 to ∆14 ± 4 mmHg; P<.001), DAP (fish oil, 
∆11 ± 2 to ∆10 ± 1 mmHg; placebo, ∆11 ± 1 to ∆10 ± 2 mmHg; P<.001), MAP (fish oil, 
∆15 ± 2 to ∆13 ± 2 mmHg; placebo, ∆14 ± 2 to ∆13 ± 2 mmHg; P<.001) in both pre and 
post trials. These responses were similar across supplementation groups (time x 
condition x drug interactions, P>.388).  
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Figure 3.5. Blood pressure responses to mental stress in normotensive and prehypertensive 
subjects pre and post fish oil or placebo supplementation. *Significantly increased responses 
during mental stress, P<0.05; N.S., no significance between pre and post trials.  
 
 
 
 46
 
Figure 3.6. Heart rate responses to mental stress in normotensive and prehypertensive subjects 
pre and post fish oil or placebo supplementation. *Significantly increased responses during 
mental stress, P<0.05;  N.S., no significance between pre and post trials.  
 
Heart rate responses to mental stress are shown in figure 3.6. Mental stress 
significantly increased HR in normotensives (fish oil, ∆23 ± 2 and ∆22 ± 3 beats/min; 
placebo, ∆13 ± 1 and ∆14 ± 2 beats/min; P<.001, pre and post respectively) groups, but 
this response was blunted post fish oil compared to placebo (time x condition x drug 
interaction, P=.015). In prehypertensives, HR responses to mental stress were 
significantly increased (fish oil, ∆18 ± 2 and ∆16 ± 2 beats/min; placebo, ∆19 ± 4 and 
∆19 ± 3 beats/min; P<.001, pre and post respectively), but were not significantly different 
between fish oil and placebo groups (time x condition x drug interaction, P=.377).  
 
3.3.4 Sympathetic Nerve Responses to Mental Stress for Normotensive and 
Prehypertensive Subjects 
MSNA responses to mental stress in normotensive (Table 3.6) and 
prehypertensive (Table 3.7) subjects are presented below. Neurograms were obtained in 
only a total of 20 normotensive subjects (8 fish oil, 12 placebo), and 9 prehypertensive (4 
fish oil, 5 placebo) subjects. This number was not enough to justify statistical analysis 
due to lack of power for a time x condition x drug comparison. Therefore data are 
presented in table format. However, review of the data appears to indicate a difference 
in total MSNA in the fish oil group but not in the placebo group for both normotensive 
and prehypertensive subjects. Therefore, we pooled the normotensive and 
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prehypertensive groups together and analyzed them as a combined group. Data are 
presented in section 3.3.6. 
 
3.3.5 Peripheral Vascular Responses to Mental Stress in Prehypertensive and 
Normotensive Subjects 
Forearm blood flow responses to mental stress in normotensive and 
prehypertensive subjects are presented in figure 3.7. In normotensives, mental stress 
elicited statistically similar increases in FBF (fish oil, ∆109.1 ± 16% and ∆104.1 ± 18%; 
placebo, ∆58.9 ± 11% and ∆54.1 ± 10%; P<.001, pre and post respectively), decreases 
in FVR (fish oil, ∆-37.9 ± 5% and ∆-35.6 ± 5%; placebo, ∆-25.6 ± 5% and ∆-20.1 ± 5%; 
P<.001, pre and post respectively), and increases in FVC (fish oil, ∆86.0  ± 14% and 
∆78.4 ± 16%; placebo, ∆45.1 ± 10% and ∆39.3 ± 9%; P<.001, pre and post 
respectively).  Forearm vascular responses to mental stress were similar in both 
supplement groups (time x condition x drug interaction, P>.653).  
In prehypertensive subjects, mental stress elicited statistically similar increases in 
FBF (fish oil, ∆71.8 ± 14% and ∆50.4 ± 13%; placebo, ∆67.6 ± 17% and ∆45.6 ± 15%; 
P<.013, pre and post respectively), decreases in FVR (fish oil, ∆-18.1 ± 7% and ∆-12.6 ± 
8%; placebo, ∆-23.6 ± 7% and ∆-14.1 ± 6%, P<.05, pre and post respectively), and 
increases in FVC (fish oil, ∆48.9  ± 13% and ∆30.8 ± 11%; placebo, ∆45.4 ± 14% and 
∆31.2 ± 14%; P<.05). Similar to normotensive subjects, there were no significant 
differences between supplement groups (time x condition x drug interaction, P>.697).  
 
 
 
Table 3.6. Changes in MSNA during mental stress pre and post fish oil or placebo 
supplementation in normotensive subjects. 
 
  
  
Fish Oil Placebo 
PRE POST PRE POST 
ΔMSNA (bursts/min) 6 ± 2 7 ± 1 6 ± 2 7 ± 2 
ΔMSNA (bursts/100hb) 5 ± 4 6 ± 2 5 ± 2 5 ± 2 
ΔTotal MSNA (arb. units) 9414 ± 3145 4944 ± 849 5547 ± 1670 7463 ± 2688 
Values are mean ± SE. MSNA, muscle sympathetic nerve activity (n = 8 for fish oil and n = 12 
for placebo); Total MSNA (n = 7 for fish oil and n = 10 for placebo).  
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Table 3.7. Changes in MSNA during mental stress pre and post fish oil or placebo 
supplementation in prehypertensive subjects. 
 
  
  
Fish Oil Placebo 
PRE POST PRE POST 
ΔMSNA (bursts/min) 5 ± 3 0 ± 2 6 ± 2 4 ± 2 
ΔMSNA (bursts/100hb) 3 ± 4 -3 ± 2 1 ± 2 1 ± 3 
ΔTotal MSNA (arb. units) 17349 ± 6974 -745 ± 1273 10143 ± 2405 3402 ± 2263 
Values are mean ± SE. MSNA, muscle sympathetic nerve activity (n = 4 for fish oil and n = 5 for 
placebo); Total MSNA (n = 3 for fish oil and n = 4 for placebo).  
 
 
Figure 3.8 represents the calf vascular responses to mental stress in 
normotensive and prehypertensive subjects. In the normotensive group, mental stress 
significantly increased CBF (fish oil, ∆53 ± 12% and ∆32.9 ± 8%; placebo ∆25.2 ± 9% 
and ∆22.7 ± 10%; P<.05, pre and post respectively). Fish oil groups CVR responses to 
mental stress were mixed (fish oil, ∆-15.1 ± 7% pre; P<.04, and ∆-6.5 ± 5% post; 
P=.243), and placebo CVR responses did not change (fish oil, ∆-6.7 ± 4% and ∆-2.3 ± 
6%; P>.135, pre and post respectively). CVC significantly increased fish oil (∆36.3 ± 
11% and ∆16.1 ± 7%; P<.05, pre and post respectively), but not placebo (∆14.6 ± 8% 
and ∆10.4 ± 9%; P>.074, pre and post respectively). Fish oil supplementation blunted 
CBF (P=.011), CVR (P=.004) and CVC (P=.007) responses to mental stress in fish oil 
but not placebo.  
Prehypertensive calf vascular responses to mental stress were mixed. CBF 
increased pre and post fish oil and placebo (∆29.9 ± 9% pre, ∆19.1 ± 7% post, fish oil; 
∆23.4 ± 7% pre, ∆23 ± 8% post, placebo; P<.02), but responses were not different pre 
vs. post in either group (time x condition x drug interaction, P>.160). CVR did not change 
during mental stress (∆3.1 ± 9% pre, ∆3.2 ± 6% post, fish oil; ∆-0.6 ± 5% pre, ∆-3.1 ± 6% 
post, placebo; P=.883), nor was there a difference pre vs. post in either fish oil or 
placebo group (time x condition x drug interaction, P=.781). Similarly, CVC did not 
change during mental stress (∆12.1 ± 8% pre, ∆3.74 ± 7% post, fish oil; ∆6.2 ± 6% pre, 
∆5.8 ± 5% post, placebo; P=.093), and these responses were not different when 
comparing pre vs. post supplement (time x condition x drug interaction, P=.233). 
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Figure 3.7. Changes (Δ) in forearm blood flow (FBF), vascular resistance (FVR) and vascular 
conductance (FVC) during mental stress in normotensive and prehypertensive subjects pre and 
post fish oil or placebo supplementation. *Significantly increased or decreased responses during 
mental stress, P<0.05; N.S., no significance between pre and post trials.  
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Figure 3.8. Changes (Δ) in calf blood flow (CBF), vascular resistance (CVR) and vascular 
conductance (CVC) during mental stress in normotensive and prehypertensive subjects pre and 
post fish oil or placebo supplementation. *Significantly increase or decrease responses during 
mental stress, P<0.05; N.S., no significance between pre and post trials.  
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3.3.6 Responses to Mental Stress for Combined Non-Hypertensive Subjects 
Combined blood pressure and heart rate responses to mental stress between 
fish oil and placebo trials are represented in figure 3.8. Mental stress significantly 
increased SAP (fish oil, ∆13 ± 2 mmHg to ∆13 ± 2 mmHg; placebo, ∆11 ± 1 to ∆11 ± 2 
mmHg; P<.001), DAP (fish oil, ∆10 ± 1 to ∆10 ± 1 mmHg; placebo, ∆9 ± 1 to ∆9 ± 1 
mmHg; P<.001), and MAP (fish oil, ∆13 ± 1 to ∆13 ± 1 mmHg; placebo, ∆11 ± 1 to ∆11 ± 
1 mmHg; P<.001). However, blood pressure responses were not different following fish 
oil or placebo supplementation (time x condition x drug interaction; P>.340). HR 
responses to mental stress were attenuated following fish oil supplementation (fish oil, 
21.8 ± 2 to Δ19.0 ± 2 beats/min, P=.002), but not placebo (Δ15.3 ± 2 to Δ15.5 ± 2 
beats/min, P=.801). 
MSNA responses to mental stress are represented in figure 3.9. MSNA burst 
frequency (fish oil, ∆6 ± 2 and ∆5 ± 1 bursts/min; placebo, ∆6 ± 1 and ∆6 ± 1 bursts/min; 
P<.001, pre and post respectively) and MSNA burst incidence (fish oil, ∆4 ± 2 and ∆3 ± 3 
bursts/100hb; placebo, ∆4 ± 2 and ∆4 ± 2 bursts/100hb; P<.001) significantly increased. 
However, there were no differences between supplementation groups (time x condition x 
drug interaction, P>.700). In contrast, total MSNA (figure 3.10) was reduced post fish oil 
(Δ9628 ± 2407 to Δ3830 ± 1029 a.u., P=.029), but not in the placebo group (Δ6860 ± 
1463 to Δ6302 ± 2042 a.u., P=.756).  
Combined forearm vascular responses to mental stress are shown in figure 3.12. 
Mental stress increased FBF (fish oil, ∆92 ± 11% and ∆80 ± 11%; ∆62 ± 9% and ∆51 ± 
8%; P<.001, pre and post respectively), FVC (fish oil, ∆69 ± 10% and ∆57 ± 11%; 
placebo, ∆45 ± 8% and ∆36 ± 8%; P<.001, pre and post respectively), but there were no 
significant differences between groups (time x condition x drug interaction P>.800). 
Similarly, mental stress decreased FVR (fish oil, ∆-30 ± 4% and ∆-25 ± 5%; placebo, ∆-
25 ± 4% and ∆-18 ± 4%; P<.001, pre and post respectively), but these responses were 
not significant between groups (time x condition x drug interaction P=.733). 
 
 
 52
 
 
Figure 3.9. Changes (Δ) in systolic (SAP), diastolic (DAP), mean (MAP) arterial pressures and 
heart rate (HR) during mental stress in combined normotensive and prehypertensive (non-
hypertensive) subjects pre and post fish oil or placebo supplementation. *Significantly increased 
responses during mental stress, P<0.05; N.S., no significance between pre and post trials. 
 
Combined calf vascular responses to mental stress are shown in figure 3.13. 
Mental stress increased CBF (fish oil, ∆42 ± 8% and ∆27 ± 6%; placebo, ∆25 ± 6% and 
∆23 ± 7%; P<.002, pre and post respectively). However, the fish oil group demonstrated 
a blunted calf vascular response during mental stress compared to placebo (time x 
condition x drug interaction, P=.004). Mental stress did not change CVR in either the fish 
oil (∆-7 ± 6% and ∆-2 ± 4% pre and post respectively) or placebo (∆-4 ± 3% and ∆-3 ± 
4%, pre and post respectively). Mental stress significantly increased CVC in the fish oil 
group (∆25 ± 7% and ∆10 ± 5%; P<.05, pre and post respectively), but only during the 
pre testing in the placebo group (∆11 ± 5% pre, P<.012, ∆10 ± 6% post; P<.147). Fish oil 
significantly blunted the vascular conductance response (P=.003) in the calf compared 
to no change in the placebo group at rest (time x condition x drug interaction P=.034). 
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Figure 3.10. Changes (Δ) in muscle sympathetic nerve activity (MSNA), expressed as bursts per 
minute and bursts per 100 heartbeats, during mental stress in combined normotensive and 
prehypertensive (non-hypertensive) subjects pre and post fish oil or placebo supplementation. 
*Significantly increased responses during mental stress, P<0.05; N.S., no significance between 
pre and post trials. 
 
 
 
 
 
 
 
 
 
Figure 3.11. Changes (Δ) in muscle sympathetic nerve activity (MSNA), expressed as total 
activity, during mental stress in combined normotensive and prehypertensive (non-hypertensive) 
subjects pre and post fish oil or placebo supplementation. *Significantly increased responses 
during mental stress, P<0.05; N.S., no significance between pre and post trials. 
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Figure 3.12. Changes (Δ) in forearm blood flow (FBF), vascular resistance (FVR) and vascular 
conductance (FVC) during mental stress in combined normotensive and prehypertensive (non-
hypertensive) subjects pre and post fish oil or placebo supplementation. *Significantly increased 
or decreased responses during mental stress, P<0.05; N.S., no significance between pre and 
post trials.  
 
 
 
 
 
 55
 
 
 
 
 
 
Figure 3.13. Changes (Δ) in calf blood flow (CBF), vascular resistance (CVR) and vascular 
conductance (CVC) during mental stress in combined normotensive and prehypertensive (non-
hypertensive) subjects pre and post fish oil or placebo supplementation. *Significantly increased 
or decreased responses during mental stress, P<0.05; N.S., no significance between pre and 
post trials. 
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3.4 Discussion 
The current investigation offers several new and novel insights into the 
mechanistic influence of omega-3 fatty acids on neural and cardiovascular function. 
First, fish oil did not reduce that resting blood pressure or MSNA in either normotensive 
or prehypertensive individuals. However, further analysis of combined groups revealed a 
significant correlation between changes in arterial pressure and changes in MSNA 
following fish oil supplementation. This suggests that fish oil may have an influence on 
the sympathetic nervous system in individuals who experience a reduction in blood 
pressure following fish oil supplementation. Second, fish oil attenuated heart rate 
response during mental stress, and this effect may be mediated by the sympathetic 
nervous system (i.e., total MSNA). Third, omega-3 supplementation may improve 
peripheral vascular function at rest, but this does not appear to be specific to fish oils. 
Combined, these observations offer new information regarding the mechanistic affect 
omega-3s have on cardiovascular function at rest and during mental stress. 
 
3.4.1 Resting Neurovascular Responses to Omega-3 supplementation 
Fish oil has been suggested to lower blood pressure in hypertensive rather than 
normotensive individuals (Appel et al., 1993; Morris et al., 1993). This is the first study to 
investigate the effect of fish oil in prehypertension. Contrary to our original hypothesis, 
fish oil supplementation did not reduce resting blood pressure or resting MSNA in 
prehypertensive individuals. This finding is consistent with a prior study demonstrating 
no effect of fish oil on resting blood pressure, heart rate or MSNA in healthy 
normotensive individuals (Monahan et al., 2004).  However, we did observe a modest, 
yet significant, positive correlation between change in sympathetic nerve activity and 
change in blood pressure in the fish oil group. More specifically, subjects demonstrating 
a decrease of blood pressure after supplementation demonstrated a concomitant 
decrease in MSNA. Similarly, we found that a decrease in resting heart rate was 
significantly correlated with subject’s resting blood pressure. It appears that fish oil may 
have a bradycardic influence as resting arterial pressure increases. Sympathetic nerve 
activity plays a strong role in both blood pressure regulation and heart rate. Our findings 
provide new evidence that fish oil may, in part, reduce blood pressure and heart rate via 
sympathetic neural mechanisms. 
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To date, only one study has investigated the effect of fish oil on MSNA. Monahan 
et al. (2004) reported that fish oil did not alter resting MSNA levels, however the 
relationship between changes in MSNA and changes in blood pressure or heart rate 
were not examined. It has been reported that resting heart rate decreases more 
dramatically in patients with elevated resting heart rates following fish oil 
supplementation (Mozaffarian et al., 2005). Additionally, EPA and DHA have been 
reported to lower plasma norepinephrine in healthy volunteers (Hamazaki et al., 2005), 
and improve heart rate variability measures in older adults (Mozaffarian et al., 2008). 
These studies support our finding of altered autonomic function as a potential 
mechanism by which fish oil works to reduce cardiovascular risk. A large scale, 
longitudinal investigation on cardiovascular disease known as the Framingham study 
reported that elevated heart rate is linked with a higher incidence of cardiac mortality 
(Kannel et al., 1987). Additionally, a decrease in heart rate may have significant 
implications in cardiovascular health (Jouven et al., 2001). We suggest the sympathetic 
nervous system as a potential mechanism in the reduction of cardiovascular disease 
from fish oil. However, we recognize this is unlikely to be the only mechanism by which 
fish oil can play a role in cardiovascular disease prevention. 
 
3.4.2 Neurovascular Responses to Mental Stress Pre and Post Omega-3 
Supplementation 
Fish oil has been suggested to reduce blood pressure through several 
mechanisms including altered endothelial function, reduced vascular restriction, and 
changes in the autonomic nervous system (Kannel et al., 1987; Mori & Woodman, 
2006). During mental stress, the classic physiological response is increased heart rate, 
blood pressure and sympathetic nerve activity with reduced vasoconstriction to the 
forearm. However the affect of omega-3 fatty acids on these neurovascular mechanisms 
has not been previously investigated. 
Currently, only one study has examined the cardiovascular effects of omega-3 
fatty acids during mental stress in humans. Delarue et al. (2003) reported that the 
circulating plasma catecholamine responses were blunted during mental stress following 
fish oil supplementation (Delarue et al., 2003). Mental stress is known to simultaneously 
increase norepinephrine and epinephrine (Esler et al., 1984b). However, epinephrine 
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appears to increase more dramatically during psychological stimulation compared to 
norepinephrine (LeBlanc et al., 1979; Dimsdale & Moss, 1980). The epinephrine 
response during mental stress has been linked to sympathetic activation of the adrenal 
medulla (Reims et al., 2004). We did not analyze circulating catecholamines in the 
present study. However, MSNA is known to be a robust model of measuring direct 
sympathetic neural activity. Additionally, it has been demonstrated that MSNA correlates 
strongly with norepinephrine spillover analysis (Wallin et al., 1992; Kingwell et al., 1994). 
Fish oil did not alter MSNA burst frequency or burst incidence responses to 
mental stress, but did reduce total MSNA. This divergent sympathetic response may be 
an important distinction in understanding potential mechanisms underlying the effect of 
fish oil on the sympathetic nervous system during stress. Previously, it has been 
suggested that sympathetic burst activity and total MSNA operate off of two separate 
central nervous system (CNS) inputs (Reims et al., 2004). The generation of a burst is 
suggested to be controlled through a gated (i.e. on/off) mechanism, while the total 
MSNA appears to operate via graded input. Whereas this gated mechanism may 
operate off of one CNS input, the graded mechanism may respond to multiple CNS 
inputs (Kienbaum et al., 2001; Keller et al., 2006). Recently, Keller et al. (2006) 
demonstrated that whole body heating increased burst activity (i.e. via the gating 
mechanism), but did not affect the total MSNA response, supporting the theory 
presented by Kienbaum et al. (2001) that these two mechanisms of muscle sympathetic 
nerve activity operate on two separate CNS inputs. Using this information, Steinback et 
al. (2010) began to investigate the neuron recruitment strategies of the sympathetic 
nerves that cause a greater burst size (i.e. total MSNA). Steinback et al. (2010) showed 
that the neuron recruitment in muscle sympathetic nerves may follow a similar pattern as 
the recruitment of skeletal muscle fibers proposed by Henneman et al. (1965). This 
theory proposes that recruitment of fibers is graded based on size, where the smaller 
slower fibers are recruited first followed by bigger fibers as greater force or stimulation is 
required (Henneman et al., 1965; Keller et al., 2006). Collectively, physical stressors 
have demonstrated different mechanisms in increasing MSNA activity through burst 
activity (Steinback et al., 2010) or through total MSNA (Keller et al., 2006). Mental stress 
typically increases both burst activity and total MSNA (Anderson et al., 1991; Callister et 
al., 1992). Based on the previous findings of Kienbaum et al. (2001), this suggests that 
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multiple mechanisms are influencing CNS control over sympathetic nerve activity during 
mental stress. The current study suggests that fish oil blunts the total MSNA response to 
mental stress, but not the burst frequency. This infers that fish oil may be affecting 
sympathetic neuron recruitment more so than a gating mechanism.  
The current study demonstrated a blunted heart rate response to mental stress in 
the fish oil group but not the placebo in combined subjects (i.e., normotensive and 
prehypertensive groups). There are several possible mechanisms that could contribute 
to a reduction in heart rate. One such mechanism is sympathetic withdrawal which we 
have demonstrated through blunted total MSNA. Another mechanism could be an 
increase in parasympathetic nerve activity. Previous research has suggested that 
parasympathetic tone increases following fish oil supplementation (Mozaffarian et al., 
2008) and it has been suggested that hypertensive individuals have reduced 
parasympathetic activation on the heart during mental stress (Das, 2000). The only 
method for indirectly measuring parasympathetic nerve activity is via spectral analysis of 
heart rate variability. One recent study found that fish oil did not affect HRV during 
physiological stressors in dogs (Billman & Harris, 2011). Though we analyzed heart rate 
variability, the results did not offer any clear insight into the effects of omega 3 fatty acids 
on parasympathetic activity in normotensive or prehypertensives during mental stress. 
Therefore the affect of omega-3 fatty acids on the parasympathetic nervous system 
during mental stress remains equivocal.  
Finally, altered vascular function has also been proposed as a potential 
mechanism for the cardiovascular benefits associated with fish oil. In the present study 
we monitored forearm and calf vascular response to mental stress. Whereas the BP, HR 
and MSNA responses to mental stress between prehypertensive and normotensive (as 
well as combined subjects) showed a clear picture of the effects of fish oil, the peripheral 
vascular responses to mental stress post omega-3 supplementation were inconsistent. 
At rest, the combined non-hypertensive individuals demonstrated increased baseline 
forearm blood flow, but there was no difference between fish oil and placebo. In contrast 
to the forearm response, there were no significant changes in calf vascular function at 
rest. Moreover, vascular responses to mental stress did not change in response to fish 
oil or placebo. These findings provide inconclusive evidence as to the effects of omega-3 
fatty acids on the peripheral vasculature, although it is clear that fish oil and placebo 
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appeared to not have any consistent influence on either forearm or calf vascular 
responses to mental stress. The selective improvement of omega-3 fatty acids on resting 
forearm vascular function remains unclear. The evidence that there was no difference 
between fish oil and placebo might suggest methodological flaws. The current study 
used olive oil as the placebo treatment, which is an omega-3 fatty acid. Olive oil is 
commonly used in placebo-based fish oil studies (Monahan et al., 2004), but may have a 
beneficial effect on vascular function similar to that suggested by fish oil. It has been 
previously reported that olive oil may contribute to improvement in endothelial function, 
inflammation, and decrease the risk of cardiovascular disease (Ruediger et al., 2004). 
To this point, most research using olive oil as a placebo in a fish oil based study have 
found fish oil to be more effective at lowering blood pressure, and therefore it is 
commonly used as a placebo. Our findings suggest that olive oil may exert some 
positive vascular adaptations, thus may not be an ideal placebo. More research 
comparing olive oil and fish oil appears warranted to establish the true mechanisms 
behind  
In conclusion, we found that fish oil does not consistently decrease resting 
arterial blood pressure or MSNA in normotensive or prehypertensive humans. However, 
changes in arterial blood pressure are significantly correlated to changes in MSNA after 
fish oil, suggesting the sympathetic nervous system does play a role when a fish oil-
induced hypotensive response is observed. Moreover, fish oil decreased heart rate and 
total MSNA responses to mental stress, suggesting fish oil may have positive health 
benefits regarding neural cardiovascular reactivity in humans. These findings provide 
new mechanistic insight into nonpharmacological approaches to treating and/or 
preventing hypertension and other cardiovascular conditions.  
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Chapter 4 
Summary and Future Directions 
4.1  Summary 
Prehypertension is a relatively new classification of blood pressure. This moderate level 
of blood pressure has been linked to a heightened risk of future development of 
hypertension (Zhang et al., 2006; Egan & Julius, 2008). However, the mechanisms 
responsible for this increased risk are not fully understood. Earlier research investigating 
borderline hypertensives indicates that the neurovascular system may play a key role in 
the development of cardiovascular disease (Mark, 1984; Anderson et al., 1989; 
Santangelo et al., 1989; Matsukawa et al., 1991), and mental stress may potentiate this. 
However, these mechanisms have not been investigated in prehypertensive patients. It 
is becoming increasingly important to use preventative measures to decrease the 
increasing incidence of hypertension and cardiovascular disease. Therefore, we 
conducted two investigations to further our understanding of the mechanisms 
contributing to prehypertension (Study 1), and the role of non-pharmacological 
intervention via fish oil in this same population (Study 2).  
In Study 1 we investigated possible mechanisms contributing to prehypertension 
in young males including sympathetic nerve activity and peripheral vascular responses 
to mental stress. In Study 2 we added omega-3 fatty acids from fish oil to the normal 
diet of young males and females in order to investigate the mechanisms behind the 
cardiovascular effects of fish oil on blood pressure and mental stress. We found several 
novel findings which may lead to a better understanding of prehypertension, 
hypertension and the role omega-3 fatty acids have on the cardiovascular system.  
From Study 1 we were able to demonstrate that young prehypertensive males 
experience augmented blood pressure responses to a mental stress task compared to 
their normotensive counterparts. These responses appear to be linked to a blunted 
peripheral vasodilation, not an increase in sympathetic nerve activity. Study 2 
demonstrated that fish oil had no discernable influence on cardiovascular and nervous 
system function at rest in prehypertensive or normotensive humans. However, further 
analysis of the data revealed that fish oil may have had a variable response such that 
individuals who experienced a decrease in blood pressure also demonstrated a 
concomitant decrease in MSNA. Moreover, fish oil reduced neural (i.e., total MSNA) and 
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cardiovascular (i.e., heart rate) reactivity to mental stress.  Robust cardiovascular 
reactivity has been shown to increase the risk of future development of hypertension 
(Matthews et al., 1993). 
These are the first studies to collectively investigate the neurocardiovascular 
responses to mental stress both before and after fish oil supplementation in 
prehypertensive humans. We have several novel findings that further our understanding 
of prehypertension, hypertension and the possible role that fish oil might play in disease 
prevention. However, the novel discoveries also introduced more questions that could be 
answered in future investigations 
 
4.2  Future Directions – Nitric Oxide 
We have suggested that prehypertensive individuals demonstrate blunted 
vascular responses to mental stress, and these responses were not mediated through 
MSNA. Our study only measured whole limb changes blood flow during mental stress. 
We were unable to investigate other mechanisms that contribute to increased blood flow 
in the limbs, such as nitric oxide (NO). It has been demonstrated that vascular 
endothelial cells have the ability to secrete NO as a powerful local vasodilator (Radomski 
et al., 1987; Shepherd & Katusic, 1991). The release of NO has been suggested to be 
mediated by both shear stress on the vascular wall, and by the nervous system, both of 
which can be affected by hypertension. In humans, mental stress has elicited a NO-
mediated forearm vasodilatory response (Dietz et al., 1994; Cardillo et al., 1997), and a 
response that has been blunted hypertensive individuals (Cardillo et al., 1998). 
Collectively, it is possible that nitric oxide could be playing an important role in the 
blunted responses we observe in prehypertensive individuals during mental stress. 
Interestingly, one mechanism by which omega-3 fatty acids has been suggested to lower 
blood pressure is through nitric oxide mediators (Harris et al., 1997; De Caterina et al., 
2000). Future research should investigate the role of nitric oxide in peripheral 
vasodilation in prehypertension. 
 
4.3  Conclusion 
This dissertation reports novel and clinically relevant information regarding the 
prehypertensive population. Furthermore, we have comprehensively investigated the 
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role of fish oil plays on neurovascular function. It is clear that there are altered vascular 
responses to a psychological stress response in prehypertensives, and these responses 
may be contributing to the further development of hypertension. As public knowledge of 
prehypertension begins to grow, it will be important to use this classification as an early 
indicator for preventative care in order to reduce the risks of cardiovascular disease. 
Fish oil is one current method that is prescribed as a preventative mechanism. We report 
mixed results regarding the influence of fish oil on neurovascular control in humans. 
However, our findings suggest a potentially important interaction between fish oil, the 
sympathetic nervous system, and arterial blood pressure, especially regarding neural 
and hemodynamic responses to mental stress.  
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Appendix A 
Table A.1.  Raw data for subject characteristics in normotensive group for Study 1. 
 
Subject Age (yrs) Height (cm) Weight (kg) BMI (kg/m2) Gender 
1 25 176 100 32 Male 
2 18 173 71 24 Male 
3 19 177 60 19 Male 
4 23 179 66 21 Male 
5 20 167 63 23 Male 
6 18 185 98 29 Male 
7 39 168 60 21 Male 
8 19 196 106 28 Male 
9 20 185 60 18 Male 
10 19 177 75 24 Male 
11 22 184 80 24 Male 
12 18 170 63 22 Male 
13 20 174 79 26 Male 
14 23 161 70 27 Male 
15 22 181 72 22 Male 
16 19 179 91 28 Male 
17 40 184 89 26 Male 
18 30 170 77 27 Male 
 
 
BMI; Body Mass Index 
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Table A.2.  Raw data for subject characteristics in prehypertensive group for Study 1. 
 
 
Subject Age (yrs) Height (cm) Weight (kg) BMI (kg/m2) Gender 
1 32 184 97 29 Male 
2 19 178 83 26 Male 
3 20 178 84 27 Male 
4 22 178 84 27 Male 
5 21 176 77 25 Male 
6 21 179 87 27 Male 
7 23 183 92 27 Male 
8 21 179 67 21 Male 
9 19 185 81 24 Male 
10 18 166 85 31 Male 
11 20 189 92 26 Male 
12 20 174 95 31 Male 
13 23 177 76 24 Male 
14 21 184 84 25 Male 
15 21 173 82 27 Male 
16 28 189 86 24 Male 
17 20 174 81 27 Male 
 
 
 
BMI; Body Mass Index 
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Table A.3 Raw data for seated resting measurements in normotensive group for Study 1. 
 
Subject 
SAP 
(mmHg) 
DAP 
(mmHg)
MAP 
(mmHg)
HR 
(beats/min) 
1 116.3 61.6 79.8 71.0 
2 116.3 62.1 80.2 74.8 
3 107.8 64.2 78.7 82.8 
4 110.0 57.0 74.7 60.0 
5 108.6 68.2 81.7 73.6 
6 116.4 76.2 89.6 68.9 
7 103.3 65.0 77.8 68.9 
8 117.4 69.6 85.5 63.9 
9 109.0 56.0 73.7 58.1 
10 109.3 63.4 78.7 47.7 
11 113.6 65.6 81.6 72.3 
12 111.7 65.2 80.7 68.0 
13 103.4 66.2 78.6 60.3 
14 115.7 62.9 80.5 78.9 
15 106.0 51.6 69.7 73.3 
16 119.0 65.0 83.0 59.4 
17 111.0 67.2 81.8 77.9 
18 116.2 71.4 86.3 73.3 
 
 
SAP; Systolic Arterial Pressure 
 
DAP; Diastolic Arterial Pressure 
 
MAP; Mean Arterial Pressure 
 
HR; Heart Rate 
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Table A.4. Raw data for seated resting measurements in prehypertensive group for Study 1 
 
Subject 
SAP 
(mmHg)
DAP 
(mmHg)
MAP 
(mmHg)
HR 
(beats/min) 
1 120.3 66.4 84.4 60.6 
2 132.9 77.0 95.6 69.6 
3 118.0 81.0 93.3 81.8 
4 125.0 71.0 89.0 84.0 
5 139.9 77.4 98.2 71.4 
6 139.7 84.4 102.8 59.1 
7 133.0 66.0 88.3 77.0 
8 124.7 69.1 87.6 80.7 
9 121.5 67.5 85.5 68.6 
10 122.4 72.8 89.3 95.0 
11 122.0 63.6 83.1 64.3 
12 121.2 78.8 92.9 95.0 
13 133.4 73.8 93.7 72.3 
14 123.6 69.6 87.6 88.9 
15 121.9 50.2 74.1 55.7 
16 128.6 69.0 88.9 75.7 
17 125.6 62.4 83.5 71.1 
 
 
SAP; Systolic Arterial Pressure 
 
DAP; Diastolic Arterial Pressure 
 
MAP; Mean Arterial Pressure 
 
HR; Heart Rate 
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Table A.5.  Raw data for 5 minute average measurements of systolic arterial pressure as 
measured by the finometer in normotensive group for Study 1. 
 
Subject Base MS  Rec 
1 138.5 158.3 154.3 
2 133.9 145.4 134.9 
3 115.5 114.2 104.1 
4 108.4 132.6 110.6 
5 127.7 135.2 130.9 
6 124.0 134.0 117.1 
7 123.1 124.0 112.7 
8 121.7 124.0 120.8 
9 122.1 133.3 131.0 
10 120.6 118.8 124.9 
11 128.5 144.7 135.3 
12 127.1 124.3 129.7 
13 118.6 121.5 118.6 
14 133.8 147.7 137.9 
15 116.0 131.7 108.0 
16 129.1 133.1 132.9 
17 129.6 137.2 127.8 
18 120.6 139.1 132.3 
 
 
Base; Baseline 
 
MS; Mental Stress  
 
Rec; Recovery 
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Table A.6.  Raw data for 5 minute average measurements of systolic arterial pressure as 
measured by the finometer in prehypertensive group for Study 1. 
 
Subject Base MS  Rec 
1 124.8 135.7 129.3 
2 141.2 150.1 146.9 
3 138.6 145.0 133.2 
4 107.3 130.8 122.7 
5 141.5 157.1 145.4 
6* -- -- -- 
7 122.1 152.1 131.4 
8 129.7 155.6 135.1 
9 123.7 134.8 131.0 
10 121.7 123.7 121.7 
11 117.7 129.4 114.5 
12 110.1 118.2 112.4 
13 136.4 146.4 141.7 
14 118.8 138.9 123.8 
15 123.6 137.3 129.1 
16 129.2 144.2 132.8 
17 144.2 155.9 141.7 
 
* Subject data not collected due to Finometer equipment malfunction during protocol. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.7.  Raw data for 5 minute average measurements of diastolic arterial pressure as 
measured by the finometer in normotensive group for Study 1. 
 
Subject Base MS  Rec 
1 78.3 94.4 87.0 
2 76.7 88.1 76.5 
3 79.8 85.2 76.1 
4 60.7 71.9 59.9 
5 67.4 76.2 68.5 
6 72.1 76.2 69.9 
7 66.8 74.2 65.2 
8 71.9 75.0 74.1 
9 71.1 80.5 76.2 
10 71.6 74.9 75.0 
11 68.7 79.6 72.3 
12 73.4 78.9 74.5 
13 73.5 79.1 75.0 
14 83.2 95.4 86.3 
15 68.5 80.9 67.4 
16 68.8 72.4 70.3 
17 71.5 77.8 71.6 
18 72.8 82.4 76.7 
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Table A.8.  Raw data 5 minute average measurements of diastolic arterial pressure as measured 
by the finometer in prehypertensive group for Study 1. 
 
Subject Base MS  Rec 
1 74.7 81.7 75.9 
2 74.1 83.6 73.8 
3 81.9 92.9 82.4 
4 80.8 92.1 78.5 
5 75.6 87.5 77.6 
6* -- -- -- 
7 71.4 94.3 73.2 
8 70.9 87.0 72.7 
9 71.9 83.1 73.2 
10 70.0 73.6 70.4 
11 64.4 72.4 65.9 
12 66.8 76.4 67.3 
13 84.5 89.2 88.4 
14 71.8 82.3 73.7 
15 66.3 79.4 69.9 
16 70.2 80.8 72.7 
17 68.4 79.4 69.4 
 
* Subject data not collected due to Finometer equipment malfunction during protocol. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.9. Raw data 5 minute average measurements of mean arterial pressure as measured by 
the finometer in normotensive group for Study 1. 
 
Subject Base MS  Rec 
1 97.2 116.6 109.5 
2 98.5 110.7 98.6 
3 93.5 97.5 88.2 
4 76.3 93.1 77.7 
5 88.6 98.9 91.2 
6 89.2 94.6 86.3 
7 87.5 92.6 83.7 
8 87.3 90.9 89.2 
9 87.7 99.1 94.9 
10 85.8 90.2 90.9 
11 89.1 103.6 94.3 
12 91.1 95.7 93.5 
13 89.1 95.0 91.1 
14 101.2 116.2 105.7 
15 82.2 99.4 80.6 
16 88.2 93.3 90.9 
17 90.9 98.9 91.7 
18 90.4 104.5 97.6 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Appendix A.10.  Raw data for 5 minute average measurements of mean arterial pressure as 
measured by the finometer in prehypertensive group for Study 1. 
 
Subject Base MS  Rec 
1 90.4 101.0 93.1 
2 97.9 110.3 100.3 
3 100.6 111.9 100.6 
4 90.7 107.6 93.9 
5 97.5 115.4 101.1 
6* -- -- -- 
7 90.0 114.0 93.8 
8 90.1 111.3 93.2 
9 90.1 102.4 93.4 
10 83.8 89.5 85.1 
11 79.5 90.4 81.3 
12 80.8 91.6 82.3 
13 102.3 111.9 107.5 
14 85.5 101.4 89.2 
15 84.0 99.4 88.9 
16 89.7 103.5 93.5 
17 88.6 101.9 88.7 
 
* Subject data not collected due to Finometer equipment malfunction during protocol. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.11.  Raw data for 5 minute average measurements of heart rate as measured by the 
finometer in normotensive group for Study 1. 
 
Subject Base MS  Rec 
1 67.7 94.9 75.5 
2 74.6 126.2 79.7 
3 65.7 98.1 65.1 
4 51.1 73.8 50.4 
5 64.1 80.6 63.3 
6 68.8 73.5 69.5 
7 61.6 76.4 59.2 
8 57.2 60.1 57.5 
9 48.8 74.8 49.5 
10 47.7 72.9 48.6 
11 66.7 91.8 67.5 
12 62.0 92.6 61.7 
13 52.9 69.9 53.5 
14 58.0 74.3 57.8 
15 58.2 75.7 57.4 
16 54.6 72.8 58.6 
17 60.8 68.0 61.6 
18 64.0 88.1 67.0 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.12  Raw data for 5 minute average measurements of heart rate as measured by the 
finometer in prehypertensive group for Study 1. 
 
Subject Base MS  Rec 
1 51.2 64.8 53.4 
2 71.0 87.9 67.7 
3 72.0 83.7 76.0 
4 81.2 88.3 77.1 
5 67.4 84.3 65.0 
6 49.6 73.6 54.0 
7 71.2 128.9 80.9 
8 80.3 114.2 83.2 
9 62.0 73.8 64.6 
10 71.9 92.7 78.8 
11 52.9 70.6 58.0 
12 77.4 88.9 77.4 
13 69.1 86.6 70.0 
14 79.1 86.2 78.6 
15 51.8 66.4 54.5 
16 63.5 72.1 65.8 
17 63.5 76.1 60.9 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.13. Raw data for 5 minute average measurements of muscle sympathetic nerve activity 
(MSNA) bursts/min in normotensive group for Study 1. 
 
 
Subject Base MS Rec 
1 8.6 12.4 6.4 
2 2.6 -- -- 
3 -- -- -- 
4 6.6 12.6 11.6 
5 6.2 24.2 7.8 
6 15.6 21.2 19.2 
7 9.2 21.0 16.4 
8 6.0 -- -- 
9 4.0 5.8 3.2 
10 -- -- -- 
11 -- -- -- 
12 8.8 11.8 13.2 
13 16.0 17.0 28.0 
14 10.6 -- -- 
15 4.0 14.0 9.2 
16 10.4 -- -- 
17 29.4 37.2 29.6 
18 8.2 -- -- 
 
Missing data is due to either loss of nerve recordings during protocol, or unsuccessful location of 
nerve activity. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.14. Raw data for 5 minute average measurements of MSNA bursts/min in 
prehypertensive group for Study 1. 
 
 
Subject Base MS Rec 
1 7.0 -- -- 
2 27.0 31.7 -- 
3 25.2 29.2 28.8 
4 11.4 32.4 17.0 
5 -- -- -- 
6 3.4 -- -- 
7 8.2 19.0 23.4 
8 3.8 9.6 6.2 
9 2.8 6.2 6.0 
10 7.2 -- -- 
11 18.0 -- -- 
12 7.0 -- -- 
13 10.8 12.6 15.2 
14 17.0 11.8 17.8 
15 8.0 13.6 13.0 
16 4.5 9.0 7.3 
17 6.4 20.3 -- 
        
Missing data is due to either loss of nerve recordings during protocol, or unsuccessful location of 
nerve activity. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.15. Raw data for 5 minute average measurements of MSNA bursts per 100 heart beats 
in normotensive group for study 1. 
 
 
Subject Base MS Rec 
1 12.7 13.2 8.4 
2 3.5 -- -- 
3 -- -- -- 
4 12.9 17.9 23.1 
5 9.7 30.2 12.4 
6 23.1 29.1 28.3 
7 15.0 27.7 28.0 
8 10.9 -- -- 
9 8.3 7.8 6.5 
10 -- -- -- 
11 -- -- -- 
12 14.2 12.8 21.5 
13 30.4 24.4 52.8 
14 18.4 -- -- 
15 6.96 18.6 16.1 
16 19.1 -- -- 
17 48.6 54.6 48.2 
18 12.9 -- -- 
 
Missing data is due to either loss of nerve recordings during protocol, or unsuccessful location of 
nerve activity. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.16. Raw data for 5 minute average measurements of MSNA bursts per 100 heart beats 
in prehypertensive group for study 1. 
 
 
Subject Base MS Rec 
1 13.7 -- -- 
2 38.7 36.8 -- 
3 35.0 35.1 38.0 
4 14.1 36.9 22.0 
5 -- -- -- 
6 7.0 -- -- 
7 11.7 14.2 29.1 
8 4.8 8.4 7.4 
9 4.6 8.4 9.4 
10 10.5 -- -- 
11 34.2 -- -- 
12 9.1 -- -- 
13 15.7 14.5 21.8 
14 21.7 13.8 22.7 
15 15.4 20.6 23.8 
16 7.2 12.5 11.2 
17 10.1 26.1 -- 
    
Missing data is due to either loss of nerve recordings during protocol, or unsuccessful location of 
nerve activity. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.17.   Raw data for 5 minute average measurements of total MSNA (arbitrary units) in 
normotensive group for study 1. 
 
 
Subject Base MS Rec 
1 4665.4 12323.9 4687.6 
2 2265.5 -- -- 
3 -- -- -- 
4 3346.8 12917.3 9870.0 
5 3143.7 16129.0 2970.2 
6 7878.0 8252.9 6569.8 
7 2350.2 7873.3 3258.2 
8 2185.5 -- -- 
9 1921.1 4301.4 1921.2 
10 -- -- -- 
11 -- -- -- 
12 4209.9 6218.5 4504.8 
13 6464.1 13705.9 11897.5 
14 6906.8 -- -- 
15 1286.6 8854.8 3526.3 
16 4874.6 -- -- 
17 -- -- -- 
18 3072.2 -- -- 
 
Missing data is due to either loss of nerve recordings during protocol, or unsuccessful location of 
nerve activity. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.18.   Raw data for 5 minute average measurements of total MSNA (arbitrary units) in 
prehypertensive group for study 1. 
 
 
Subject Base MS Rec 
1 3919.4 -- -- 
2 15174.3 25679.3 -- 
3 9522.4 26003.6 9210.4 
4 4552.6 22021.3 7797.7 
5 -- -- -- 
6 2048.1 -- -- 
7 -- -- -- 
8 2427.1 7951.7 2560.0 
9 1349.4 4434.6 4417.1 
10 2875.2 -- -- 
11 9547.2 -- -- 
12 3173.9 -- -- 
13 4089.3 14199.4 6910.5 
14 8623.5 9246.8 9207.2 
15 4086.3 7066.5 5199.3 
16 1722.9 3605.4 2304.8 
17 4365.1 13956.6 -- 
    
Missing data is due to either loss of nerve recordings during protocol, or unsuccessful location of 
nerve activity. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.19.   Raw data for 5 minute average measurements of forearm blood flow 
(mL/100mL/min) in normotensive group for study 1. 
 
  
Subject Base MS Rec 
1 2.78 4.01 2.87 
2 2.41 2.19 2.06 
3 2.02 2.74 2.04 
4 -- -- -- 
5 3.21 5.34 3.27 
6 2.63 3.14 2.75 
7 2.20 3.78 2.41 
8 3.88 5.80 3.93 
9 1.84 2.28 2.28 
10 3.04 3.57 3.37 
11 1.64 2.08 1.65 
12 -- -- -- 
13 1.74 2.91 1.51 
14 2.05 2.61 1.90 
15 1.59 2.60 1.84 
16 1.01 1.42 1.00 
17 3.60 3.05 3.11 
18 2.92 6.23 2.90 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.20.   Raw data for 5 minute average measurements of forearm blood flow 
(mL/100mL/min) in prehypertensive group for study 1. 
 
  
Subject Base MS Rec 
1 2.49 4.68 2.53 
2 2.69 3.54 2.47 
3 2.25 3.24 2.65 
4 -- -- -- 
5 4.21 6.91 3.96 
6 1.28 3.09 1.29 
7 5.34 10.77 6.17 
8 3.72 8.37 3.66 
9 2.65 3.87 3.38 
10 2.40 5.15 2.88 
11 3.61 6.15 3.54 
12 4.38 7.50 4.00 
13 3.43 4.36 3.90 
14 5.93 5.64 5.79 
15 3.68 4.88 3.92 
16 2.91 3.36 2.48 
17 4.15 5.22 3.19 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.21.   Raw data for 5 minute average measurements of forearm vascular resistance 
(mmHg/mL/100mL/min) in normotensive group for study 1. 
 
  
Subject Base MS Rec 
1 16.99 12.19 16.32 
2 24.21 11.11 24.96 
3 33.66 12.66 28.28 
4 37.69 13.29 39.22 
5 44.76 20.22 50.66 
6 40.18 25.39 31.57 
7 33.84 28.18 37.46 
8 -- -- -- 
9 48.97 25.98 56.82 
10 49.85 28.39 51.41 
11 46.85 31.43 62.82 
12 41.18 16.75 49.94 
13 55.22 27.33 40.40 
14 41.67 29.03 44.41 
15 47.10 26.13 53.49 
16 48.08 30.23 44.59 
17 29.26 31.63 28.62 
18 30.98 18.01 33.73 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.22.   Raw data for 5 minute average measurements of forearm vascular resistance 
(mmHg/mL/100mL/min) in prehypertensive group for study 1. 
 
  
Subject Base MS Rec 
1 36.57 24.07 37.17 
2 37.92 34.36 43.98 
3 44.86 36.57 38.45 
4 -- -- -- 
5 23.34 18.45 25.87 
6 -- -- -- 
7 16.87 10.67 15.34 
8 24.49 15.15 26.01 
9 34.72 27.66 30.63 
10 35.11 17.80 29.72 
11 23.21 17.57 23.02 
12 18.51 12.92 20.60 
13 29.98 26.22 28.01 
14 14.47 18.20 15.44 
15 23.14 20.44 22.96 
16 31.28 36.07 37.94 
17 21.38 20.81 27.85 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.23.   Raw data for 5 minute average measurements of forearm vascular conductance 
(mL/100mL/min/mmHg) in normotensive group for study 1. 
 
  
Subject Base MS Rec 
1 0.060 0.084 0.062 
2 0.042 0.096 0.041 
3 0.030 0.084 0.037 
4 0.027 0.078 0.026 
5 0.022 0.064 0.020 
6 0.025 0.041 0.032 
7 0.030 0.036 0.027 
8 -- -- -- 
9 0.020 0.042 0.018 
10 0.020 0.039 0.020 
11 0.022 0.035 0.016 
12 0.025 0.063 0.021 
13 0.018 0.037 0.026 
14 0.024 0.035 0.023 
15 0.021 0.040 0.019 
16 0.021 0.034 0.022 
17 0.034 0.033 0.036 
18 0.032 0.060 0.030 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.24.   Raw data for 5 minute average measurements of forearm vascular conductance 
(mL/100mL/min/mmHg)  in prehypertensive group for study 1. 
 
  
Subject Base MS Rec 
1 0.028 0.047 0.027 
2 0.028 0.032 0.025 
3 0.022 0.029 0.026 
4 -- -- -- 
5 0.043 0.061 0.039 
6 -- -- -- 
7 0.059 0.094 0.066 
8 0.041 0.076 0.039 
9 0.029 0.037 0.036 
10 0.029 0.057 0.034 
11 0.045 0.069 0.044 
12 0.054 0.082 0.049 
13 0.034 0.039 0.036 
14 0.069 0.055 0.065 
15 0.044 0.049 0.044 
16 0.032 0.033 0.027 
17 0.047 0.052 0.036 
 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.25.  Raw data for 5 minute average measurements of calf blood flow (mL/100mL/min) in 
normotensive group for study 1. 
 
  
Subject Base MS Rec 
1 3.18 4.34 -- 
2 3.58 4.50 3.50 
3 2.18 4.71 2.00 
4 1.21 1.20 1.12 
5 1.79 1.98 2.12 
6 1.94 2.28 2.07 
7 1.52 1.32 1.58 
8 2.51 3.17 2.27 
9 1.66 3.83 1.73 
10 1.84 3.10 1.92 
11 1.40 2.44 1.23 
12 -- -- -- 
13 3.02 3.46 2.26 
14 1.80 2.41 1.76 
15 2.38 2.77 1.42 
16 1.86 2.36 1.66 
17 1.60 1.72 1.56 
18 1.70 4.11 2.32 
 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.26.  Raw data for 5 minute average measurements of calf blood flow (mL/100mL/min) in 
prehypertensive group for study 1. 
  
Subject Base MS Rec 
1 2.78 4.01 2.87 
2 2.41 2.19 2.06 
3 2.02 2.74 2.04 
4 -- -- -- 
5 3.21 5.34 3.27 
6 2.63 3.14 2.75 
7 2.20 3.78 2.41 
8 3.88 5.80 3.93 
9 1.84 2.28 2.28 
10 3.04 3.57 3.37 
11 1.64 2.08 1.65 
12 -- -- -- 
13 1.74 2.91 1.51 
14 2.05 2.61 1.90 
15 1.59 2.60 1.84 
16 1.01 1.42 1.00 
17 3.60 3.50 3.11 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.27.   Raw data for 5 minute average measurements of calf vascular resistance 
(mmHg/mL/100mL/min) in normotensive group for study 1. 
 
  
Subject Base MS Rec 
1 31.03 32.37 -- 
2 27.66 26.09 30.37 
3 43.80 26.03 44.69 
4 63.18 82.52 70.01 
5 49.94 51.17 43.25 
6 46.00 43.00 41.78 
7 58.77 72.71 56.56 
8 35.00 29.06 40.28 
9 53.14 30.72 55.10 
10 46.66 32.05 47.79 
11 65.85 43.86 78.13 
12 -- -- -- 
13 29.54 27.59 41.58 
14 56.41 48.90 61.41 
15 34.71 36.27 58.14 
16 47.48 39.88 55.91 
17 57.38 57.52 59.33 
18 54.10 28.00 42.52 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.28.   Raw data for 5 minute average measurements of calf vascular resistance 
(mmHg/mL/100mL/min) in prehypertensive group for study 1. 
 
  
Subject Base MS Rec 
1 32.54 28.64 32.48 
2 41.44 52.62 49.10 
3 49.91 42.67 49.57 
4 -- -- -- 
5 30.77 21.98 31.12 
6 -- -- -- 
7 41.22 33.78 39.25 
8 23.27 21.87 23.85 
9 49.26 45.69 41.68 
10 27.68 25.86 25.40 
11 49.30 43.84 49.50 
12 -- -- -- 
13 58.92 46.26 71.28 
14 41.84 39.78 47.12 
15 53.54 40.38 49.55 
16 89.62 81.05 96.48 
17 24.72 31.31 28.62 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.29.   Raw data for 5 minute average measurements of calf vascular conductance 
(mL/100mL/min/mmHg) in normotensive group for study 1. 
 
  
Subject Base MS Rec 
1 0.033 0.037 -- 
2 0.036 0.041 0.035 
3 0.023 0.048 0.023 
4 0.016 0.013 0.014 
5 0.020 0.020 0.023 
6 0.022 0.024 0.024 
7 0.017 0.014 0.019 
8 0.029 0.035 0.025 
9 0.019 0.039 0.018 
10 0.021 0.034 0.021 
11 0.016 0.024 0.013 
12 -- -- -- 
13 0.034 0.036 0.025 
14 0.018 0.021 0.017 
15 0.029 0.028 0.018 
16 0.021 0.025 0.018 
17 0.018 0.017 0.017 
18 0.019 0.040 0.024 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Table A.30.   Raw data for 5 minute average measurements of calf vascular conductance 
(mL/100mL/min/mmHg)  in prehypertensive group for study 1. 
 
  
Subject Base MS Rec 
1 0.031 0.040 0.031 
2 0.025 0.020 0.021 
3 0.020 0.024 0.020 
4 -- -- -- 
5 0.033 0.046 0.032 
6 -- -- -- 
7 0.024 0.033 0.026 
8 0.043 0.053 0.042 
9 0.020 0.022 0.024 
10 0.036 0.040 0.040 
11 0.021 0.023 0.020 
12 -- -- -- 
13 0.017 0.026 0.014 
14 0.024 0.025 0.021 
15 0.019 0.026 0.021 
16 0.011 0.014 0.011 
17 0.041 0.035 0.035 
 
Missing data is due to either artifact during protocol, or mechanical issues with the equipment. 
 
 
Base; Baseline 
 
MS; Mental Stress 
 
Rec; Recovery 
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Appendix B 
Table B.1. Baseline comparisons between normotensive (nt) and prehypertensive (pht) groups 
for Study 1. Independent t-tests are presented as two-tailed significance.  
 
Variable Mean Diff. 
Std. 
Error 
95% Conf. Interval Sig. N 
nt/pht Lower Upper 
Age (yrs) -1.29 1.82 -5.00 2.41 .482 18/17 
BMI (kg/m2) 1.75 1.12 -.523 4.03 .126 18/17 
SAP (mmHg) 14.97 1.98 10.94 18.99 .000 18/17 
DAP (mmHg) 6.23 2.36 1.44 11.03 .012 18/17 
MAP (mmHg) 9.14 1.92 5.23 13.04 .000 18/17 
HR (beats/min) 6.24 3.50 -.869 13.36 .083 18/17 
MSNA (bursts/min) .735 2.55 -4.48 5.95 .775 15/16 
MSNA (bursts/100hb) -.612 3.96 -8.72 7.49 .878 15/16 
FBF (mL/100mL/min) .922 .393 .120 1.72 .026 17/16 
FVR (mmHg/mL/100mL/min) -4.91 4.46 -14.00 4.18 .279 17/16 
FVC (mL/100mL/min/mmHg) .0074 .0048 -.0023 .017 .129 17/16 
CBF (mL/100mL/min) .308 .259 -.222 .837 .245 17/15 
CVR (mmHg/mL/100mL/min) -.565 5.00 -10.80 9.67 .990 17/15 
CVC (mL/100mL/min/mmHg) .001 .003 -.006 .008 .753 17/15 
 
Table B.2. Repeated Measures ANOVA of changes in 5 minute average ΔSAP (mmHg) in Study 
1, 2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .050 
 
Table B.3. Post-hoc paired t-test of changes in ΔSAP (mmHg) base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 8.90 8.07 4.89 12.92 .000 18 
Prehypertensive 14.01 7.47 10.00 18.00 .000 16 
 
Table B.4. Post-hoc independent t-test of changes in ΔSAP (mmHg) base to mental stress. 
 
Group Mean Diff. 
Std. 
Error 
95% Confidence Interval 
Sig. 
Lower  Upper 
Normotensive vs. 
Prehypertensive 5.11 2.68 -.344 10.57 .033 
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Table B.5. Repeated Measures ANOVA of changes in 5 minute average ΔDAP (mmHg) in Study 
1, 2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .065 
 
Table B.6. Post-hoc paired t-test of changes in ΔDAP (mmHg) base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 8.12 3.77 6.25 9.99 .000 18 
Prehypertensive 10.76 4.43 8.40 13.12 .000 16 
 
 
Table B.7. Post-hoc independent t-test of changes in ΔDAP (mmHg) base to mental stress. 
 
Group Mean Std. Error 
95% Confidence Interval 
Sig. 
Lower  Upper 
Normotensive vs. 
Prehypertensive 2.64 1.41 -.225 5.50 .035 
 
 
 
 
Table B.8. Repeated Measures ANOVA of changes in 5 minute average ΔMAP (mmHg) in Study 
1, 2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .017 
 
 
Table B.9. Post-hoc paired t-test of changes in ΔMAP (mmHg) base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 9.83 5.33 7.18 12.48 .000 18 
Prehypertensive 13.90 4.56 11.46 16.33 .000 16 
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Table B.10. Post-hoc independent t-test of changes in ΔMAP (mmHg) base to mental stress. 
 
Group Mean Std. Error 
95% Confidence Interval 
Sig. 
Lower  Upper 
Normotensive vs. 
Prehypertensive 4.07 1.71 .577 7.56 .017 
 
 
Table B.11. Repeated Measures ANOVA of changes in 5 minute average ΔHR (beats/min) in 
Study 1, 2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed 
significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .195 
 
 
Table B.12. Post-hoc paired t-test of changes in ΔHR (beats/min) base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 21.12 11.30 15.50 26.74 .000 18 
Prehypertensive 17.49 12.49 10.84 24.15 .000 16 
 
 
 
 
Table B.13. Repeated Measures ANOVA of changes in 5 minute average ΔMSNA (bursts/min) in 
Study 1, 2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed 
significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .479 
 
 
Table B.14. Post-hoc paired t-test of changes in ΔMSNA (bursts/min) base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 6.88 5.23 3.14 10.62 .001 10 
Prehypertensive 6.39 6.84 1.80 10.98 .005 11 
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Table B.15. Repeated Measures ANOVA of changes in 5 minute average ΔTotal MSNA 
(arbitrary units) in Study 1, 2 condition vs. 2 groups (Normotensive/Prehypertensive), presented 
as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .244 
 
 
Table B.16. Post-hoc paired t-test of changes in ΔTotal MSNA (arbitrary units) base to mental 
stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 6145.7 4015.7 3058.9 9232.4 .001 9 
Prehypertensive 7825.2 5980.2 3547.3 12103.2 .002 10 
 
 
 
Table B.17. Repeated Measures ANOVA of changes in 5 minute average ΔFBF (%) in Study 1, 2 
condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .005 
 
 
Table B.18. Post-hoc paired t-test of changes in ΔFBF (%)  base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 116.03 65.68 82.26 149.8 .000 17 
Prehypertensive 62.18 42.55 39.51 84.85 .000 16 
 
 
Table B.19. Post-hoc independent t-test of changes in ΔFBF (%) base to mental stress. 
 
Group Mean Std. Error 
95% Confidence Interval 
Sig. 
Lower  Upper 
Normotensive vs. 
Prehypertensive 53.84 19.15 14.58 93.11 .005 
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Table B.20. Repeated Measures ANOVA of changes in 5 minute average ΔFVR (%) in Study 1, 
2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .001 
 
 
Table B.21. Post-hoc paired t-test of changes in ΔFVR (%)  base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive -40.97 18.10 -50.27 -31.66 .000 17 
Prehypertensive -17.85 20.02 -28.93 -6.77 .002 15 
 
 
 
 
 
Table B.22. Post-hoc independent t-test of changes in ΔFVR (%) base to mental stress. 
 
Group Mean Std. Error 
95% Confidence Interval 
Sig. 
Lower  Upper 
Normotensive vs. 
Prehypertensive -23.12 6.73 -36.87 -9.36 .001 
 
 
Table B.23. Repeated Measures ANOVA of changes in 5 minute average ΔFVC (%) in Study 1, 
2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .001 
 
 
Table B.24. Post-hoc paired t-test of changes in ΔFVC (%)  base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 94.47 57.57 64.87 124.07 .000 17 
Prehypertensive 36.53 32.60 18.48 54.59 .000 15 
 
 
 
 
 113
Table B.25. Post-hoc independent t-test of changes in ΔFVC (%) base to mental stress. 
 
Group Mean Std. Error 
95% Confidence Interval 
Sig. 
Lower  Upper 
Normotensive vs. 
Prehypertensive 57.93 16.30 24.41 91.46 .000 
 
 
 
Table B.26. Repeated Measures ANOVA of changes in 5 minute average ΔCBF (%) in Study 1, 
2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .302 
 
Table B.27. Post-hoc paired t-test of changes in ΔCBF (%)  base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 43.14 46.58 19.19 67.09 .001 17 
Prehypertensive 36.08 24.92 22.28 49.88 .000 15 
 
 
 
Table B.28. Repeated Measures ANOVA of changes in 5 minute average ΔCVR (%) in Study 1, 
2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .005 
Condition x Group .313 
 
 
Table B.29. Post-hoc paired t-test of changes in ΔCVR (%)  base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive -11.47 22.36 -22.96 .029 .025 17 
Prehypertensive -7.93 16.39 -17.39 1.54 .047 14 
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Table B.30. Repeated Measures ANOVA of changes in 5 minute average ΔCVC (%) in Study 1, 
2 condition vs. 2 groups (Normotensive/Prehypertensive), presented as one-tailed significance. 
 
Source Base – Mental Stress 
Condition .000 
Condition x Group .210 
 
 
Table B.31. Post-hoc paired t-test of changes in ΔCVC (%)  base to mental stress. 
 
Group Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Normotensive 29.03 42.24 7.31 50.75 .006 17 
Prehypertensive 18.90 20.25 7.21 30.59 .002 14 
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Appendix C 
Table C.1. Anthropometric data for the normotensive group in study 2 
   Pre Supplementation Post Supplementation 
Sub-
ject 
Gend
er Drug 
Age 
yr 
Height 
cm 
Weight 
kg 
BMI 
kg/m2 
Age 
yr 
Height 
cm 
Weight 
kg 
BMI 
kg/m2 
1 M FO 25 176 99.5 32 25 176 100.5 33 
2 F PL 39 176 79.5 26 39 175 79.5 26 
3 M FO 18 173 71.0 24 19 173 72.0 24 
4 F FO 18 166 61.0 22 18 166 62.0 22 
5 M FO 19 177 60.0 19 19 177 60.5 19 
6 F PL 18 161 68.0 26 18 162 69.0 26 
7 F PL 18 163 56.0 21 18 163 57.0 21 
8 F PL 19 174 68.0 22 19 174 69.5 23 
9 F FO 20 169 69.5 24 20 169 72.0 25 
10 F PL 21 152 60.5 26 21 157 61.5 25 
11 M FO 23 179 66.0 21 23 181 66.0 20 
12 F FO 20 168 62.5 22 20 169 64.0 22 
13 F FO 21 160 57.0 22 21 163 57.5 22 
14 F FO 20 155 52.0 22 20 154 52.0 22 
15 F FO 23 171 55.0 19 23 171 56.5 19 
16 F FO 22 149 62.5 28 22 149 64.0 29 
17 F PL 18 161 65.5 25 18 161 65.5 25 
18 F FO 21 163 57.5 22 22 163 55.5 21 
19 F PL 21 166 74.0 27 21 166 73.0 26 
20 M PL 20 167 63.0 23 20 168 62.5 22 
21 M PL 18 185 97.5 28 19 185 101.5 30 
22 M PL 39 168 60.0 21 39 167 60.5 22 
23 M PL 20 185 60.0 18 20 185 60.0 18 
24 M FO 19 177 75.0 24 19 177 74.0 24 
25 F PL 20 163 57.0 21 20 163 56.0 21 
26 M FO 22 184 80.0 24 22 186 77.0 22 
27 M FO 18 170 62.5 22 19 168 63.0 22 
28 M PL 20 174 79.0 26 20 171 80.0 27 
29 M PL 23 161 69.8 27 23 171 71.0 24 
30 M PL 22 181 72.0 22 22 182 72.0 22 
31 F PL 21 173 72.0 24 21 171 72.0 25 
32 F FO 21 169 77.6 27 21 169 79.0 28 
33 M FO 40 184 89.0 26 40 186 87.0 25 
34 M FO 30 170 77.0 27 30 170 77.5 27 
35 F PL 52 178 77.5 24 52 179 78.0 24 
36 F FO 53 163 62.5 24 54 162 62.5 24 
37 M PL 19 170 76.0 26 19 170 74.5 26 
38 M PL 25 173 81.5 27 25 173 80.0 27 
 
M, Male; F, Female; FO, Fish Oil; PL, Placebo; BMI, Body Mass Index 
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Table C.2. Anthropometric data for prehypertensive group in Study 2 
 
   Pre Supplementation Post Supplementation 
Subj-
ect 
Gen-
der Drug 
Age 
yr 
Height 
cm
Weight 
kg
BMI 
kg/m2
Age 
yr
Height 
cm 
Weight 
kg 
BMI 
kg/m2
39 M FO  32 184 97.0 29 32 184 97.0 29 
40 M PL 19 178 82.5 26 19 179 82.5 26 
41 M PL 20 178 84.0 27 20 178 82.0 26 
42 M FO  21 176 77.0 25 21 175 79.0 26 
43 M PL 21 179 87.0 27 21 180 87.5 27 
44 M PL 23 183 91.5 27 23 183 92.5 28 
45 M FO 21 179 66.5 21 21 179 67.0 21 
46 M FO 19 185 81.0 24 19 184 85.0 25 
47 M PL 18 166 85.0 31 18 166 77.5 28 
48 M PL 20 189 92.0 26 21 189 91.0 25 
49 M PL 20 174 95.0 31 20 174 96.0 32 
50 M FO 23 177 75.5 24 23 172 75.0 25 
51 M FO 21 184 83.5 25 22 184 82.0 24 
52 M FO 20 174 80.5 27 20 174 82.0 27 
53 M FO 26 185 95.0 28 26 186 97.5 28 
54 M FO 20 185 113.0 33 20 184 112.5 33 
55 M PL 31 184 91.0 27 31 183 91.0 27 
56 M PL 52 192 102.5 28 52 192 101.5 28 
57 M FO 33 173 97.0 32 34 172 96.5 33 
58 M FO 19 176 87.0 28 20 176 84.0 27 
59 F PL 50 164 81.0 30 50 164 82.0 30 
60 M PL 18 176 90.5 29 18 175 92.0 30 
61 M FO 18 176 75.5 24 18 176 77.0 25 
62 M PL 20 188 79.5 22 21 183 88.0 26 
63 M FO 23 170 92.0 32 23 170 92.0 32 
64 M FO 22 170 103.5 36 22 171 102.5 35 
65 M PL 19 172 67.5 23 19 172 66.5 22 
66 M FO 21 189 109.5 31 21 189 110.0 31 
67 M PL 19 179 87.5 27 19 179 86.5 27 
 
M, Male; F, Female; FO, Fish Oil; PL, Placebo; BMI, Body Mass Index 
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Table C.3. Raw data for seated resting blood pressure (mmHg) and heart rate (beats/min) for 
normotensive group in study 2. 
 Pre supplementation Post supplementation 
Subject SAP DAP MAP HR SAP DAP MAP HR 
1 116.3 61.6 79.8 71.0 114.8 63.0 80.3 78.9 
2 104.0 66.0 78.7 75.1 104.2 63.0 76.7 70.8 
3 116.3 62.1 80.2 74.8 115.1 62.0 79.7 64.1 
4 117.9 70.0 86.0 80.3 109.9 68.3 82.2 80.4 
5 107.8 64.2 78.7 82.8 110.8 74.1 86.3 89.6 
6 104.1 68.0 80.0 90.6 107.3 68.0 81.1 95.7 
7 102.7 66.2 78.4 79.4 98.8 66.3 77.1 76.8 
8 99.1 57.8 71.6 68.9 101.8 61.8 75.1 68.3 
9 105.0 64.0 77.7 66.0 106.1 67.9 80.6 65.6 
10 97.0 67.0 77.0 71.0 100.0 66.7 77.8 71.6 
11 110.0 57.0 74.7 60.0 107.0 62.7 77.5 64.6 
12 106.0 64.9 78.6 68.2 114.9 72.1 86.4 71.3 
13 92.2 59.1 70.1 62.1 96.2 62.9 74.0 58.2 
14 106.7 70.3 82.4 85.2 103.7 71.9 82.5 84.6 
15 110.9 68.3 82.5 73.2 107.4 64.9 79.1 75.6 
16 104.9 65.7 78.8 73.7 97.8 65.4 76.2 65.2 
17 105.1 68.3 80.6 85.1 101.7 62.0 75.2 72.8 
18 99.6 72.9 81.8 81.1 90.2 63.2 72.2 87.9 
19 105.2 66.2 79.2 69.2 100.4 61.0 74.1 60.9 
20 108.6 68.2 81.7 73.6 109.4 70.7 83.6 65.9 
21 116.4 76.2 89.6 68.9 122.6 80.9 94.8 85.1 
22 103.3 65.0 77.8 68.9 107.4 66.2 79.9 73.6 
23 109 56.0 73.7 58.1 110.6 61.7 78.0 67.8 
24 109.3 63.4 78.7 47.7 109.6 60.9 77.1 47.7 
25 95.9 64.3 74.8 76.6 90.7 61.7 71.4 76.6 
26 113.6 65.6 81.6 72.3 111.5 69.7 83.6 67.3 
27 111.7 65.2 80.7 68 104.8 64.9 78.2 72.8 
28 103.4 66.2 78.6 60.3 106.8 69.8 82.1 67.3 
29 115.7 62.9 80.5 78.9 121.2 65.8 84.3 79.0 
30 106 51.6 69.7 73.3 116.7 61.6 80.0 86.4 
31 105.2 63.3 77.3 75.7 106.0 62.6 77.1 71.0 
32 111.8 66.4 81.5 77.2 100.7 64.3 76.4 69.6 
33 111 67.2 81.8 77.9 108.4 60.8 76.7 75.6 
34 116.2 71.4 86.3 73.3 108.0 70.6 83.1 72.0 
35 113.2 75.8 88.3 64.2 100.2 65.2 76.9 63.3 
36 113.3 72.2 85.9 56.1 118.1 72.9 88.0 58.6 
37 114.3 60.4 78.4 76.6 110.7 72.7 85.4 91.1 
38 118.6 66 83.5 92.4 111.6 71.2 84.7 94.8 
 
SAP, systolic arterial pressure 
DAP, diastolic arterial pressure 
MAP, mean arterial pressure 
HR, heart rate 
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Table C.4. Raw data for seated resting blood pressure (mmHg) and heart rate (beats/min) for 
prehypertensive group in study 2 
 Pre supplementation Post supplementation 
Subject SAP DAP MAP HR SAP DAP MAP HR 
39 120.3 66.4 84.4 60.6 123.4 68.6 86.9 60.9 
40 132.9 77.0 95.6 69.6 127.2 68.4 88.0 54.9 
41 118.0 81.0 93.3 81.8 119.4 79.0 92.5 78.4 
42 139.9 77.4 98.2 71.4 125.3 69.7 88.2 64.0 
43 139.7 84.4 102.8 59.1 121.2 71.9 88.3 58.2 
44 133.0 66.0 88.3 77.0 125.2 63.9 84.3 80.3 
45 124.7 69.1 87.6 80.7 128.7 69.9 89.5 89.2 
46 121.5 67.5 85.5 68.6 123.2 68.9 87.0 69.9 
47 122.4 72.8 89.3 95.0 131.1 78.4 96.0 90.6 
48 122.0 63.6 83.1 64.3 118.4 64.6 82.5 62.0 
49 121.2 78.8 92.9 95.0 121.6 82.7 95.7 90.9 
50 133.4 73.8 93.7 72.3 125.1 73.9 91.0 66.7 
51 123.6 69.6 87.6 88.9 121.6 66.3 84.7 86.3 
52 125.6 62.4 83.5 71.1 124.3 63.0 83.4 70.6 
53 127.9 66.6 87.0 69.8 132.2 74.4 93.7 77.8 
54 128.3 66.7 87.2 70.0 128.4 67.9 88.1 77.3 
55 124.6 68.4 87.1 80.6 123.7 74.3 90.8 75.4 
56 121.9 72.0 88.6 69.1 124.9 76.4 92.6 72.9 
57 125.2 79.9 95.0 75.1 126.0 78.0 94.0 75.0 
58 129.3 66.2 87.2 68.8 129.4 67.9 88.4 71.3 
59 115.7 82.7 93.7 80.5 111.8 76.1 88.0 77.9 
60 124.3 63.1 83.5 63.7 114.0 58.0 76.7 51.9 
61 122.6 76.8 92.1 96.3 115.7 65.6 82.3 78.6 
62 131.2 70.7 90.9 68.7 132.2 72.7 92.5 77.2 
63 126.0 65.2 85.5 75.8 117.4 63.1 81.2 71.2 
64 134.1 70.7 91.8 68.5 135.2 69.4 91.3 69.0 
65 133.2 78.7 96.9 78.5 132.6 82.0 98.9 81.1 
66 123.1 45.4 71.3 60.7 123.2 49.1 73.8 61.9 
67 127.0 79.8 95.5 83.1 121.9 80.8 94.5 84.6 
 
SAP, systolic arterial pressure 
DAP, diastolic arterial pressure 
MAP, mean arterial pressure 
HR, heart rate 
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Table C.4. Raw data for 5 minute average systolic arterial pressure (mmHg) as measured by the 
finometer for normotensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
1 138.5 158.3 154.3  125.0 148.3 137.4 
2 113.5 126.4 116.4  134.9 148.8 138.3 
3 133.9 145.4 134.9  137.9 151.6 130.1 
4 128.8 147.6 140.6  137.2 149.4 143.6 
5 115.5 114.2 104.1  125.1 122.2 141.9 
6 131.3 138.2 133.9  103.5 110.5 107.1 
7 123.4 128.7 129.6  121.6 124.9 128.0 
8 113.8 120.6 97.4  124.1 137.0 119.4 
9 125.7 138.0 127.0  115.6 139.0 121.8 
10 129.0 139.0 117.1  124.3 131.1 131.3 
11 108.4 132.6 110.6  125.3 146.3 118.0 
12 132.9 153.4 138.6  131.8 147.9 138.1 
13 118.4 130.3 123.5  116.0 139.2 121.5 
14 137.1 147.2 140.0  119.8 138.5 -- 
15 112.8 121.1 116.6  120.0 128.8 120.1 
16 115.5 133.8 124.6  117.5 126.4 120.8 
17 116.8 125.6 123.9  120.1 136.9 129.3 
18 130.9 149.5 137.5  114.9 123.2 118.5 
19 133.8 139.7 135.7  119.0 131.7 124.0 
20 127.7 135.2 130.9  126.1 125.6 130.5 
21 124.0 134.0 117.1  126.7 128.4 124.9 
22 123.1 124.0 112.7  119.1 115.3 103.3 
23 122.1 133.3 131.0  112.1 107.9 111.5 
24 120.6 118.8 124.9  121.4 117.3 133.8 
25 120.5 132.5 128.1  121.0 128.0 128.4 
26 128.5 144.7 135.3  112.2 125.6 115.5 
27 127.1 124.3 129.7  114.9 121.3 126.7 
28 118.6 121.5 118.6  106.5 114.2 107.8 
29 133.8 147.7 137.9  113.4 125.7 116.0 
30 116.0 131.7 108.0  118.5 136.6 128.1 
31 134.5 134.8 138.7  126.9 130.6 130.6 
32 127.3 131.7 128.8  133.6 141.1 136.6 
33 129.6 137.2 127.8  118.7 131.8 117.4 
34 120.6 139.1 132.3  123.4 137.2 132.9 
35 124.4 138.8 130.5  87.8 100.7 91.6 
36 148.0 164.6 159.1  135.6 147.5 139.0 
37 130.2 148.8 129.0  111.4 129.5 112.5 
38 112.0 125.1 129.1  105.2 117.8 115.0 
 
Missing data point was due to power outage and loss of recovery data. 
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Table C.5. Raw data for 5 minute average systolic arterial pressure (mmHg) as measured by the 
finometer for prehypertensive group in  
study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
39 124.8 135.7 129.3  135.8 142.1 139.2 
40 141.2 150.1 146.9  138.2 150.1 150.0 
41 138.6 145.0 133.2  123.2 129.1 123.4 
42 141.5 157.1 145.4  140.9 155.9 132.2 
43 122.6 -- 124.5  -- -- -- 
44 122.1 152.1 131.4  134.1 176.5 129.6 
45 129.7 155.6 135.1  114.1 149.1 119.6 
46 123.7 134.8 131.0  131.8 134.3 135.4 
47 121.7 123.2 122.2  121.6 122.4 116.3 
48 117.7 129.4 114.5  111.6 124.6 117.5 
49 110.1 118.2 112.4  119.6 125.3 120.5 
50 136.4 146.4 141.7  134.7 145.9 141.2 
51 118.8 138.9 123.8  111.4 124.2 128.1 
52 144.2 155.9 141.7  119.8 143.6 121.0 
53 164.9 187.8 168.2  153.2 169.4 156.0 
54 119.8 142.2 136.1  130.1 136.5 133.0 
55 127.9 143.0 126.6  119.8 124.2 115.4 
56 135.0 148.8 131.2  135.5 140.8 139.1 
57 141.5 154.7 144.7  128.6 142.5 134.8 
58 139.1 135.8 137.0  138.5 144.1 145.4 
59 165.5 199.9 166.1  144.1 182.7 156.7 
60 126.7 139.3 133.0  132.1 135.2 134.7 
61 136.6 148.0 140.5  -- -- -- 
62 144.0 154.5 148.2  151.3 171.6 162.6 
63 138.9 150.4 140.4  121.2 134.3 120.1 
64 138.4 175.1 146.7  136.1 164.7 151.4 
65 139.3 151.7 146.8  146.8 156.0 157.2 
66 150.6 149.4 161.4  156.0 155.8 157.3 
67 138.5 152.8 148.3  120.1 147.1 144.1 
 
Missing data points are due to subject withdrawal and equipment error. 
 
 
 
 
 
 
 
 
 
 
 
 121
Table C.6. Raw data for 5 minute average diastolic arterial pressure (mmHg) as measured by the 
finometer for normotensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
1 78.3 94.4 87.0  73.5 86.7 77.8 
2 76.4 89.1 76.2  75.9 88.3 76.8 
3 76.7 88.1 76.5  74.8 87.9 74.4 
4 80.3 94.5 80.5  72.7 86.6 71.3 
5 79.8 85.2 76.1  83.0 91.2 95.2 
6 79.9 84.6 79.7  68.5 74.5 70.1 
7 74.9 79.3 78.2  68.8 72.2 71.3 
8 75.4 83.9 70.6  74.3 87.2 73.2 
9 73.7 82.1 73.6  60.9 80.1 66.7 
10 75.0 84.3 68.9  67.8 74.8 71.0 
11 60.7 71.9 59.9  68.3 80.8 64.4 
12 71.3 84.4 72.4  65.0 76.7 67.4 
13 59.8 74.3 63.1  58.0 73.2 62.4 
14 75.9 84.3 78.5  66.8 78.9 -- 
15 66.2 72.6 63.5  70.8 78.4 72.4 
16 66.5 76.1 68.4  65.2 72.0 66.1 
17 62.1 72.5 67.0  63.3 78.6 69.3 
18 74.0 88.2 77.8  61.3 71.2 59.9 
19 73.8 81.8 73.0  61.8 71.5 63.8 
20 67.4 76.2 68.5  67.4 73.9 69.2 
21 72.2 76.2 69.9  76.4 77.6 75.6 
22 66.8 74.2 65.2  64.4 69.4 61.0 
23 71.1 80.5 76.2  71.7 76.6 75.5 
24 71.6 74.9 75.0  67.6 75.4 75.8 
25 69.5 76.0 73.9  68.9 72.8 70.6 
26 68.7 79.6 72.3  63.1 73.4 66.2 
27 73.4 78.9 74.5  68.4 77.8 75.5 
28 73.5 79.1 75.0  64.8 72.6 68.1 
29 83.2 95.4 86.3  68.2 77.8 69.5 
30 68.5 80.9 67.4  59.9 71.9 63.7 
31 74.7 75.9 77.8  69.3 73.6 71.0 
32 75.0 79.4 76.1  76.3 83.5 78.4 
33 71.5 77.8 71.6  65.2 73.8 66.6 
34 72.8 82.4 76.7  72.6 81.4 76.7 
35 70.4 76.9 73.4  67.9 78.4 79.5 
36 72.4 83.1 78.5  62.1 70.0 64.3 
37 73.4 87.8 74.3  66.9 76.3 68.0 
38 70.5 78.9 78.8  64.5 71.1 70.5 
 
Missing data point was due to power outage and loss of recovery data. 
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Table C.7. Raw data for 5 minute average diastolic arterial pressure (mmHg) as measured by the 
finometer for prehypertensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
39 74.7 81.7 75.9  79.9 85.9 81.9 
40 74.1 83.6 73.8  73.5 83.7 78.1 
41 81.9 92.9 82.4  68.1 73.5 67.5 
42 75.6 87.5 77.6  68.1 80.3 67.2 
43 67.5 -- 71.7  -- -- -- 
44 71.4 94.3 73.2  69.2 91.1 69.9 
45 70.9 87.0 72.7  62.9 81.8 66.1 
46 71.9 83.1 73.2  70.8 76.6 74.1 
47 70.0 73.2 70.9  67.0 71.5 64.8 
48 64.4 72.4 65.9  69.0 78.1 71.3 
49 66.8 76.4 67.3  70.2 77.6 70.3 
50 84.5 89.2 88.4  76.7 85.0 81.0 
51 71.8 82.3 73.7  63.5 72.4 74.7 
52 68.4 79.4 69.4  65.0 76.4 67.5 
53 97.6 106.4 91.3  82.6 96.5 85.8 
54 63.6 81.3 75.1  63.2 75.5 69.9 
55 72.1 83.0 71.1  68.2 73.5 69.1 
56 72.6 79.8 71.2  74.5 79.0 76.1 
57 82.4 90.2 83.3  75.2 82.0 78.3 
58 73.1 77.9 75.2  76.4 80.6 79.4 
59 88.7 106.6 88.0  80.7 99.5 84.7 
60 72.3 80.7 72.7  75.4 81.0 74.6 
61 82.5 88.7 82.3  -- -- -- 
62 71.6 81.6 74.6  88.9 99.8 92.7 
63 81.2 89.9 79.9  63.2 73.0 64.1 
64 74.3 97.6 79.0  75.0 92.9 83.5 
65 73.8 87.7 79.5  80.5 91.3 83.8 
66 80.0 83.3 86.8  82.5 84.8 85.0 
67 95.4 104.4 101.0  72.9 91.4 84.2 
 
Missing data points are due to subject withdrawal and equipment error. 
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Table C.8.  Raw data for 5 minute average mean arterial pressure (mmHg) as measured by the 
finometer for normotensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
1 97.2 116.6 109.5  89.9 106.7 97.6 
2 90.1 104.5 90.7  97.2 113.6 99.3 
3 98.5 110.7 98.6  96.4 110.4 94.1 
4 102.2 118.5 105.4  100.0 115.5 100.1 
5 93.5 97.5 88.2  99.8 104.1 113.9 
6 97.1 103.6 98.3  81.0 88.1 83.7 
7 91.6 97.8 97.3  87.6 92.3 92.2 
8 89.1 98.3 81.8  90.7 106.0 89.3 
9 91.8 104.8 93.6  79.3 103.6 87.4 
10 97.4 109.1 90.4  88.7 95.8 94.0 
11 76.3 93.1 77.7  86.5 103.1 82.2 
12 96.1 115.2 99.2  87.4 105.9 92.1 
13 81.0 97.3 87.5  78.7 95.0 85.2 
14 101.1 105.6 100.8  86.4 104.1 -- 
15 82.6 91.1 81.0  90.7 98.3 90.5 
16 86.9 103.3 93.0  87.1 97.3 89.6 
17 82.0 93.7 88.8  84.9 102.5 93.6 
18 99.6 116.4 104.5  83.8 94.1 83.6 
19 95.3 105.2 95.5  81.4 93.8 84.9 
20 88.6 98.9 91.2  87.7 94.7 91.1 
21 89.2 94.6 86.3  92.7 94.5 92.0 
22 87.5 92.6 83.7  81.8 84.3 75.6 
23 87.7 99.1 94.9  83.8 87.5 87.4 
24 85.8 90.2 90.9  84.5 91.0 96.0 
25 90.1 99.2 96.6  88.9 95.9 93.1 
26 89.1 103.6 94.3  81.0 93.9 84.9 
27 91.1 95.7 93.5  84.9 94.7 94.0 
28 89.1 95.0 91.1  80.2 88.3 84.0 
29 101.2 116.2 105.7  85.0 97.0 87.5 
30 82.2 99.4 80.6  77.7 93.5 83.4 
31 95.3 98.1 99.5  91.3 96.8 94.1 
32 94.8 100.3 95.9  97.4 105.8 100.0 
33 90.9 98.9 91.7  83.9 95.3 85.7 
34 90.4 104.5 97.6  90.4 102.9 96.9 
35 92.7 101.0 96.7  76.2 86.4 84.0 
36 102.0 116.0 110.6  89.7 99.8 92.5 
37 89.4 108.0 90.3  80.6 92.7 81.7 
38 84.4 95.5 96.3  78.1 87.6 85.0 
 
Missing data points are due to subject withdrawal and equipment error. 
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Table C.9.Raw data for 5 minute average mean arterial pressure (mmHg) as measured by the 
finometer for prehypertensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
39 90.4 101.0 93.1  97.8 105.9 100.9 
40 97.9 110.3 100.3  94.7 110.4 102.3 
41 100.6 111.9 100.6  86.2 92.2 86.2 
42 97.5 115.4 101.1  90.2 106.8 88.0 
43 86.7 -- 92.4  -- -- -- 
44 90.0 114.0 93.8  91.0 118.5 90.4 
45 90.1 111.3 93.2  80.5 105.4 85.4 
46 90.1 102.4 93.4  91.1 97.2 95.1 
47 83.8 89.3 85.9  82.8 87.7 80.8 
48 79.5 90.4 81.3  81.7 93.1 86.1 
49 80.8 91.6 82.3  87.4 95.9 87.9 
50 102.3 111.9 107.5  94.9 106.2 101.2 
51 85.5 101.4 89.2  77.8 88.9 92.4 
52 88.6 101.9 88.7  82.1 96.5 85.1 
53 114.2 139.0 119.0  102.7 121.9 107.4 
54 81.1 102.6 96.0  82.7 96.2 90.4 
55 90.4 103.4 90.5  83.1 88.1 83.3 
56 96.7 106.0 95.0  97.3 102.1 100.7 
57 104.4 114.9 107.0  95.4 105.7 100.6 
58 95.5 101.2 98.2  98.6 105.0 103.3 
59 120.4 146.7 119.4  108.5 135.8 115.4 
60 91.4 103.4 93.9  92.7 101.0 94.4 
61 101.5 111.6 102.9  -- -- -- 
62 93.9 106.1 97.6  109.8 124.7 116.5 
63 100.9 111.8 100.9  82.2 94.4 83.4 
64 96.9 127.4 103.6  95.1 119.1 106.3 
65 94.5 110.7 102.0  102.1 115.0 108.1 
66 98.0 103.4 106.9  100.8 105.9 104.5 
67 110.9 122.7 118.4  89.2 111.7 105.1 
 
Missing data points are due to subject withdrawal and equipment error. 
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Table C.10. Raw data for 5 minute average heart rate (beats per minute) as measured by the 
finometer for normotensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
1 67.7 94.9 75.5  66.9 93.5 73.1 
2 64.5 75.7 65.1  63.0 75.2 61.7 
3 74.6 126.2 79.7  77.7 115.5 71.4 
4 71.3 112.1 67.4  66.1 109.7 58.8 
5 65.7 98.1 65.1  78.4 109.2 73.9 
6 89.1 96.3 86.1  87.3 94.1 87.9 
7 62.0 70.6 60.3  61.0 70.0 56.5 
8 60.6 69.1 60.9  62.1 75.3 58.9 
9 65.3 83.8 64.9  60.8 76.9 64.6 
10 57.1 70.6 56.1  67.5 78.8 65.8 
11 51.1 73.8 50.4  63.9 83.8 57.1 
12 58.0 91.2 58.1  55.8 76.1 56.6 
13 49.6 70.0 51.3  52.9 71.3 52.5 
14 78.6 102.4 74.5  77.8 107.3 -- 
15 73.4 100.5 71.9  67.1 83.2 61.7 
16 64.5 80.2 64.5  63.6 75.2 63.9 
17 75.6 91.7 74.0  73.2 97.1 68.6 
18 80.4 103.3 76.5  82.8 99.0 77.0 
19 63.6 72.8 65.5  62.0 68.5 64.9 
20 64.1 80.6 63.3  63.3 81.3 58.9 
21 68.8 73.5 69.5  72.3 76.5 68.7 
22 61.6 76.4 59.2  70.4 83.6 69.9 
23 48.8 74.8 49.5  59.2 86.1 56.7 
24 47.7 72.9 48.6  49.4 78.3 48.5 
25 58.4 76.3 59.2  70.7 91.2 70.7 
26 66.7 91.8 67.5  60.0 78.4 62.2 
27 62.0 92.6 61.7  48.0 87.7 57.6 
28 52.9 69.9 53.5  56.6 76.5 61.6 
29 58.0 74.3 57.8  62.4 81.0 61.8 
30 58.2 75.7 57.4  62.0 77.2 65.8 
31 65.2 73.7 64.7  64.5 73.1 65.2 
32 57.4 70.3 61.2  56.2 63.4 57.3 
33 60.8 68.0 61.6  63.4 69.0 62.6 
34 64.0 88.1 67.0  58.1 77.7 64.1 
35 60.2 62.0 59.7  69.5 68.2 66.2 
36 48.3 56.5 49.4  50.6 54.6 51.6 
37 65.4 84.0 63.9  72.4 92.9 66.3 
38 82.6 93.2 84.2  84.0 94.4 84.9 
 
Missing data points are due to subject withdrawal and equipment error. 
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Table C.11. Raw data for 5 minute average heart rate (beats per minute) as measured by the 
finometer for prehypertensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
39 51.2 64.8 53.4  56.3 66.4 57.5 
40 71.0 87.9 67.7  56.9 83.4 57.2 
41 72.0 83.7 76.0  71.2 80.8 74.1 
42 67.4 84.3 65.0  63.0 74.5 60.0 
43 49.6 73.6 54.0  -- -- -- 
44 71.2 128.9 80.9  89.3 132.0 92.9 
45 80.3 114.2 83.2  67.0 96.2 76.3 
46 62.0 73.8 64.6  60.4 71.4 62.9 
47 71.9 92.7 78.8  73.0 91.4 76.7 
48 52.9 70.6 58.0  58.0 73.9 62.0 
49 77.4 88.9 77.4  63.0 74.6 59.4 
50 69.1 86.6 70.0  57.2 71.3 59.9 
51 79.1 86.2 78.6  74.4 82.0 78.3 
52 63.5 76.1 60.9  67.1 78.6 66.0 
53 67.1 96.6 65.8  70.9 89.5 67.8 
54 59.0 72.3 61.7  57.8 77.8 66.2 
55 69.8 80.1 74.7  69.8 71.9 69.0 
56 62.9 65.2 62.9  64.1 65.2 66.0 
57 81.1 100.2 79.1  72.5 89.7 72.4 
58 68.1 79.6 65.9  70.9 75.1 65.6 
59 76.8 92.7 77.6  69.7 95.9 73.1 
60 61.2 82.2 65.1  50.1 73.1 54.0 
61 69.0 80.6 67.8  -- -- -- 
62 65.1 79.5 64.0  78.7 92.1 76.3 
63 72.8 92.2 77.2  66.7 86.0 70.9 
64 69.2 91.2 72.4  72.6 95.6 75.9 
65 66.8 88.4 67.9  65.8 88.5 65.4 
66 55.4 78.5 59.3  52.8 73.5 50.6 
67 63.4 88.2 72.3  61.8 88.9 68.0 
 
Missing data points are due to subject withdrawal and equipment error. 
 
 
 
 
 
 
 
 
 
 
 
 
 127
Table C.12. Raw data for 5 minute average MSNA (burst per minute) for normotensive group in 
study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
1 8.6 12.4 6.4  8.2 18.0 15.4 
2 5.2 -- --  13.6 20.5 19.8 
3 2.6 -- --  12.6 17.4 17.2 
4 16.6 25.2 27.8  11.6 14.8 15.4 
5 -- -- --  -- -- -- 
6 6.2 -- --  -- -- -- 
7 13.8 18.2 20.2  -- -- -- 
8 7.2 11.4 17.0  3.8 10.6 -- 
9 20.0 -- --  20.2 24.2 28.2 
10 10.4 10.8 18.0  4.2 5.4 4.6 
11 6.6 12.6 11.6  2.0 -- -- 
12 12.7 -- --  12.4 16.0 15.8 
13 1.0 19.4 --  6.4 12.4 4.4 
14 8.8 13.2 10.8  3.6 10.8 -- 
15 13.4 18.4 24.6  16.3 -- -- 
16 10.8 7.0 8.2  7.6 12.2 9.0 
17 7.6 -- --  7.2 9.8 9.0 
18 8.2 -- --  5.0 -- -- 
19 10.8 -- --  12.2 19.8 10.2 
20 6.2 24.2 7.8  4.8 14.0 6.4 
21 15.6 21.2 19.2  9.4 12.8 15.2 
22 9.2 21.0 16.4  28.4 42.6 32.6 
23 4.0 5.8 3.2  7.8 11.0 12.6 
24 -- -- --  4.6 9.0 8.8 
25 6.6 -- 10.2  8.0 -- -- 
26 -- -- --  12.4 18.6 26.4 
27 8.8 11.8 13.2  5.6 11.2 12.0 
28 16.0 17.0 28.0  9.2 15.2 14.8 
29 10.6 -- --  6.4 -- -- 
30 4.0 14.0 9.2  14.0 28.0 17.2 
31 9.0 10.0 9.8  16.0 22.0 15.0 
32 10.3 -- --  3.7 6.2 6.0 
33 29.4 37.2 29.6  13.0 23.2 23.4 
34 8.2 -- --  8.8 -- -- 
35 22.4 28.8 20.4  38.4 34.7 -- 
36 10.6 19.8 16.8  18.2 29.0 -- 
37 6.8 16.6 21.2  9.6 19.6 10.2 
38 24.6 26.8 31.0  20.6 30.4 29.0 
 
Missing MSNA data are due to either failure to locate the nerve or loss of nerve during recording 
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Table C.13. Raw data for 5 minute average MSNA (burst per minute) for prehypertensive group 
in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 7.0 -- --  19.2 20.4 22.2 
40 27.0 31.7 --  13.0 19.4 24.8 
41 25.2 29.2 28.8  11.0 18.4 11.4 
42 -- -- --  3.0 -- -- 
43 3.4 -- --  4.8 7.0 11.7 
44 8.2 19.0 23.4  3.4 10.0 6.4 
45 3.8 9.6 6.2  3.0 -- -- 
46 2.8 6.2 6.0  -- -- -- 
47 7.2 -- --  10.2 13.2 12.8 
48 18.0 -- --  27.0 22.8 32.0 
49 7.0 -- --  -- -- -- 
50 10.8 12.6 15.2  14.2 14.4 20.4 
51 17.0 11.8 17.8  7.0 -- -- 
52 6.4 20.3 --  13.2 16.0 14.6 
53 21.4 -- --  18.0 -- -- 
54 4.8 13.6 10.0  8.8 -- -- 
55 26.8 28.6 38.2  18.4 21.0 -- 
56 9.3 -- 15.2  4.2 9.6 4.6 
57 2.6 3.6 7.0  7.4 2.6 8.2 
58 13.2 -- --  19.2 27.2 15.6 
59 9.4 -- --  -- -- -- 
60 9.6 18.2 15.6  10.0 7.0 14.0 
61 9.6 13.2 15.0  -- -- -- 
62 17.0 34.3 30.0  -- -- -- 
63 14.0 15.3 21.0  6.2 8.4 6.6 
64 16.4 27.0 27.2  -- -- -- 
65 19.0 30.8 27.2  -- -- -- 
66 10.8 -- --  3.8 -- -- 
67 7.4 -- 15.6  7.8 11.2 6.0 
 
Missing MSNA data are due to either failure to locate the nerve or loss of nerve during recording 
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Table C.14. Raw data for 5 minute average MSNA (burst per 100 heart beats) for normotensive 
group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 12.7 13.2 8.4  12.3 19.4 21.2 
2 8.1 -- --  21.7 27.2 32.3 
3 3.5 -- --  17.0 15.0 24.8 
4 23.4 22.8 41.6  17.7 13.6 26.2 
5 -- -- --  -- -- -- 
6 7.0 -- --  -- -- -- 
7 22.5 26.0 33.8  -- -- -- 
8 12.0 16.6 28.7  6.2 14.6 -- 
9 30.8 -- --  33.6 31.7 43.8 
10 18.4 15.4 32.1  6.3 6.9 7.0 
11 12.9 17.9 23.1  3.1 -- -- 
12 22.0 -- --  22.2 21.1 28.1 
13 2.0 28.1 --  12.2 17.5 8.5 
14 11.3 13.2 14.6  4.6 10.3 -- 
15 18.5 18.3 34.9  24.7 -- -- 
16 16.8 9.0 12.9  12.0 16.4 14.1 
17 10.2 -- --  10.0 10.2 13.4 
18 11.1 -- --  6.1 -- -- 
19 17.2 -- --  19.8 29.0 15.9 
20 9.7 30.2 12.4  7.8 17.3 11.0 
21 23.1 29.1 28.3  13.4 17.0 22.4 
22 15.0 27.7 28.0  40.6 51.3 46.8 
23 8.3 7.8 6.5  13.3 12.9 22.4 
24 -- -- --  9.3 11.8 18.0 
25 11.5 -- 17.3  11.4 -- -- 
26 -- -- --  20.7 24.1 42.5 
27 14.2 12.8 21.5  11.8 12.8 21.2 
28 30.4 24.4 52.8  16.4 19.9 24.2 
29 18.4 -- --  10.3 -- -- 
30 7.0 18.6 16.1  22.7 36.4 26.4 
31 14.3 13.7 15.5  24.9 30.1 23.2 
32 18.0 -- --  6.7 9.8 10.5 
33 48.6 54.6 48.2  20.6 33.9 37.4 
34 12.9 -- --  15.7 -- -- 
35 37.3 46.8 34.2  55.2 50.7 -- 
36 22.0 35.1 34.1  36.2 51.8 -- 
37 10.4 20.1 33.3  13.5 21.7 15.5 
38 29.8 28.6 36.9  24.5 32.3 34.3 
 
Missing MSNA data are due to either failure to locate the nerve or loss of nerve during recording 
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Table C.15. Raw data for 5 minute average MSNA (burst per 100 heart beats) for 
prehypertensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 13.7 -- --  34.2 30.9 38.7 
40 38.7 36.8 --  23.2 23.4 43.4 
41 35.0 35.1 38.0  15.5 22.9 15.4 
42 -- -- --  4.9 -- -- 
43 7.0 -- --  9.0 8.7 18.8 
44 11.7 14.2 29.1  3.8 7.8 7.0 
45 4.8 8.4 7.4  4.5 -- -- 
46 4.6 8.4 9.4  -- -- -- 
47 10.5 -- --  14.1 14.5 16.9 
48 34.2 -- --  47.0 31.2 51.8 
49 9.1 -- --  -- -- -- 
50 15.7 14.5 21.8  25.0 20.3 34.2 
51 21.7 13.8 22.7  9.4 -- -- 
52 10.1 26.1 --  19.8 20.6 22.3 
53 32.1 -- --  26.0 -- -- 
54 8.2 19.1 16.4  15.4 -- -- 
55 38.6 35.7 51.2  26.5 29.0 -- 
56 14.6 -- 24.2  6.6 14.9 7.1 
57 3.2 3.5 8.9  10.3 2.8 11.4 
58 19.5 -- --  27.4 36.6 24.1 
59 12.3 -- --  -- -- -- 
60 16.1 22.7 24.2  20.5 9.6 27.3 
61 14.0 16.6 22.2  -- -- -- 
62 26.5 44.0 47.2  -- -- -- 
63 19.3 16.5 27.3  9.5 9.9 9.3 
64 23.9 30.2 38.0  -- -- -- 
65 28.6 35.1 40.2  -- -- -- 
66 19.8 -- --  7.4 -- -- 
67 11.8 -- 21.8  12.7 12.3 8.9 
 
Missing MSNA data are due to either failure to locate the nerve or loss of nerve during recording 
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Table C.16.  Raw data for 5 minute average total MSNA (arbitrary units) for normotensive group 
in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery
1 4665.4 12323.9 4687.6  3820.1 11286.9 7339.5 
2 2704.6 -- --  6662.3 18142.9 12903.2 
3 2265.5 -- --  6584.6 6934.1 5706.1 
4 6730.0 24173.5 19916.7  5967.3 11408.5 7038.5 
5 -- -- --  -- -- -- 
6 3065.7 -- --  -- -- -- 
7 5554.5 7736.9 7285.6  -- -- -- 
8 3667.7 7267.5 7422.4  224.6 615.8 -- 
9 9606.9 -- --  10124.0 12093.9 10585.7 
10 5046.7 9533.7 8090.3  2241.0 -- 2193.5 
11 3346.8 12917.3 9870.0  935.8 -- -- 
12 4938.3 -- --  5586.5 6831.5 6436.7 
13 800.5 24062.9 --  3496.2 11280.5 3698.6 
14 4711.7 14853.2 9564.4  1152.1 6194.4 -- 
15 5748.1 10092.1 12825.4  7294.1 -- -- 
16 4574.9 4998.9 2618.6  3289.1 7299.5 3498.3 
17 2571.1 -- --  2546.9 7136.8 3388.1 
18 3098.4 -- --  1817.0 -- -- 
19 4260.0 -- --  5683.6 14405.7 4319.5 
20 3143.7 16129.0 2970.2  2640.1 9107.4 3399.0 
21 7878.0 8252.9 6569.8  5130.1 10731.5 6840.0 
22 2350.2 7873.3 3258.2  14351.3 28460.9 17619.9 
23 1921.1 4301.4 1921.2  3973.7 9161.5 7003.4 
24 -- -- --  1963.6 7147.8 3867.8 
25 2973.5 -- 4466.0  3614.3 -- -- 
26 -- -- --  6025.5 6699.9 8232.9 
27 4209.9 6218.5 4504.8  3132.7 4552.0 3263.5 
28 6464.1 13705.9 11897.5  4365.2 6656.8 5332.4 
29 6906.8 -- --  4188.6 -- -- 
30 1286.6 8854.8 3526.3  8400.2 26312.9 9876.6 
31 5684.6 5717.6 6768.9  5462.7 8503.3 5482.3 
32 5504.7 -- --  1591.1 3297.7 3265.0 
33 -- -- --  5099.0 12838.4 14463.3 
34 3072.2 -- --  3417.9 -- -- 
35 10041.5 10316.6 5727.2  16248.8 12310.7 -- 
36 2843.0 7800.8 3868.1  5269.1 8711.6 -- 
37 3140.3 18631.6 12948.5  4424.3 28032.8 6547.7 
38 12032.9 15429.1 17749.6  7990.9 -- -- 
 
Missing MSNA data are due to either failure to locate the nerve or loss of nerve during recording 
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Table C.17.  Raw data for 5 minute average total MSNA (arbitrary units) for prehypertensive 
group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 3919.4 -- --  5162.6 11610.4 5027.6 
40 15174.3 25679.3 --  6096.6 10364.8 12806.8 
41 9522.4 26003.6 9210.4  6195.4 15282.2 5933.5 
42 -- -- --  1665.6 -- -- 
43 2048.1 -- --  2345.6 4604.0 3760.4 
44 -- -- --  351.2 13771.8 3820.4 
45 2427.1 7951.7 2560.0  1884.8 -- -- 
46 1349.4 4434.6 4417.1  -- -- -- 
47 2875.2 -- --  6176.8 15374.2 9785.8 
48 9547.2 -- --  14516.6 15627.3 16769.1 
49 3173.9 -- --  -- -- -- 
50 4089.3 14199.4 6910.5  6542.0 4607.5 6222.0 
51 8623.5 9246.8 9207.2  3472.3 -- -- 
52 4365.1 13956.6 --  -- -- -- 
53 10038.6 -- --  9243.8 -- -- 
54 2691.8 10415.2 5714.0  3574.1 -- -- 
55 11721.3 20335.4 26744.4  6887.0 8873.3 -- 
56 3117.0 -- 6244.8  1545.2 3976.4 1160.3 
57 1017.4 -- --  2139.2 695.2 1795.5 
58 6540.3 -- --  9107.3 -- -- 
59 2077.1 -- --  -- -- -- 
60 5505.9 10479.3 8407.0  3909.1 2175.1 3979.0 
61 5691.5 11318.9 9139.0  -- -- -- 
62 7047.0 13083.2 15772.5  -- -- -- 
63 8480.7 19125.3 18473.9  2315.6 4114.8 3247.8 
64 8304.4 39597.7 23942.1  -- -- -- 
65 9208.9 24776.4 14069.5  -- -- -- 
66 5690.6 -- --  2259.4 -- -- 
67 3395.2 -- 10171.7  4884.4 7990.8 2819.0 
 
Missing MSNA data are due to either failure to locate the nerve or loss of nerve during recording 
 
 133
Table C.18. Raw data for 5 minute average forearm blood flow for normotensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 5.80 9.77 6.78  5.21 7.64 7.53 
2 3.31 4.26 3.53  2.76 4.47 2.88 
3 4.10 10.50 4.03  3.84 6.43 2.89 
4 3.55 9.23 3.35  5.21 14.98 3.94 
5 2.84 8.17 3.25  5.66 9.03 4.42 
6 2.94 3.59 2.69  3.61 2.90 2.74 
7 2.07 4.49 2.04  3.10 4.23 2.65 
8 2.18 3.10 1.72  1.98 3.03 1.52 
9 2.36 3.75 2.50  2.31 4.17 2.39 
10 1.45 1.86 1.36  1.92 2.64 1.82 
11 2.04 6.81 2.00  3.48 7.43 2.60 
12 2.54 5.99 2.44  2.32 5.52 1.77 
13 1.16 -- 1.29  1.80 -- 1.46 
14 2.72 4.04 2.56  3.01 5.73 2.88 
15 1.70 5.08 1.84  -- -- -- 
16 1.15 2.47 1.34  1.37 2.18 1.28 
17 3.91 5.13 3.23  3.52 6.69 2.74 
18 1.81 2.54 1.55  1.04 2.73 1.40 
19 2.49 4.72 3.41  2.07 4.21 2.23 
20 1.99 6.27 1.84  -- -- -- 
21 2.23 4.09 2.80  3.06 4.82 3.28 
22 2.61 3.35 2.25  2.12 2.27 1.57 
23 1.79 4.16 1.68  1.41 3.33 1.31 
24 1.73 3.57 1.80  2.08 4.10 1.94 
25 1.36 3.13 1.26  1.22 -- 1.21 
26 1.94 3.63 1.54  2.01 2.41 2.04 
27 2.25 6.00 1.93  1.75 6.91 1.89 
28 1.62 3.57 2.62  3.55 4.90 4.50 
29 2.44 3.82 2.39  3.09 3.81 3.25 
30 1.75 3.99 1.54  2.34 4.05 3.12 
31 0.96 1.30 1.28  1.22 1.48 1.28 
32 1.41 2.11 1.44  1.19 1.55 1.27 
33 3.12 3.22 3.32  3.48 5.06 3.32 
34 2.92 6.64 2.90  2.03 5.60 2.56 
35 1.02 -- 1.16  0.93 -- 1.05 
36 1.20 -- 1.45  3.03 -- 3.35 
37 1.98 5.45 1.83  3.67 7.55 2.91 
38 3.16 5.25 3.98  2.61 3.69 2.39 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.19. Raw data for 5 minute average forearm blood flow for prehypertensive group in study 
2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 2.49 4.68 2.53  3.34 5.31 3.24 
40 2.69 3.54 2.47  2.55 -- 2.24 
41 2.25 3.24 2.65  2.27 3.30 3.27 
42 4.21 6.91 3.96  3.46 5.57 3.17 
43 1.28 3.09 1.29  -- -- -- 
44 5.34 10.05 6.17  9.61 11.41 9.11 
45 3.72 8.37 3.66  3.08 7.01 3.28 
46 2.65 3.74 3.38  2.08 3.26 2.36 
47 2.40 5.48 2.85  4.09 4.66 3.50 
48 3.61 4.15 3.54  3.21 5.30 3.79 
49 4.38 7.50 4.00  3.48 4.13 2.79 
50 3.43 4.36 3.90  2.07 3.49 2.52 
51 5.93 5.69 5.79  3.49 2.91 3.58 
52 4.15 5.22 3.19  6.55 6.35 5.21 
53 2.23 6.06 2.09  2.52 3.71 1.37 
54 3.77 4.73 3.32  2.60 3.83 2.72 
55 2.52 2.65 2.35  2.19 2.61 2.20 
56 3.76 3.87 3.88  3.63 3.81 4.07 
57 4.03 8.85 3.38  3.61 8.61 3.48 
58 4.16 8.80 3.44  4.41 5.56 3.05 
59 2.81 -- 3.08  1.38 -- 1.69 
60 3.92 6.36 3.93  1.61 4.26 2.02 
61 2.35 3.96 2.38  -- -- -- 
62 2.59 5.23 2.67  5.91 8.77 5.84 
63 3.42 6.89 4.30  4.84 6.51 4.54 
64 3.81 5.17 3.43  4.25 4.57 2.95 
65 2.15 5.54 2.21  2.27 3.59 2.33 
66 6.40 -- 6.17  2.81 -- 2.45 
67 2.64 4.65 2.05  1.58 -- 1.58 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.20. Raw data for 5 minute average forearm vascular resistance for normotensive group 
in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 16.99 12.19 16.32  17.26 14.16 13.11 
2 27.35 25.61 25.75  35.37 26.01 34.85 
3 24.21 11.11 24.96  28.34 20.50 33.82 
4 28.98 12.93 31.64  19.88 7.94 25.62 
5 33.66 12.66 28.28  18.62 11.96 26.12 
6 33.22 29.51 36.66  22.46 30.71 30.75 
7 45.99 22.12 48.87  28.95 21.94 35.43 
8 42.23 32.29 48.65  45.92 36.93 60.39 
9 38.97 33.78 37.71  34.42 26.74 36.69 
10 67.21 59.29 66.82  46.16 36.49 52.20 
11 37.69 14.06 39.22  24.90 16.92 32.12 
12 37.93 19.73 40.66  37.83 19.51 52.49 
13 70.74 -- 68.13  43.69 -- 60.14 
14 37.29 28.47 39.62  28.74 18.46 -- 
15 49.64 18.70 44.07  -- -- -- 
16 76.10 44.11 70.75  63.97 45.05 70.44 
17 21.18 18.57 27.87  24.72 16.68 34.65 
18 55.04 46.71 67.59  80.54 37.58 59.70 
19 38.59 22.47 28.19  39.50 23.53 38.68 
20 44.76 20.22 50.66  -- -- -- 
21 40.18 23.50 31.57  30.95 21.07 28.57 
22 33.84 28.18 37.46  39.91 39.30 51.99 
23 48.97 25.98 56.82  60.20 29.39 71.06 
24 49.85 28.39 51.41  41.88 22.68 50.51 
25 66.44 31.94 77.24  73.03 -- 77.61 
26 46.85 31.43 62.82  40.55 40.56 41.73 
27 41.18 16.75 49.94  50.96 13.96 52.00 
28 55.22 26.59 35.73  22.82 18.09 19.19 
29 41.67 30.99 44.41  27.60 25.88 26.90 
30 47.10 26.13 53.49  33.59 24.23 28.09 
31 101.3 76.79 79.25  76.21 66.75 76.13 
32 66.52 47.95 67.41  81.65 68.59 79.19 
33 29.26 31.63 28.62  24.14 20.83 26.00 
34 30.98 16.72 33.73  45.46 18.65 38.25 
35 92.95 -- 84.29  83.08 -- 80.69 
36 84.72 -- 76.94  29.62 -- 27.71 
37 46.01 29.68 50.34  22.55 17.36 28.14 
38 27.07 18.67 24.83  30.16 24.45 35.57 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.21. Raw data for 5 minute average forearm vascular resistance for prehypertensive 
group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 36.57 24.07 37.17  29.42 22.40 31.40 
40 37.92 34.36 43.98  38.66 -- 46.75 
41 44.86 36.57 38.45  38.68 33.66 26.86 
42 23.34 18.45 25.87  26.86 20.78 27.95 
43 73.32 -- 73.27  -- -- -- 
44 16.87 11.32 15.34  9.56 10.51 9.98 
45 24.49 15.15 26.01  26.22 16.09 26.68 
46 34.72 27.73 30.63  44.27 33.42 42.21 
47 35.11 18.09 30.41  20.48 20.87 23.90 
48 23.21 22.32 23.02  25.64 17.90 22.78 
49 18.51 12.92 20.60  25.10 24.69 31.64 
50 29.98 26.22 28.01  46.78 31.18 41.47 
51 14.47 17.72 15.44  22.40 31.91 26.64 
52 21.38 20.81 27.85  12.56 15.58 16.46 
53 51.64 25.84 59.20  48.41 34.64 79.67 
54 21.69 25.80 29.42  32.03 27.46 33.84 
55 36.14 39.17 38.59  38.44 34.49 38.64 
56 25.92 28.33 24.85  26.87 27.62 24.94 
57 26.20 15.26 32.13  26.57 14.41 29.01 
58 23.08 12.92 28.75  22.56 22.66 34.14 
59 43.04 -- 39.12  83.39 -- 70.34 
60 23.48 16.72 24.02  58.51 25.34 51.22 
61 43.93 32.30 44.13  -- -- -- 
62 37.23 20.77 36.85  18.74 14.50 20.19 
63 29.58 16.35 23.69  16.99 14.70 18.58 
64 25.94 27.69 30.33  22.79 28.92 36.33 
65 44.02 23.48 46.28  45.32 35.84 46.45 
66 15.40 -- 17.34  36.66 -- 44.11 
67 44.32 31.42 57.95  56.63 -- 67.97 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.22. Raw data for 5 minute average forearm vascular conductance for normotensive 
group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 0.060 0.084 0.062  0.058 0.072 0.077 
2 0.037 0.041 0.039  0.028 0.040 0.029 
3 0.042 0.096 0.041  0.040 0.059 0.031 
4 0.035 0.078 0.032  0.052 0.130 0.039 
5 0.030 0.084 0.037  0.057 0.087 0.039 
6 0.030 0.035 0.027  0.045 0.033 0.033 
7 0.023 0.046 0.021  0.036 0.046 0.029 
8 0.024 0.032 0.021  0.022 0.029 0.017 
9 0.026 0.037 0.027  0.029 0.041 0.027 
10 0.015 0.017 0.015  0.022 0.028 0.019 
11 0.027 0.073 0.026  0.040 0.072 0.032 
12 0.026 0.052 0.025  0.027 0.052 0.019 
13 0.014 -- 0.015  0.023 -- 0.017 
14 0.027 0.038 0.025  0.035 0.055 -- 
15 0.021 0.056 0.023  -- -- -- 
16 0.013 0.024 0.014  0.016 0.022 0.014 
17 0.048 0.054 0.036  0.042 0.064 0.029 
18 0.018 0.022 0.015  0.012 0.029 0.017 
19 0.026 0.045 0.036  0.025 0.045 0.026 
20 0.022 0.064 0.020  -- -- -- 
21 0.025 0.043 0.032  0.033 0.051 0.036 
22 0.030 0.036 0.027  0.026 0.027 0.021 
23 0.020 0.042 0.018  0.017 0.039 0.015 
24 0.020 0.039 0.020  0.025 0.045 0.020 
25 0.015 0.031 0.013  0.014 -- 0.013 
26 0.022 0.035 0.016  0.025 0.026 0.024 
27 0.025 0.063 0.021  0.021 0.073 0.020 
28 0.018 0.038 0.029  0.044 0.055 0.053 
29 0.024 0.032 0.023  0.036 0.039 0.037 
30 0.021 0.040 0.019  0.030 0.044 0.037 
31 0.010 0.013 0.013  0.013 0.015 0.014 
32 0.015 0.021 0.015  0.012 0.015 0.013 
33 0.034 0.033 0.036  0.041 0.054 0.039 
34 0.032 0.064 0.030  0.023 0.055 0.026 
35 0.011 -- 0.012  0.012 -- 0.012 
36 0.012 -- 0.013  0.034 -- 0.036 
37 0.022 0.052 0.020  0.045 0.082 0.036 
38 0.038 0.055 0.041  0.033 0.042 0.028 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.23. Raw data for 5 minute average forearm vascular conductance for prehypertensive 
group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 0.028 0.047 0.027  0.034 0.051 0.032 
40 0.028 0.032 0.025  0.027 -- 0.022 
41 0.022 0.029 0.026  0.026 0.036 0.038 
42 0.043 0.061 0.039  0.038 0.053 0.036 
43 0.014 -- 0.014  -- -- -- 
44 0.059 0.089 0.066  0.105 0.096 0.101 
45 0.041 0.076 0.039  0.038 0.066 0.038 
46 0.029 0.037 0.036  0.023 0.033 0.025 
47 0.029 0.055 0.033  0.049 0.052 0.043 
48 0.045 0.045 0.044  0.039 0.057 0.044 
49 0.054 0.082 0.049  0.040 0.043 0.032 
50 0.034 0.039 0.036  0.022 0.033 0.025 
51 0.069 0.057 0.065  0.045 0.032 0.039 
52 0.047 0.052 0.036  0.080 0.066 0.061 
53 0.019 0.042 0.018  0.025 0.030 0.013 
54 0.047 0.048 0.035  0.031 0.040 0.030 
55 0.028 0.026 0.026  0.026 0.030 0.026 
56 0.039 0.037 0.041  0.037 0.037 0.040 
57 0.039 0.078 0.032  0.038 0.082 0.035 
58 0.044 0.088 0.035  0.045 0.054 0.030 
59 0.023 -- 0.026  0.013 -- 0.015 
60 0.043 0.062 0.042  0.017 0.042 0.021 
61 0.023 0.036 0.023  -- -- -- 
62 0.028 0.049 0.027  0.054 0.070 0.050 
63 0.034 0.061 0.043  0.059 0.069 0.055 
64 0.039 0.041 0.033  0.045 0.039 0.028 
65 0.023 0.051 0.022  0.022 0.032 0.022 
66 0.065 -- 0.058  0.028 -- 0.024 
67 0.024 0.038 0.017  0.018 -- 0.015 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.24. Raw data for 5 minute average calf blood flow for normotensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 3.18 4.34 --  2.59 3.15 2.89 
2 1.74 2.03 1.98  2.16 2.32 2.21 
3 3.58 4.50 3.50  2.21 2.79 1.89 
4 3.94 7.66 4.59  3.29 6.48 2.71 
5 2.18 4.71 2.00  3.14 4.25 2.47 
6 3.91 3.76 3.53  3.51 3.73 3.67 
7 2.81 3.62 2.59  2.12 2.00 1.55 
8 1.75 2.36 1.65  2.04 2.92 2.08 
9 1.70 2.74 1.87  1.89 2.57 1.79 
10 1.57 1.85 1.33  -- -- -- 
11 1.21 1.20 1.12  2.26 2.37 2.22 
12 1.53 2.79 1.35  3.39 4.61 3.19 
13 0.98 1.04 1.00  1.60 1.59 1.51 
14 2.25 3.99 2.36  2.54 4.22 2.51 
15 0.93 1.90 0.87  -- -- -- 
16 1.43 2.34 1.66  1.72 2.06 1.55 
17 2.14 3.06 1.92  3.44 5.55 3.18 
18 1.26 1.83 1.23  0.95 1.44 0.96 
19 2.49 2.81 2.89  2.70 2.70 2.89 
20 1.79 1.98 2.12  -- -- -- 
21 1.94 2.37 2.07  1.87 2.12 1.91 
22 1.52 1.32 1.58  1.79 1.79 1.80 
23 1.66 3.83 1.73  1.37 3.25 1.47 
24 1.84 3.10 1.92  2.00 2.69 1.91 
25 1.51 1.93 1.29  -- -- -- 
26 1.40 2.44 1.23  -- -- -- 
27 -- -- --  -- -- -- 
28 3.02 3.46 2.26  2.14 2.24 2.03 
29 1.80 2.41 1.76  1.50 2.22 1.58 
30 2.38 2.77 1.42  2.01 3.00 1.96 
31 0.96 1.30 1.28  1.62 1.53 1.69 
32 1.50 1.72 1.41  1.60 1.58 1.36 
33 1.60 1.72 1.56  3.01 3.37 2.59 
34 1.70 4.11 2.32  1.60 2.98 1.98 
35 1.94 -- 1.84  2.42 2.27 2.47 
36 1.67 1.53 1.57  1.71 1.53 1.62 
37 2.08 1.80 1.50  2.45 2.40 2.21 
38 2.65 2.79 2.62  4.01 3.39 4.15 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.25. Raw data for 5 minute average calf blood flow for prehypertensive group in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 2.78 4.01 2.87  3.42 4.11 3.57 
40 2.41 2.19 2.06  2.69 2.98 2.74 
41 2.02 2.74 2.04  1.80 2.35 1.84 
42 3.21 5.34 3.27  4.80 5.18 3.61 
43 -- -- --  -- -- -- 
44 2.20 3.78 2.41  3.57 5.79 3.86 
45 3.88 5.80 3.93  3.93 5.64 4.63 
46 1.84 2.28 2.28  1.66 2.20 1.70 
47 3.04 3.51 3.38  4.43 3.40 3.45 
48 1.64 2.08 1.65  -- -- -- 
49 -- -- --  2.84 3.29 2.87
50 1.74 2.91 1.51  1.36 1.59 1.37 
51 2.05 2.61 1.90  2.60 2.88 3.11 
52 3.60 3.50 3.11  3.51 3.84 2.86 
53 3.22 4.84 2.89  4.26 5.06 2.94 
54 2.42 2.32 2.36  3.52 3.89 3.92 
55 2.03 2.26 2.02  1.89 2.38 1.91 
56 3.17 3.67 3.23  4.12 4.15 4.31 
57 3.88 6.40 3.39  2.76 5.02 2.70 
58 3.86 2.47 2.49  1.76 1.46 1.29 
59 2.73 4.58 3.03  2.01 -- 2.09 
60 2.00 2.80 1.91  1.69 2.13 1.93 
61 1.62 2.46 1.50  -- -- -- 
62 1.76 1.73 1.46  1.53 2.16 1.51 
63 2.42 3.10 2.28  2.71 3.49 3.33 
64 2.68 2.94 2.30  3.82 3.25 3.09 
65 2.09 2.61 3.34  2.19 2.57 2.25 
66 2.28 -- 2.43  2.23 -- 2.04 
67 3.04 3.93 4.28  1.56 2.16 1.54 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.26. Raw data for 5 minute average calf vascular resistance for normotensive group in 
study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 31.03 32.37 --  34.72 34.50 34.12 
2 52.15 52.32 46.31  45.16 49.29 45.16 
3 27.66 26.09 30.37  45.53 43.42 50.33 
4 25.97 15.63 22.99  30.60 19.83 37.16 
5 43.80 26.03 44.69  33.23 27.30 47.28 
6 25.62 27.67 27.99  23.18 23.85 22.87 
7 33.03 27.82 38.70  43.67 47.65 61.59 
8 50.95 42.00 50.41  44.52 37.16 43.35 
9 54.15 44.34 50.76  42.40 40.61 48.78 
10 62.13 60.09 68.11  -- -- -- 
11 63.18 82.52 70.01  38.46 47.92 37.19 
12 62.83 42.31 74.26  25.87 23.10 29.04 
13 83.32 99.40 88.95  49.52 61.58 57.09 
14 44.99 29.51 45.17  34.29 25.52 -- 
15 93.09 54.98 94.13  -- -- -- 
16 61.02 46.00 57.15  50.72 48.15 58.50 
17 38.43 33.04 47.44  24.89 18.79 29.65 
18 78.96 63.94 87.09  88.47 67.29 89.65 
19 38.37 38.26 33.28  30.27 34.80 29.64 
20 49.94 51.17 43.25  -- -- -- 
21 46.00 41.07 41.78  49.82 44.49 48.70 
22 58.77 72.71 56.56  46.09 47.67 42.22 
23 53.14 30.72 55.10  63.15 28.22 60.96 
24 46.66 32.05 47.79  42.39 34.43 50.66 
25 59.57 52.17 75.16  -- -- -- 
26 65.85 43.86 78.13  -- -- -- 
27 -- -- --  -- -- -- 
28 29.54 27.59 41.58  37.55 40.40 41.80 
29 56.41 48.90 61.41  56.85 43.87 55.94 
30 34.71 36.27 58.14  38.69 31.49 42.68 
31 101.3 73.15 79.25  56.94 64.48 57.25 
32 64.73 58.56 68.61  61.28 67.34 73.66 
33 57.38 57.52 59.33  27.94 28.34 33.13 
34 54.10 28.00 42.52  57.12 36.60 49.68 
35 47.81 -- 54.44  31.51 38.10 34.06 
36 61.15 77.61 70.68  52.42 65.43 57.35 
37 43.44 61.54 62.21  33.24 40.01 37.50 
38 31.89 35.47 37.03  19.48 26.01 20.76 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.27. Raw data 5 minute average for calf vascular resistance for prehypertensive group in 
study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 32.54 28.64 32.48  28.65 25.89 28.30 
40 41.44 52.62 49.10  35.87 38.69 37.58 
41 49.91 42.67 49.57  47.92 40.91 46.85 
42 30.77 21.98 31.12  18.93 21.94 24.77 
43 -- -- --  -- -- -- 
44 41.22 33.78 39.25  25.82 21.97 23.74 
45 23.27 21.87 23.85  20.58 19.81 18.51 
46 49.26 45.69 41.68  55.08 45.17 56.74 
47 27.68 32.66 25.62  18.95 26.52 23.41 
48 49.30 43.84 49.50  -- -- -- 
49 -- -- --  30.86 30.26 30.73 
50 58.92 46.26 71.28  69.95 67.33 73.96 
51 41.84 39.78 47.12  30.06 31.36 29.72 
52 24.72 31.31 28.62  23.56 25.21 29.92 
53 35.64 31.86 41.65  24.69 26.16 36.61 
54 33.86 45.34 41.02  23.80 24.90 23.14 
55 44.70 46.05 45.36  43.97 37.36 44.24 
56 30.71 29.08 29.55  23.67 24.66 23.45 
57 26.98 19.43 31.75  34.72 22.79 37.72 
58 25.22 46.19 39.48  57.89 73.91 81.72 
59 44.67 34.02 39.46  54.34 -- 56.40 
60 46.41 38.95 49.71  55.21 49.03 49.36 
61 63.84 50.32 69.44  -- -- -- 
62 54.35 62.30 68.44  71.91 58.02 78.05 
63 41.81 36.48 44.80  30.38 27.19 25.08 
64 37.40 47.50 45.54  25.11 39.20 35.25 
65 45.78 42.50 33.21  46.77 45.28 48.40 
66 43.04 -- 44.28  45.41 -- 52.29 
67 36.64 33.86 27.76  57.25 54.62 68.36 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.28. Raw data for 5 minute average calf vascular conductance for normotensive group in 
study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
1 0.033 0.037 --  0.029 0.030 0.030 
2 0.019 0.020 0.022  0.022 0.020 0.022 
3 0.036 0.041 0.035  0.023 0.025 0.020 
4 0.039 0.065 0.044  0.033 0.057 0.027 
5 0.023 0.048 0.023  0.031 0.041 0.022 
6 0.040 0.036 0.036  0.043 0.042 0.044 
7 0.031 0.037 0.027  0.024 0.022 0.017 
8 0.020 0.024 0.020  0.022 0.028 0.023 
9 0.019 0.027 0.020  0.024 0.025 0.021 
10 0.016 0.017 0.015  -- -- -- 
11 0.016 0.013 0.014  0.026 0.023 0.027 
12 0.016 0.024 0.014  0.039 0.044 0.035 
13 0.012 0.011 0.011  0.020 0.017 0.018 
14 0.022 0.038 0.024  0.029 0.041 -- 
15 0.011 0.021 0.011  -- -- -- 
16 0.016 0.023 0.018  0.020 0.021 0.017 
17 0.026 0.033 0.022  0.041 0.054 0.034 
18 0.013 0.016 0.012  0.011 0.015 0.012 
19 0.026 0.027 0.030  0.033 0.029 0.034 
20 0.020 0.020 0.023  -- -- -- 
21 0.022 0.025 0.024  0.020 0.023 0.021 
22 0.017 0.014 0.019  0.022 0.021 0.024 
23 0.019 0.039 0.018  0.016 0.037 0.017 
24 0.021 0.034 0.021  0.024 0.030 0.020 
25 0.017 0.019 0.013  -- -- -- 
26 0.016 0.024 0.013  -- -- -- 
27 -- -- --  -- -- -- 
28 0.034 0.036 0.025  0.027 0.025 0.024 
29 0.018 0.021 0.017  0.018 0.023 0.018 
30 0.029 0.028 0.018  0.026 0.032 0.023 
31 0.010 0.014 0.013  0.018 0.016 0.018 
32 0.015 0.017 0.015  0.016 0.015 0.014 
33 0.018 0.017 0.017  0.036 0.035 0.030 
34 0.019 0.040 0.024  0.018 0.029 0.020 
35 0.021 -- 0.019  0.032 0.026 0.029 
36 0.016 0.013 0.014  0.019 0.015 0.017 
37 0.023 0.017 0.017  0.030 0.026 0.027 
38 0.031 0.029 0.027  0.051 0.039 0.049 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Table C.29. Raw data for 5 minute average calf vascular conductance for prehypertensive group 
in study 2 
 Pre supplementation  Post supplementation 
Subject Base Mental Stress Recovery  Base 
Mental 
Stress Recovery 
39 0.031 0.040 0.031  0.035 0.039 0.035 
40 0.025 0.020 0.021  0.028 0.027 0.027 
41 0.020 0.024 0.020  0.021 0.025 0.021 
42 0.033 0.046 0.032  0.053 0.049 0.041 
43 -- -- --  -- -- -- 
44 0.024 0.033 0.026  0.039 0.049 0.043 
45 0.043 0.053 0.042  0.049 0.054 0.054 
46 0.020 0.022 0.024  0.018 0.023 0.018 
47 0.036 0.031 0.039  0.054 0.038 0.043 
48 0.021 0.023 0.020  -- -- -- 
49 -- -- --  0.032 0.035 0.033 
50 0.017 0.026 0.014  0.014 0.015 0.014 
51 0.024 0.025 0.021  0.033 0.032 0.034 
52 0.041 0.035 0.035  0.043 0.040 0.034 
53 0.028 0.035 0.024  0.042 0.042 0.027 
54 0.030 0.023 0.025  0.043 0.041 0.043 
55 0.022 0.022 0.022  0.023 0.027 0.023 
56 0.033 0.035 0.034  0.042 0.041 0.043 
57 0.037 0.056 0.032  0.029 0.048 0.027 
58 0.041 0.024 0.025  0.018 0.014 0.012 
59 0.023 0.031 0.025  0.018 -- 0.018 
60 0.022 0.027 0.020  0.018 0.021 0.020 
61 0.016 0.022 0.015  -- -- -- 
62 0.019 0.016 0.015  0.014 0.017 0.013 
63 0.024 0.028 0.023  0.033 0.037 0.040 
64 0.028 0.023 0.022  0.040 0.028 0.029 
65 0.022 0.024 0.033  0.021 0.022 0.021 
66 0.023 -- 0.023  0.022 -- 0.020 
67 0.027 0.032 0.036  0.018 0.020 0.015 
 
Missing blood flow data are due to movement artifact or equipment failure during recording 
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Appendix D 
Appendix D-1. Repeated Measures ANOVA in normotensive group, 2 Time (pre/post) vs. 2 Drug 
(Fish Oil/Placebo) resting values presented; two-tailed significance 
 
Variable Time  Time x Drug Interaction 
N (fish 
oil/placebo) 
SAP (mmHg) .194 .169 19/19 
DAP (mmHg) .279 .693 19/19 
MAP (mmHg) .778 .420 19/19 
HR (beats/min) .464 .427 19/19 
MSNA (bursts/min) .729 .160 16/17 
MSNA (bursts/100hb) .864 .340 16/17 
FBF (mL/100mL/min) .045 .814 18/18 
FVR (mmHg/mL/100mL/min) .020 .681 18/18 
FVC (mL/100mL/min/mmHg) .005 .947 18/18 
CBF (mL/100mL/min) .138 .701 16/16 
CVR (mmHg/mL/100mL/min) .006 .555 16/16 
CVC (mL/100mL/min/mmHg) .012 .926 16/16 
 
Appendix D-2. Repeated Measures ANOVA in prehypertensive group, 2 Time (pre/post) vs. 2 
Drug (Fish Oil/Placebo) resting values presented; two-tailed significance 
 
Variable Time  Time x Drug Interaction 
N (fish 
oil/placebo) 
SAP (mmHg) .042 .585 15/14 
DAP (mmHg) .522 .931 15/14 
MAP (mmHg) .221 .794 15/14 
HR (beats/min) .264 .526 15/14 
MSNA (bursts/min) .288 .381 12/10 
MSNA (bursts/100hb) .448 .388 12/10 
FBF (mL/100mL/min) .797 .374 14/13 
FVR (mmHg/mL/100mL/min) .207 .752 14/13 
FVC (mL/100mL/min/mmHg) .961 .545 14/13 
CBF (mL/100mL/min) .481 .822 14/11 
CVR (mmHg/mL/100mL/min) .923 .566 14/11 
CVC (mL/100mL/min/mmHg) .155 .686 14/11 
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Table D.3. Post-hoc paired t-test of resting SAP (mmHg) prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs.  
Post Resting -1.76 5.42 -4.76 1.24 .229 15 
 
Table D.4. Post-hoc paired t-test of resting SAP (mmHg) prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting -2.99 5.56 -6.78 .795 .112 14 
 
 
Table D.5. Post-hoc paired t-test of resting FBF (mL/100mL/min) for normotensive group, fish 
oil. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting .343 .998 -.153 .840 .082 18 
 
 
Table D.6. Post-hoc paired t-test of resting FBF (mL/100mL/min) for normotensive group, 
placebo. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting .273 .763 -.107 .652 .074 18 
 
 
Table D.7. Post-hoc paired t-test of resting FVR (mmHg/mL/100mL/min) for normotensive 
group, fish oil. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting -5.25 -17.68 -14.04 3.54 .112 18 
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Table D.8. Post-hoc paired t-test of resting FVR (mmHg/mL/100mL/min) for normotensive 
group, placebo. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting -7.41 -13.20 -13.97 -.843 .015 18 
 
 
Table D.9. Post-hoc paired t-test of resting FVC (mL/100mL/min/mmHg) for normotensive 
group, fish oil. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting .005 .0097 .0002 .0098 .021 18 
 
 
Table D.10. Post-hoc paired t-test of resting FVC (mL/100mL/min/mmHg) for normotensive 
group, placebo. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting .048 .0100 -.0002 .0098 .029 18 
 
 
Table D.11. Post-hoc paired t-test of resting CVR (mmHg/mL/100mL/min) for normotensive 
group, fish oil. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting -9.12 -15.67 -17.47 -.772 16 .017 
 
 
Table D.12. Post-hoc paired t-test of resting CVR (mmHg/mL/100mL/min) for normotensive 
group, placebo. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting -6.03 -13.48 -13.22 1.15 16 .047 
 
 
 
 148
Table D.13. Post-hoc paired t-test of resting CVC (mL/100mL/min/mmHg) for normotensive 
group, fish oil. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting .0040 .0088 -.00073 .0087 16 .046 
 
 
Table D.14. Post-hoc paired t-test of resting CVC (mL/100mL/min/mmHg) for normotensive 
group, placebo. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Resting vs. 
Post Resting .0037 .0074 -.00023 .0077 16 .032 
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Table D.15. Normotensive repeated measures ANOVA of changes in 5 minute average ΔSAP 
(mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .383 
Time x Drug .267 
Condition .000 
Condition x Drug .050 
Time x Condition .383 
Time x Condition x Drug .267 
 
Table D.16. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔSAP 
(mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .422 
Time x Drug .276 
Condition .000 
Condition x Drug .495 
Time x Condition .422 
Time x Condition x Drug .276 
 
Table D.17. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔSAP (mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .249 
Time x Drug .484 
Condition .347 
Condition x Drug .145 
Time x Condition .249 
Time x Condition x Drug .484 
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Table D.18. Post-hoc paired t-test of condition interaction SAP (mmHg) responses to mental 
stress for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 12.20 8.07 8.31 16.10 .000 19 
Post Base vs. Post MS 12.45 7.83 8.68 16.22 .000 19 
 
Table D.19. Post-hoc paired t-test of condition interaction SAP (mmHg) responses to mental 
stress for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 9.32 5.00 6.91 11.72 .000 19 
Post Base vs. Post MS 8.37 6.92 5.04 11.71 .000 19 
 
 
Table D.20. Post-hoc paired t-test of condition interaction SAP (mmHg) responses to mental 
stress for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 14.57 10.10 9.00 20.16 .000 15 
Post Base vs. Post MS 13.58 9.93 7.85 19.31 .000 14 
 
 
Table D.21. Post-hoc paired t-test of condition interaction SAP (mmHg) responses to mental 
stress for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 13.83 9.01 8.39 19.28 .000 13 
Post Base vs. Post MS 14.42 13.7 6.14 22.70 .003 13 
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Table D.22. Normotensive repeated measures ANOVA of changes in 5 minute average ΔDAP 
(mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .254 
Time x Drug .101 
Condition .000 
Condition x Drug .019 
Time x Condition .254 
Time x Condition x Drug .101 
 
Table D.23. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔDAP 
(mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .189 
Time x Drug .491 
Condition .000 
Condition x Drug .428 
Time x Condition .189 
Time x Condition x Drug .491 
 
Table D.24. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔDAP (mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .262 
Time x Drug .173 
Condition .215 
Condition x Drug .175 
Time x Condition .262 
Time x Condition x Drug .173 
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Table D.25. Post-hoc paired t-test of condition interaction DAP (mmHg) responses to mental 
stress for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 9.66 3.75 7.86 11.47 .000 19 
Post Base vs. Post MS 10.70 3.27 9.12 12.28 .000 19 
 
Table D.26. Post-hoc paired t-test of condition interaction DAP (mmHg) responses to mental 
stress for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 8.15 3.37 6.53 9.78 .000 19 
Post Base vs. Post MS 7.82 3.73 6.03 9.62 .000 19 
 
 
Table D.27. Post-hoc paired t-test of condition interaction DAP (mmHg) responses to mental 
stress for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 10.49 5.50 7.32 13.67 .000 15 
Post Base vs. Post MS 9.89 4.89 7.07 12.71 .000 14 
 
 
Table D.28. Post-hoc paired t-test of condition interaction DAP (mmHg) responses to mental 
stress for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 10.87 4.96 7.87 13.86 .000 13 
Post Base vs. Post MS 10.20 5.96 6.59 13.80 .000 13 
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Table D.29. Normotensive repeated measures ANOVA of changes in 5 minute average ΔMAP 
(mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .483 
Time x Drug .150 
Condition .000 
Condition x Drug .026 
Time x Condition .483 
Time x Condition x Drug .150 
 
Table D.30. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔMAP 
(mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .079 
Time x Drug .194 
Condition .000 
Condition x Drug .382 
Time x Condition .079 
Time x Condition x Drug .194 
 
Table D.31. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔMAP (mmHg) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .204 
Time x Drug .410 
Condition .397 
Condition x Drug .064 
Time x Condition .204 
Time x Condition x Drug .410 
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Table D.32. Post-hoc paired t-test of condition interaction MAP (mmHg) responses to mental 
stress for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 12.03 5.42 9.42 14.64 .000 19 
Post Base vs. Post MS 12.82 4.90 10.46 15.18 .000 19 
 
Table D.33. Post-hoc paired t-test of condition interaction MAP (mmHg) responses to mental 
stress for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 9.99 4.26 7.94 12.04 .000 19 
Post Base vs. Post MS 9.26 4.78 6.95 11.57 .000 19 
 
 
Table D.34. Post-hoc paired t-test of condition interaction MAP (mmHg) responses to mental 
stress for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 14.67 7.17 10.72 18.67 .000 15 
Post Base vs. Post MS 13.09 6.25 9.48 16.71 .000 14 
 
 
Table D.35. Post-hoc paired t-test of condition interaction MAP (mmHg) responses to mental 
stress for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 13.52 5.70 10.08 16.97 .000 13 
Post Base vs. Post MS 13.04 8.19 8.09 17.99 .000 13 
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Table D.36. Normotensive repeated measures ANOVA of changes in 5 minute average ΔHR 
(beats/min) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .056 
Time x Drug .007 
Condition .000 
Condition x Drug .001 
Time x Condition .056 
Time x Condition x Drug .007 
 
Table D.37. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔHR 
(beats/min) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .093 
Time x Drug .189 
Condition .000 
Condition x Drug .299 
Time x Condition .093 
Time x Condition x Drug .189 
 
Table D.38. Combined-groups repeated measures ANOVA of changes in 5 minute average ΔHR 
(beats/min) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .351 
Time x Drug .009 
Condition .026 
Condition x Drug .019 
Time x Condition .351 
Time x Condition x Drug .009 
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Table D.39. Post-hoc paired t-test of condition interaction HR (beats/min) responses to mental 
stress for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 24.72 10.61 19.61 29.83 .000 19 
Post Base vs. Post MS 21.61 11.27 16.17 27.04 .000 19 
Pre MS vs. Post MS -3.11 5.91 -5.96 -.263 .034 19 
 
Table D.40. Post-hoc paired t-test of condition interaction HR (beats/min) responses to mental 
stress for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 12.86 5.81 10.06 15.67 .000 19 
Post Base vs. Post MS 13.55 7.21 10.07 17.02 .000 19 
Pre MS vs. Post MS .682 2.72 -.630 1.99 .289 19 
 
 
Table D.41. Post-hoc paired t-test of condition interaction HR (beats/min) responses to mental 
stress for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 17.52 7.26 13.50 21.54 .000 15 
Post Base vs. Post MS 15.57 6.74 11.68 19.46 .000 14 
 
 
Table D.42. Post-hoc paired t-test of condition interaction HR (beats/min) responses to mental 
stress for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 19.32 12.62 12.03 26.61 .000 13 
Post Base vs. Post MS 18.47 11.38 11.60 25.35 .000 13 
 
 
Table D.43. Post-hoc paired t-test of condition interaction HR (beats/min) responses to mental 
stress for combined-group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 21.54 9.84 18.11 24.98 .000 34 
Post Base vs. Post MS 19.05 9.95 15.52 22.58 .000 33 
Pre MS vs. Post MS -2.80 5.18 -4.63 -.959 .002 33 
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Table D.44. Post-hoc paired t-test of condition interaction HR (beats/min) responses to mental 
stress for combined-group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 15.60 9.71 12.16 19.05 .000 33 
Post Base vs. Post MS 15.55 9.29 12.20 18.90 .000 32 
Pre MS vs. Post MS .207 4.60 -1.45 1.87 .400 32 
 
 
 
Table D.45. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔMSNA (bursts/min) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug 
(fish oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .326 
Time x Drug .398 
Condition .010 
Condition x Drug .449 
Time x Condition .326 
Time x Condition x Drug .398 
 
 
Table D.46. Post-hoc paired t-test of condition interaction ΔMSNA (bursts/min) responses to 
mental stress for combined-group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 5.78 6.13 1.88 9.68 .004 12 
Post Base vs. Post MS 4.82 4.52 1.95 7.69 .002 12 
 
 
Table D.47. Post-hoc paired t-test of condition interaction ΔMSNA (bursts/min) responses to 
mental stress for combined-group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 6.00 4.86 3.50 8.50 .000 17 
Post Base vs. Post MS 5.89 5.00 3.32 8.46 .000 17 
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Table D.48. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔMSNA (bursts/100hb) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 
Drug (fish oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .398 
Time x Drug .364 
Condition .024 
Condition x Drug .457 
Time x Condition .398 
Time x Condition x Drug .364 
 
 
Table D.49. Post-hoc paired t-test of condition interaction ΔMSNA (bursts/100hb) responses to 
mental stress for combined-group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 4.19 9.59 -1.91 10.28 .080 12 
Post Base vs. Post MS 3.13 6.94 -1.29 7.54 .079 12 
 
 
Table D.50. Post-hoc paired t-test of condition interaction ΔMSNA (bursts/100hb) responses to 
mental stress for combined-group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 3.99 7.05 .368 7.62 .016 17 
Post Base vs. Post MS 3.98 6.03 .883 7.08 .008 17 
 
 
Table D.51. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔTotal MSNA (arbitrary units) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) 
vs. 2 Drug (fish oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .102 
Time x Drug .041 
Condition .113 
Condition x Drug .459 
Time x Condition .102 
Time x Condition x Drug .041 
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Table D.52. Post-hoc paired t-test of condition interaction ΔTotal MSNA (arbitrary units) 
responses to mental stress for combined-group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 9627.9 7219.5 4078.5 15177.3 .002 9 
Post Base vs. Post MS 3830.2 3087.8 1456.7 6203.6 .003 9 
Pre MS vs. Post MS -5797.7 6576.1 -10852.6 -742.9 .015 9 
 
 
Table D.53. Post-hoc paired t-test of condition interaction ΔMSNA (bursts/100hb) responses to 
mental stress for combined-group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 6860.4 5474.9 3699.3 10021.6 .000 14 
Post Base vs. Post MS 6302.3 6589.6 1890.5 10714.2 .004 14 
Pre MS vs. Post MS -558.10 6589.6 -4362.8 3246.6 .378 14 
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Table D.54. Normotensive repeated measures ANOVA of changes in 5 minute average ΔFBF 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .337 
Time x Drug .497 
Condition .000 
Condition x Drug .003 
Time x Condition .337 
Time x Condition x Drug .497 
 
Table D.55. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔFBF 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .043 
Time x Drug .491 
Condition .000 
Condition x Drug .396 
Time x Condition .043 
Time x Condition x Drug .491 
 
Table D.56. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔFBF (%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .073 
Time x Drug .478 
Condition .000 
Condition x Drug .011 
Time x Condition .073 
Time x Condition x Drug .478 
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Table D.57. Post-hoc paired t-test of condition interaction FBF (%) responses to mental stress 
for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 109.1 62.65 75.67 142.44 .000 16 
Post Base vs. Post MS 104.1 72.23 65.66 142.63 .000 16 
 
Table D.58. Post-hoc paired t-test of condition interaction FBF (%) responses to mental stress 
for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 58.86 45.64 34.54 83.18 .000 16 
Post Base vs. Post MS 54.11 40.25 32.67 75.56 .000 16 
 
 
Table D.59. Post-hoc paired t-test of condition interaction FBF (%) responses to mental stress 
for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 71.76 51.86 40.43 103.1 .000 13 
Post Base vs. Post MS 50.36 45.11 23.10 77.62 .002 13 
 
 
Table D.60. Post-hoc paired t-test of condition interaction FBF (%) responses to mental stress 
for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 67.56 52.38 30.08 105.03 .003 10 
Post Base vs. Post MS 45.57 46.34 12.43 78.72 .013 10 
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Table D.61. Normotensive repeated measures ANOVA of changes in 5 minute average ΔFVR 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .336 
Time x Drug .497 
Condition .000 
Condition x Drug .003 
Time x Condition .336 
Time x Condition x Drug .497 
 
Table D.62. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔFVR 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .081 
Time x Drug .349 
Condition .000 
Condition x Drug .351 
Time x Condition .081 
Time x Condition x Drug .349 
 
Table D.63. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔFVR (%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .024 
Time x Drug .366 
Condition .000 
Condition x Drug .127 
Time x Condition .024 
Time x Condition x Drug .366 
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Table D.64. Post-hoc paired t-test of condition interaction FVR (%) responses to mental stress 
for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -37.88 20.19 -48.64 -27.12 .000 16 
Post Base vs. Post MS -35.63 19.71 -46.13 -25.13 .000 16 
 
Table D.65. Post-hoc paired t-test of condition interaction FVR (%) responses to mental stress 
for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -25.64 18.35 -35.42 15.86 .000 16 
Post Base vs. Post MS -20.08 19.38 -30.41 -9.75 .000 16 
 
 
Table D.66. Post-hoc paired t-test of condition interaction FVR (%) responses to mental stress 
for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -18.07 24.97 -33.94 -2.21 .029 13 
Post Base vs. Post MS -12.63 28.24 -30.57 5.32 .150 13 
 
 
Table D.67. Post-hoc paired t-test of condition interaction FVR (%) responses to mental stress 
for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -23.95 21.74 -39.14 -8.04 .007 10 
Post Base vs. Post MS -14.07 19.67 -28.14 .006 .050 10 
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Table D.68. Normotensive repeated measures ANOVA of changes in 5 minute average ΔFVC 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .146 
Time x Drug .326 
Condition .000 
Condition x Drug .012 
Time x Condition .146 
Time x Condition x Drug .326 
 
Table D.69. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔFVC 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .245 
Time x Drug .413 
Condition .000 
Condition x Drug .006 
Time x Condition .244 
Time x Condition x Drug .413 
 
Table D.70. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔFVC (%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .066 
Time x Drug .407 
Condition .000 
Condition x Drug .025 
Time x Condition .066 
Time x Condition x Drug .407 
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Table D.71. Post-hoc paired t-test of condition interaction FVC (%) responses to mental stress 
for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 86.02 55.06 56.68 115.37 .000 16 
Post Base vs. Post MS 78.42 64.12 44.25 112.59 .000 16 
 
Table D.72. Post-hoc paired t-test of condition interaction FVC (%) responses to mental stress 
for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 45.13 39.66 24.00 66.26 .000 16 
Post Base vs. Post MS 39.29 36.54 19.81 58.76 .001 16 
 
 
Table D.73. Post-hoc paired t-test of condition interaction FVC (%) responses to mental stress 
for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 48.94 45.30 21.57 76.31 .002 13 
Post Base vs. Post MS 30.75 38.94 7.22 54.29 .015 13 
 
 
Table D.74. Post-hoc paired t-test of condition interaction FVC (%) responses to mental stress 
for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 45.38 44.09 13.84 76.92 .010 10 
Post Base vs. Post MS 31.21 43.49 .102 62.32 .049 10 
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Table D.75. Normotensive repeated measures ANOVA of changes in 5 minute average ΔCBF 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .007 
Time x Drug .025 
Condition .000 
Condition x Drug .080 
Time x Condition .007 
Time x Condition x Drug .025 
 
Table D.76. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔCBF 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .145 
Time x Drug .166 
Condition .000 
Condition x Drug .448 
Time x Condition .145 
Time x Condition x Drug .332 
 
Table D.77. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔCBF (%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .005 
Time x Drug .018 
Condition .000 
Condition x Drug .110 
Time x Condition .005 
Time x Condition x Drug .018 
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Table D.78. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 52.99 45.06 28.03 77.94 .000 15 
Post Base vs. Post MS 32.87 31.65 15.34 50.39 .001 15 
Pre MS vs. Post MS -20.12 26.57 -34.83 -5.41 .005 15 
 
Table D.79. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 25.21 33.24 6.81 43.62 .011 15 
Post Base vs. Post MS 22.72 39.54 .825 44.62 .043 15 
Pre MS vs. Post MS -2.49 20.12 -13.63 8.65 .639 15 
 
 
Table D.80. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for prehypertensive group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 29.87 31.63 10.75 48.99 .005 13 
Post Base vs. Post MS 19.12 25.25 3.86 34.38 .018 13 
 
 
Table D.81. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 23.42 23.08 6.91 39.94 .011 10 
Post Base vs. Post MS 22.95 23.57 6.09 39.81 .013 10 
 
Table D.82. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for combined-group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 45.61 40.33 30.82 60.40 .000 31 
Post Base vs. Post MS 26.67 28.67 15.41 37.22 .000 29 
Pre MS vs. Post MS -15.77 26.20 -25.93 -5.61 .002 29 
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Table D.83. Normotensive repeated measures ANOVA of changes in 5 minute average ΔCVR 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .011 
Time x Drug .218 
Condition .023 
Condition x Drug .198 
Time x Condition .011 
Time x Condition x Drug .218 
 
Table D.84. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔCVR 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .403 
Time x Drug .390 
Condition .441 
Condition x Drug .285 
Time x Condition .403 
Time x Condition x Drug .390 
 
Table D.85. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔCVR (%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .107 
Time x Drug .274 
Condition .088 
Condition x Drug .487 
Time x Condition .107 
Time x Condition x Drug .274 
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Table D.86. Post-hoc paired t-test of condition interaction CVR (%) responses to mental stress 
for normotensive group, fish oil. 
. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -15.13 25.09 -29.02 -1.23 .035 15 
Post Base vs. Post MS -6.46 20.52 -17.82 4.91 .243 15 
 
Table D.87. Post-hoc paired t-test of condition interaction CVR (%) responses to mental stress 
for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -6.70 16.35 -15.75 2.36 .135 15 
Post Base vs. Post MS -2.28 22.38 -14.68 10.11 .699 15 
 
 
Table D.88. Normotensive repeated measures ANOVA of changes in 5 minute average ΔCVC 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .003 
Time x Drug .036 
Condition .002 
Condition x Drug .180 
Time x Condition .003 
Time x Condition x Drug .036 
 
Table D.89. Prehypertensive repeated measures ANOVA of changes in 5 minute average ΔCVC 
(%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish oil/placebo), 
presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .243 
Time x Drug .116 
Condition .046 
Condition x Drug .428 
Time x Condition .243 
Time x Condition x Drug .116 
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Table D.90. Combined-groups repeated measures ANOVA of changes in 5 minute average 
ΔCVC (%) in Study 2, 2 time (pre/post) vs. 2 condition (base/mental stress) vs. 2 Drug (fish 
oil/placebo), presented as one-tailed significance. 
 
Interaction Base – Mental Stress 
Time .004 
Time x Drug .017 
Condition .000 
Condition x Drug .178 
Time x Condition .004 
Time x Condition x Drug .017 
 
 
Table D.91. Post-hoc paired t-test of condition interaction CVC (%) responses to mental stress 
for normotensive group, fish oil. 
. 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 36.29 41.82 13.13 59.44 .005 15 
Post Base vs. Post MS 16.14 27.95 .659 31.61 .042 15 
Pre MS vs. Post MS -20.15 24.61 -33.78 -6.52 .007 15 
 
Table D.92. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for normotensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 14.55 29.22 -1.63 30.73 .074 15 
Post Base vs. Post MS 10.42 37.22 -10.19 31.03 .297 15 
Pre MS vs. Post MS -4.13 20.52 -15.49 7.23 .449 15 
 
Table D.93. Post-hoc paired t-test of condition interaction CVC (%) responses to mental stress 
for prehypertensive group, fish oil. 
 
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 12.10 28.84 -5.33 29.53 .156 13 
Post Base vs. Post MS 3.74 23.41 -10.40 17.89 .575 13 
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Table D.94. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for prehypertensive group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 6.22 18.53 -7.04 19.48 .316 10 
Post Base vs. Post MS 8.46 17.17 -3.82 20.74 .154 10 
 
 
Table D.95. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for combined-group, fish oil. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS 28.41 37.91 14.50 42.31 .000 31 
Post Base vs. Post MS 10.15 25.79 .337 19.96 .043 29 
Pre MS vs. Post MS -14.68 24.19 -24.06 -5.29 .003 29 
 
 
Table D.96. Post-hoc paired t-test of condition interaction CBF (%) responses to mental stress 
for combined-group, placebo. 
  
Variable Mean Std. Dev. 
95% Confidence Interval 
Sig. N 
Lower  Upper 
Pre Base vs. Pre MS -11.68 23.75 2.81 20.55 .012 30 
Post Base vs. Post MS -8.52 29.59 -3.19 20.22 .147 27 
Pre MS vs. Post MS -1.58 18.95 -9.41 6.24 .680 27 
 
 
 
Table D.97. Combined-group regression analyses of ΔMSNA (bursts/min) with ΔMAP and 
Resting HR following fish oil supplementation. 
 
 
Variable ΔMSNA (bursts/min) 
ΔMAP 
(mmHg) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
.354 
.035 
27 
Resting HR 
(beats/min) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
-.466 
.007 
27 
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Table D.98. Combined-group regression analyses of ΔMSNA (bursts/min) with ΔMAP and 
Resting HR following placebo supplementation. 
 
 
Variable ΔMSNA (bursts/min) 
ΔMAP 
(mmHg) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
-.036 
.860 
27 
Resting HR 
(beats/min) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
-.227 
.123 
28 
 
 
Table D.99. Combined-group regression analyses of ΔMSNA (bursts/100hb) with ΔMAP and 
Resting HR following fish oil supplementation. 
 
 
Variable ΔMSNA (bursts/100hb) 
ΔMAP 
(mmHg) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
.325 
.049 
27 
Resting HR 
(beats/min) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
-.429 
.013 
27 
 
 
 
Table D.100. Combined-group regression analyses of ΔMSNA (bursts/100hb) with ΔMAP and 
Resting HR following placebo supplementation. 
 
 
Variable ΔMSNA (bursts/100hb) 
ΔMAP 
(mmHg) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
-.062 
.758 
28 
Resting HR 
(beats/min) 
 
Pearson Correlation 
Sig. (one-tailed) 
N 
 
-.219 
.131 
28 
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Appendix E 
 
 
